WO2014184163A1 - Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection - Google Patents

Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection Download PDF

Info

Publication number
WO2014184163A1
WO2014184163A1 PCT/EP2014/059699 EP2014059699W WO2014184163A1 WO 2014184163 A1 WO2014184163 A1 WO 2014184163A1 EP 2014059699 W EP2014059699 W EP 2014059699W WO 2014184163 A1 WO2014184163 A1 WO 2014184163A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolo
chloro
methyl
pyridin
cyclopropane
Prior art date
Application number
PCT/EP2014/059699
Other languages
French (fr)
Inventor
Song Feng
Lu Gao
Lei Guo
Mengwei Huang
Chungen Liang
Baoxia Wang
Lisha Wang
Guolong Wu
Hongying Yun
Weixing Zhang
Xiufang ZHENG
Wei Zhu
Original Assignee
F. Hoffmann-La Roche Ag
Hoffmann-La Roche Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc. filed Critical F. Hoffmann-La Roche Ag
Priority to CN201480028073.XA priority Critical patent/CN105392787B/en
Priority to KR1020157035224A priority patent/KR20160007629A/en
Priority to RU2015148926A priority patent/RU2015148926A/en
Priority to JP2016513325A priority patent/JP2016518421A/en
Priority to CA2910508A priority patent/CA2910508A1/en
Priority to MX2015015691A priority patent/MX2015015691A/en
Priority to EP14723783.8A priority patent/EP2997028A1/en
Priority to BR112015028475A priority patent/BR112015028475A2/en
Publication of WO2014184163A1 publication Critical patent/WO2014184163A1/en
Priority to US14/942,725 priority patent/US10189838B2/en
Priority to HK16110598.7A priority patent/HK1222395A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to respiratory syncytial virus (RSV) inhibitors useful for treating RSV infection.
  • RSV respiratory syncytial virus
  • Respiratory Syncytial Virus belongs to the family of Paramyxoviridae, subfamily of Pneumovirinae.
  • the human RSV is a major cause of acute upper and lower respiratory tract infection in infants and children. Almost all children are infected by RSV at least once by age of three.
  • Natural human immunity against RSV is incomplete. In normal adults and elder children, RSV infection is mainly associated with upper respiratory track symptoms. Severe case of RSV infection often leads to bronchiolitis and pneumonia, which requires hospitalization.
  • High-risk factors for lower respiratory tract infections include premature birth, congenital heart disease, chronic pulmonary disease, and immunocompromised conditions. A severe infection at young age may lead to recurrent wheezing and asthma. For the elderly, RSV-related mortality rate becomes higher with advancing age.
  • RSV Fusion (F) protein is a surface glycoprotein on the viral envelope which, together with the G surface glycoprotein, mediates viral entry into host cell.
  • the F protein initiates viral penetration by fusing viral and host cellular membranes and subsequently promotes viral spread after infection by melding infected cells to adjacent uninfected cells, resulting in characteristic syncytial formation.
  • treatment with chemicals described here will decrease the duration and severity of respiratory symptoms and subsequent risk of prolonged hospitalization and complications. It is also expected to limit the ability of individuals to transmit RSV within households, nursing homes and the hospital setting to other hosts potentially at high risk of complications.
  • RSV-IGIV brand name RespiGam
  • RSV-IGIV brand name RespiGam
  • palivizumab brand name Synagis®
  • RSV fusion (F) protein a humanized monoclonal antibody against RSV fusion (F) protein approved for prophylaxis in high-risk infants in 1998.
  • palivizumab demonstrated 45 - 55% reduction of hospitalization rate caused by RSV infection in selected infants (Pediatrics. 1998 Sep; 102(3):531-7; Feltes TF et al, J Pediatr. 2003 Oct; 143(4):532-40).
  • palivizumab is not effective in the treatment of established RSV infection.
  • motavizumab A newer version monoclonal antibody, motavizumab, was designed as potential replacement of palivizumab but failed to show additional benefit over palivizumab in recent Phase III clinical trials (Feltes TF et al, Pediatr Res. 2011 Aug; 70(2): 186-91).
  • RSV inhibitors A number of small molecule RSV inhibitors have been discovered. Among them, only a few reached Phase I or II clinical trials. Arrow Therapeutics (now a group in AstraZeneca, UK) completed a five-year Phase II trial of nucleocapsid (N) protein inhibitor, RSV-604, in stem cell transplantation patients by February 2010 (www.clinicaltrials.gov), but has not released the final results. Most of other small molecules were put on hold for various reasons.
  • RNAi therapeutics against RSV has also been thoroughly studied.
  • ALN-RSV01 (Alnylam Pharmaceuticals, MA, USA) is a siRNA targeting on RSV gene.
  • a nasal spray administered for two days before and for three days after RSV inoculation decreased infection rate among adult volunteers (DeVincenzo J. et al, Proc Natl Acad Sci U S A. 2010 May 1 1 ; 107(19): 8800-5).
  • results were not sufficient for conclusion of antiviral efficacy, though certain health benefits have been observed (Zamora MR et al, Am J Respir Crit Care Med. 2011 Feb 15;183(4):531-8).
  • Additional Phase lib clinical trials in similar patient population for ALN-RSV01 are on-going
  • Objects of the present invention are novel compounds of formula I, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I for the treatment or prophylaxis of RS V infection.
  • Ci- alkyl alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1 -butyl, 2-butyl, tert-butyl and the like.
  • Particular "Ci -6 alkyl” groups are methyl, ethyl, isopropyl and tert-butyl.
  • C x H 2x alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 2 to 6, particularly 2 to 4 carbon atoms.
  • Particular “C x H 2x” groups are saturated, linear alkyl chain containing 2 to 6, particularly 2 to 4 carbon atoms.
  • C y H 2y alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms.
  • Particular “C y H 2y” groups are saturated, linear alkyl chain containing 1 to 6, particularly 1 to 4 carbon atoms.
  • cycloalkyl refers to a saturated carbon ring containing from 3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • Particular "cycloalkyl” groups are cyclopropyl, cyclopentyl and cyclohexyl.
  • Ci- alkyl-0- wherein the "Ci -6 alkyl” is as defined above; for example methoxy, ethoxy, propoxy, wo-propoxy, n-butoxy, wo-butoxy, 2-butoxy, tert-butoxy and the like.
  • Particular "Ci- alkoxy” groups are methoxy and ethoxy and more particularly methoxy.
  • cyano alone or in combination refers to the group -CN.
  • amino alone or in combination, refers to primary (-NH 2 ), secondary (-NH-) or
  • halogen means fluorine, chlorine, bromine or iodine. Halogen is particularly fluorine, chlorine or bromine.
  • hydroxy alone or in combination refers to the group -OH.
  • carbonyl alone or in combination refers to the group -C(O)-.
  • the compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
  • Acid-addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as -toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like.
  • Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide.
  • the chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of
  • Racemates can be separated according to known methods into the enantiomers.
  • diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.
  • the present invention provides (i) novel compounds having the general formula I:
  • A is phenyl or pyridinyl, which is unsubstituted or substituted by Ci -6 alkyl, Ci -6 alkoxy, halogen, trifluoromethyl or cyano;
  • X is nitrogen, -CH or -CR ; provided that
  • R 1 is Ci -6 alkylsulfonylphenyl-C y H 2y -, thietan-3-yl-C y H 2y -, dioxothietan-3-yl-C y H 2y -, oxetan-3-yl-C y H 2y -, aminooxetan-3-yl-C x H 2x -, hydroxy-C x H 2x -, Ci_
  • R and R J are hydrogen or deuterium simultaneously
  • R 4 and R 5 with the carbon atom to which they are attached, form cycloalkyl
  • R 6 is hydrogen or halogen
  • W is nitrogen or -CR , wherein R is hydrogen or halogen
  • W 2 is -CH or nitrogen
  • W is -CH or nitrogen; provided that at most one of W , W and W is nitrogen;
  • x 2-6;
  • y is 1-6;
  • Another embodiment of present invention is (ii) a compound of formula I, wherein
  • A is phenyl, which is unsubstituted or once or twice substituted by Ci -6 alkyl, Ci -6 alkoxy, halogen, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by Ci_
  • X is nitrogen, -CH or -CR 7 ; provided that
  • R is hydrogen, wherein R is Ci- alkylsulfonyl-C y H2 y -;
  • R 1 is Ci -6 alkylsulfonylphenyl-C y H2y-, thietan-3-yl-C y H 2y -, dioxothietan-3-yl-C y H 2 y-, oxetan-3-yl-C y H 2y -, aminooxetan-3-yl-C x H 2x -, hydroxy-C x H 2x -, d.
  • R 2 and R 3 are hydrogen or deuterium simultaneously;
  • R 4 and R 5 with the carbon atom to which they are attached, form cycloalkyl
  • R 6 is hydrogen or halogen
  • W 1 is nitrogen or -CR 12 , wherein R 12 is hydrogen or halogen;
  • W 2 is -CH or nitrogen
  • W 3 is -CH or nitrogen; provided that at most one of W 1 , W 2 and W 3 is nitrogen; x is 2-6;
  • y is 1-6;
  • A is phenyl, which is unsubstituted or once or twice substituted by methyl, ethyl, fluoro, chloro, bromo, methoxy, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by methyl or chloro;
  • X is nitrogen, -CH or -CR 7 ; provided that
  • R is hydrogen, wherein R is ethylsulfonylethyl, methylsulfonylethyl or methylsulfony lpropyl ;
  • R 1 is acetylaminoethyl, acetylaminosulfonylpropyl, 4- acetylpiperazin-l-ylethyl, aminocarbonylethyl, amino carbony lpropyl, aminoethyl, 3- aminooxetan-3-ylmethyl, aminosulfonylpropyl, carboxyethyl,
  • dimethylaminosulfonylpropyl ethoxycarbonylethyl, ethylsulfonylethyl, ethylsulfonylpropyl, hydroxyethylaminopropyl, hydroxypropyl, methoxycarbonylaminopropyl,
  • methylsulfonylphenylmethyl 4-(methylsulfonyl)piperazin- 1 -ylethyl, methylsulfonylpropyl, oxetan-3-ylethyl, oxetan-3-ylmethyl, piperazin-l-ylethyl, piperazin-l-ylsulfonylpropyl, thietan-
  • IC and R J are hydrogen or deuterium simultaneously;
  • R 4 and R 5 with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl or cyclopentyl;
  • R 6 is hydrogen, fluoro, chloro or bromo
  • W 1 is nitrogen, -CH or -CF
  • W 2 is -CH or nitrogen
  • W 3 is -CH or nitrogen; provided that at most one of W 1 , W 2 and W 3 is nitrogen;
  • Another embodiment of present invention is (iv) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein A is phenyl, which is unsubstituted or once or twice substituted by d- 6 alkyl, Ci ⁇ alkoxy, halogen, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by Ci- 6 alkyl or halogen;
  • X is nitrogen, -CH or -CR 7 ; provided that
  • R 1 is hydrogen, wherein R 7 is Ci. 6 alkylsulfonyl-C y H 2y -;
  • R 1 is Ci -6 alkylsulfonylphenyl-C y H 2y -, thietan-3-yl-C y H 2y -, dioxothietan-3-yl-C y H 2y -, oxetan-3-yl-C y H 2y -, aminooxetan-3-yl-C x H 2x -, hydroxy-C x H 2x -, C ⁇ .
  • R 9 is Ci -6 alkoxy, amino, hydroxy, cycloalkylsulfonylamino
  • R and R J are hydrogen or deuterium simultaneously
  • R 4 and R 5 with the carbon atom to which they are attached, form cycloalkyl
  • R 6 is hydrogen
  • W 1 is -CH
  • W is nitrogen
  • W 3 is -CH
  • x 2-6;
  • y is 1-6.
  • A is phenyl, which is unsubstituted or once or twice substituted by methyl, ethyl, fluoro, chloro, bromo, methoxy, trifluoromethyl or cyano; or pyridinyl; which is unsubstituted or once substituted by methyl or chloro;
  • X is nitrogen, -CH or -CR 7 ; provided that
  • R 1 is hydrogen, wherein R 7 is methylsulfonylethyl or
  • R 1 is acetylaminoethyl, acetylaminosulfonylpropyl, 4- acetylpiperazin-l-ylethyl, aminocarbonylethyl, aminocarbonylpropyl, aminoethyl, 3- aminooxetan-3-ylmethyl, aminosulfonylpropyl, carboxyethyl,
  • cyclopropylsulfonylaminocarbonylethyl cyclopropylsulfonylamino(methyl)carbonylethyl, cyclopropylsulfonylethyl, cyclopropylsulfonylpropyl, dimethylaminosulfonylethyl, dimethylaminosulfonylpropyl, ethoxycarbonylethyl, ethylsulfonylethyl, ethylsulfonylpropyl, hydroxyethylaminopropyl, hydroxypropyl, methoxycarbonylaminopropyl,
  • R 2 and R 3 are hydrogen or deuterium simultaneously;
  • R 4 and R 5 with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl or cyclopentyl;
  • R 6 is hydrogen
  • W 1 is -CH
  • W 2 is nitrogen
  • W 3 is -CH.
  • Still further embodiment of present invention is (vi) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
  • A is phenyl, which is unsubstituted or once or twice substituted by Ci -6 alkyl, Ci_ 6 alkoxy, halogen, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by Ci. alkyl or halogen;
  • X is nitrogen, -CH or -CR 7 ; provided that
  • R 1 when X is -CR 7 , R 1 is hydrogen, wherein R 7 is Ci- alkylsulfonyl-C y H 2y - when X is nitrogen or -CH, R 1 is Ci -6 alkylsulfonylphenyl-C y H 2y -, thietan-3-yl-C y H 2y -, dioxothietan-3-yl-C y H 2y -, oxetan-3-yl-C y H 2y -, aminooxetan-3-yl-C x H 2x -, hydroxy-C x H 2x -, Ci.
  • R 9 is Ci- alkoxy, amino, hydroxy, cycloalkylsulfonylamino,
  • R and R are hydrogen or deuterium simultaneously
  • R 4 and R 5 with the carbon atom to which they are attached, form cyclopropyl
  • R 6 is hydrogen
  • W 1 is -CH
  • W is nitrogen
  • W 3 is -CH
  • x 2-6;
  • y is 1-6.
  • More further embodiment of present invention is (vii) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
  • A is phenyl, which is unsubstituted or once or twice substituted by methyl, ethyl, fluoro, chloro, bromo, methoxy, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by methyl or chloro;
  • X is nitrogen, -CH or -CR 7 ; provided that
  • R 1 is hydrogen, wherein R 7 is methylsulfonylethyl or
  • R 1 is acetylaminoethyl, acetylaminosulfonylpropyl, 4- acetylpiperazin-l-ylethyl, aminocarbonylethyl, aminocarbonylpropyl, aminoethyl, 3- aminooxetan-3-ylmethyl, aminosulfonylpropyl, carboxy ethyl,
  • dimethylaminosulfonylpropyl ethoxycarbonylethyl, ethylsulfonylethyl, ethylsulfonylpropyl, hydroxyethylaminopropyl, hydroxypropyl, methoxycarbonylaminopropyl,
  • R z and R J are hydrogen or deuterium simultaneously;
  • R 4 and R 5 with the carbon atom to which they are attached, form cyclopropyl
  • R 6 is hydrogen
  • W 1 is -CH
  • W 3 is -CH.
  • Still further embodiment of present invention is (viii) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
  • A is phenyl or pyridinyl, which is once substituted by halogen
  • X is -CH
  • R 1 is Ci- 6 alkylsulfonyl-C y H 2y -;
  • R 2 is hydrogen
  • R is hydrogen
  • R 4 and R 5 with the carbon atom to which they are attached, form cyclobutyl or cyclopentyl;
  • R 6 is hydrogen
  • W 1 is -CH
  • W 2 is nitrogen
  • W 3 is -CH
  • y is 1-6.
  • More further embodiment of present invention is (ix) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
  • X is -CH
  • R 1 is methylsulfonylethyl or methylsulfonylpropyl
  • R is hydrogen
  • R 3 is hydrogen
  • R 4 and R 5 with the carbon atom to which they are attached, form cyclobutyl or cyclopentyl;
  • R 6 is hydrogen;
  • W ! is -CH
  • W 2 is nitrogen
  • W 3 is -CH.
  • Another embodiment of present invention is (x) a compound of formula I or a
  • A is phenyl or pyridinyl, which is once substituted by halogen
  • X is nitrogen, -CH or -CR 7 ; provided that
  • R 1 is hydrogen, wherein R 7 is Ci.6alkylsulfonyl-CyH 2 y-;
  • R 1 is Ci, 6 alkylsulfonyl-C y H 2y - or aminocarbonyl-C y H 2y -;
  • R is hydrogen
  • R 3 is hydrogen
  • R 4 and R 5 with the carbon atom to which they are attached, form cycloalkyl
  • R 6 is hydrogen or halogen
  • W 1 is nitrogen or -CR 12 , wherein R 12 is hydrogen or halogen;
  • W 2 is -CH
  • W 3 is -CH or nitrogen; provided that W 1 and W 3 are not nitrogen simultaneously;
  • x 2-6;
  • y is 1-6.
  • X is nitrogen, -CH or -CR 7 ; provided that
  • R 1 is ethylsulfonylethyl, methylsulfonylethyl,
  • R is hydrogen
  • R is hydrogen
  • R > 4 4 and R 5 , with the carbon atom to which they are attached, form cyclopropyl
  • R 6 is hydrogen, fluoro, chloro or bromo
  • W is nitrogen, -CH or -CF
  • W 2 is -CH
  • W 3 is -CH or nitrogen
  • the single dose PK in male ICR mouse was performed to assess their pharmacokinetic properties.
  • Two groups of animals were dosed via either bolus intravenous (IV) or oral gavage (PO) of the respective compound.
  • the animals for oral administration were fasted overnight prior to dosing and food was resumed 4 hours postdose.
  • Blood samples (approximately 400 ⁇ ,) were collected via cardiac puncture after euthanasia by carbon dioxide inhalation at 2 minutes, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, and 24 hours postdose for IV group, and at 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, and 24 hours postdose for PO group.
  • Blood samples were placed into tubes containing sodium heparin and centrifuged at 8000 rpm for 6 minutes at 4°C to separate plasma from the samples.
  • AUC ( o- t) area under the curve from 0 to t hour;
  • IV intravenous
  • the compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R 1 to R 6 , W 1 to W 3 , A and X are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.
  • Hydroxymethyl indole IVa can be prepared by reduction of Ci ⁇ alkyl ester Ila.
  • the conversion can be carried out by treating Ci -6 alkyl ester Ila with lithium aluminum hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours.
  • Sulfone Via can be prepared by coupling of hydroxymethyl indole IVa and (C ⁇ .
  • reaction can be carried out with a suitable base such as cesium carbonate in a suitable organic solvent such as acetonitrile or N,N-dimethylformamide at a temperature between room temperature and 50 °C for several hours.
  • Intermediate Vila can be prepared by treating hydroxy Via with thionyl chloride or methanesulfonyl chloride.
  • L 3 is chloride
  • the reaction can be carried out by treating hydroxy Via with thionyl chloride in dichloromethane at a temperature between room temperature and 60 °C for 30 minutes to several hours.
  • the reaction can be carried out by treating hydroxy Via with methanesulfonyl chloride in the presence of an organic base such as triethylamine or diisopropylethylamine in dichloromethane at a temperature between 0 °C and room temperature for one to several hours.
  • an organic base such as triethylamine or diisopropylethylamine in dichloromethane at a temperature between 0 °C and room temperature for one to several hours.
  • Compound of interest Iaa can be prepared by Mitsunobu reaction of hydroxy Via and amide III.
  • the reaction can be carried out in the presence of a phosphine reagent such as triphenylphosphine or tributylphosphine, and an azidocarbonyl reagent such as diethyl azodicarboxylate, diisopropyl azodicarboxylate, l, l-(azodicarbonyl)dipiperidine or ⁇ , ⁇ , ⁇ , ⁇ - tetramethylazodicarboxamide in an inert organic solvent such as tetrahydrofuran, diethyl ether, acetonitrile or toluene at a temperature between room temperature and 80 °C for several hours.
  • a phosphine reagent such as triphenylphosphine or tributylphosphine
  • an azidocarbonyl reagent such as diethyl azodicar
  • Compound of interest Iaa can also be prepared by reaction of intermediate Vila and amide III.
  • the reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium fert-butoxide in an organic solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 0 °C to room temperature for one to several hours.
  • a base such as cesium carbonate, sodium hydride or sodium fert-butoxide
  • organic solvent such as acetonitrile or N,N- dimethylformamide
  • X 1 is chloro, bromo, iodo, 4-methylbenzenesulfonate or hydroxy
  • L is alkyl
  • L 3 is chloro or -OS0 2 CH 3 .
  • N-Substituted indole Villa can be prepared by reaction of Ila and Vb.
  • X 1 is chloro, bromo, iodo or 4-methylbenzenesulfonate
  • the reaction can be carried out in the presence of a base such as potassium carbonate or cesium carbonate in a suitable solvent such as acetonitrile or N,N-dimethylformamide at a temperature between 70 °C and 100 °C for several hours.
  • the reaction can be carried out in the presence of a phosphine reagent such as triphenylphosphine or tributylphosphine and an azidocarbonyl reagent such as diethyl azodicarboxylate, diisopropyl azodicarboxylate, l,l-(azodicarbonyl)dipiperidine or ⁇ , ⁇ , ⁇ , ⁇ - tetramethylazodicarboxamide in an inert organic solvent such as tetrahydrofuran, diethyl ether, acetonitrile or toluene at a temperature between room temperature and 80 °C for several hours.
  • a phosphine reagent such as triphenylphosphine or tributylphosphine
  • an azidocarbonyl reagent such as diethyl azodicarboxylate, diisopropyl azodicarboxylate, l,l-(azodicarbonyl)
  • Hydroxy VIb can be prepared by reduction of Ci-6alkyl ester Villa in the presence of lithium aluminum hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours.
  • Intermediate Vllb can be prepared by treating hydroxy VIb with thionyl chloride or methanesulfonyl chloride.
  • L is chloro
  • the reaction can be carried out by treating hydroxy Via with thionyl chloride in dichloromethane at a temperature between room temperature and 60 °C for 30 minutes to several hours.
  • L 3 is methanesulfonate
  • the reaction can be carried out by treating hydroxy Via with methanesulfonyl chloride in the presence of an organic base such as triethylamine or diisopropylethylamine in dichloromethane at a temperature between 0 °C and room temperature for one to several hours.
  • Compound of interest lab can be prepared by reaction of intermediate Vllb and amide III.
  • the reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium teri-butoxide in an organic solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
  • a base such as cesium carbonate, sodium hydride or sodium teri-butoxide
  • organic solvent such as acetonitrile or N,N- dimethylformamide
  • X 2 is chloro, bromo, iodo or 4-methylbenzenesulfonate
  • L is C ⁇ e alkyl
  • N-protected indole IX can be prepared by reaction of indole Ila and benzenesulfonyl chloride. The reaction can be carried out in the presence of sodium hydride in N,N- dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
  • Hydroxy Xa can be prepared by reduction of ester IX in the presence of lithium aluminum hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours.
  • Chloride XI can be prepared by treating hydroxy Xa with thionyl chloride. The reaction can be carried out in dichloromethane at a temperature between room temperature and 60 °C for 30 minutes to several hours.
  • Compound XII can be prepared by reaction of chloride XI and amide III.
  • the reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium tert- butoxide in an organic solvent such as acetonitrile or N,N-dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
  • a base such as cesium carbonate, sodium hydride or sodium tert- butoxide
  • organic solvent such as acetonitrile or N,N-dimethylformamide
  • Key intermediate Xllla can be prepared by deprotection of benzenesulfonyl XII.
  • the reaction can be carried out in the presence of tetrabutylammonium fluoride in tetrahydrofuran at room temperature for several hours.
  • Compound of interest lac can be prepared by substitution reaction of intermediate Xllla and intermediate Vc.
  • the reaction can be carried out in the presence of a base such as potassium carbonate or cesium carbonate in a suitable solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 70 °C and 100 °C for several hours.
  • a base such as potassium carbonate or cesium carbonate
  • a suitable solvent such as acetonitrile or N,N- dimethylformamide
  • X 2 is chloro, bromo, iodo or 4-met ylbenzenesulfonate
  • L 3 is chloro or -OS0 2 CH 3 .
  • Silyloxy XV can be prepared by reaction of hydroxy IVa and tert- butyl(chloro)dimethylsilane. The reaction can be carried out in the presence of imidazole in dichloromethane at room temperature for several hours.
  • N-Substituted indole XVI can be prepared by substitution reaction of indole XV and intermediate Vc.
  • the reaction can be carried out in the presence of a base such as potassium carbonate or cesium carbonate in a suitable solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 70 °C and 100 °C for several hours.
  • Hydroxy VIb can be prepared by deprotection of silyloxy XVI.
  • the reaction can be carried out by treating silyloxy XVI with tetrabutylammonium fluoride in tetrahydrofuran at room temperature for several hours.
  • L 1 is C ⁇ alkyl.
  • ethylsulfanyl XVII can be prepared by reaction of indole Ila and bromide Vd and then followed by the reaction with sodium methanethiolate.
  • the reaction of indole Ila and bromide Vd can be carried out in the presence of a base such as potassium carbonate or cesium carbonate in a suitable solvent such as acetone, acetonitrile or N, N-dimethylformamide at a temperature between 55 °C and 80 °C for several hours.
  • the reaction of bromide with sodium methanethiolate can be carried out in ethanol at room temperature for several hours.
  • Hydroxymethyl indole XVIII can be prepared by reduction of ester XVII in the presence of lithium aluminum hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours.
  • ethylsulfoxide XIX can be prepared by reaction of hydroxymethyl indole XVIII and tert- butyl(chloro)dimethylsilane and then followed by oxidation of methylsulfanyl.
  • the reaction of hydroxy XVIII with tert-butyl(chloro)dimethylsilane can be carried out in the presence of 4- dimethylaminopyridine and triethylamine in dichloromethane at a temperature between 0 °C and room temperature for several hours.
  • Oxidation reaction can then be carried out with 3- chlorobenzene-l-carboperoxoic acid in dichloromethane at room temperature for several hours.
  • Trifluoroacetyl sulfonimidoyl XX can be prepared by reaction of methylsulfoxide XIX and trifluoroacetamide. The reaction can be carried out in the presence of magnesium oxide and rhodium(II) acetate in an organic solvent such as dichloromethane at room temperature for several hours or overnight. Sulfonimidoyl Vic can be generated by removal of trifluoroacetyl and 1 ⁇ 2rt-butyl(dimethyl)silyl of trifluoroacetyl sulfonimidoyl XX in the presence of
  • Chloromethyl indole VIIc can be prepared by treating hydroxy Vic with thionyl chloride. The reaction can be carried out in dichloromethane at room temperature for several hours.
  • Compound of interest lae can be prepared by reaction of chloromethyl indole VIIc and amide III.
  • the reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium teri-butoxide in an organic solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
  • a base such as cesium carbonate, sodium hydride or sodium teri-butoxide
  • organic solvent such as acetonitrile or N,N- dimethylformamide
  • Compound of interest Iaf can be prepared by acetylation of sulfonimidoyl Compound lae.
  • the reaction can be carried out by treating sulfonimidoyl lae with acyl chloride in the presence of a base such as triethylamine at room temperature for several hours.
  • Ester lag can be prepared according to Scheme 4.
  • Amide Iah can be prepared by ammonolysis of ester lag in the presence of ammonia in an organic solvent such as methanol or ethanol at a temperature about 70 °C for several days.
  • Carboxylic acid lai can be prepared by hydrolysis of ester lag.
  • the reaction can be carried out in the presence of a suitable base such as sodium hydroxide, potassium hydroxide or lithium hydroxide in a mixture of tetrahydrofuran and water at a temperature between room temperature and 80 °C for several hours.
  • a suitable base such as sodium hydroxide, potassium hydroxide or lithium hydroxide in a mixture of tetrahydrofuran and water at a temperature between room temperature and 80 °C for several hours.
  • Methyl ester Iaj can be prepared by reaction of carboxylic acid lai in methanol. The reaction can be carried out in the presence of thionyl chloride in methanol at a temperature between 50 °C and 65 °C for several hours.
  • N-(Ci -6 alkylsulfonyl)Ci- 6 alkylamide Iak can be prepared by reaction of carboxylic acid lai and sulfonamide XXI. The reaction can be carried out in the presence of N-[3- (dimethylamino)propyl]-N 1 -ethylcarbodiimide hydrochloride and 4-dimethylamiopryidine in dichloromethane at room temperature for several hours.
  • Xlllb can be prepared in analogy to XHIa in Scheme 3.
  • Bromide XXII can be prepared by reaction of Xlllb with dibromoalkane Vd.
  • the reaction can be carried out in the presence of a suitable base such as potassium carbonate or cesium carbonate in an organic solvent such as acetonitrile or acetone at a temperature between 60 °C and 80 °C for several hours to several days.
  • a suitable base such as potassium carbonate or cesium carbonate
  • an organic solvent such as acetonitrile or acetone
  • Compound of interest lam can be prepared by reaction of bromide XXII with
  • reaction can be carried out in the presence of a suitable base such as potassium carbonate or cesium carbonate and tetrabutylamine fluoride in an organic solvent such as tetrahydrofuran, acetonitrile or acetone at room temperature for several hours to several days.
  • a suitable base such as potassium carbonate or cesium carbonate and tetrabutylamine fluoride in an organic solvent such as tetrahydrofuran, acetonitrile or acetone
  • Compound of interest Ian can be prepared by reaction of bromide XXII with (3R)- pyrrolidin-3-ol.
  • the reaction can be carried out in the presence of a suitable base such as potassium carbonate or cesium carbonate in an organic solvent such as N.N-dirnethylformamide, acetonitrile or acetone at a temperature between 60 °C and 80 °C for several hours.
  • L 3 is chloro or -OS0 2 CH 3 ;
  • L 6 is C ⁇ alkyl
  • BromoCi- 6 alkyl indole XXIII can be prepared in analogy to bromide XXII in Scheme 7 by reaction of indole lib with dibromoalkane Vd.
  • (Ci. 6 alkylsufonyl)Ci -6 alkyl indole VHIb can be prepared by reaction of bromide XXIII and sodium Ci -6 alkylsulfinate XXIV. The reaction can be carried out in N,N-dimethylformamide at a temperature between 50 °C and 100 °C for several hours.
  • Hydroxymethyl indole VId can be prepared by reduction of ethyl ester VHIb in the presence of lithium aluminum hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours.
  • Intermediate Vlld can be prepared by treating hydroxy VId with thionyl chloride or methanesulfonyl chloride.
  • L 3 is chloro
  • the reaction can be carried out by treating hydroxy Vld with thionyl chloride in dichloromethane at a temperature between room temperature and 60 °C for 30 minutes to several hours.
  • L 3 is methanesulfonate
  • the reaction can be carried out by treating hydroxy VId with methanesulfonyl chloride in an organic base such as triethylamine or diisopropylethylamine in dichloromethane at a temperature between 0 °C and room
  • Compound of interest Iao can be prepared by reaction of intermediate Vlld with amide III.
  • the reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium teri-butoxide in an organic solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
  • a base such as cesium carbonate, sodium hydride or sodium teri-butoxide
  • organic solvent such as acetonitrile or N,N- dimethylformamide
  • X 3 is chloro or bromo
  • V is -C x H 2x ;
  • L 8 is hydrogen or C,_ 6 alkyl
  • Intermediate XXVI can be prepared by reaction of indole Xlllb and halide Ve.
  • the reaction can be carried out in the presence of a suitable base such as cesium carbonate, potassium carbonate or potassium rt-butoxide in an organic solvent such as acetone, acetonitrile or N,N- dimethylformamide at a temperature between room temperature and 0 °C for one to several hours.
  • Compound of interest lap can be prepared by removal of tert-b ty ⁇ carboxylate of Compound XXVI.
  • the conversion can be achieved by treating of XXVI with hydrochloride in ethyl acetate or trifluoroacetic acid in dichloromethane at room temperature for several hours.
  • L 0 is benzyl
  • Compound las can be prepared by removal of benzyl group of Compound Iaq wherein L 9 is Ci- 6 alkyl and L 10 is benzyl.
  • the conversion can be achieved by treating N-benzyl sulfonamides Iaq with concentrated sulfuric acid at 0 °C for several minutes to 1 hour.
  • Compound lar can be prepared by removal of p-methoxybenzyl group of Compound Iaq wherein both L 9 and L 10 are p-methoxybenzyl.
  • the conversion can be achieved by treating sulfonamides Iaq with trifluoroacetic acid at room temperature for several hours.
  • L 11 is -C x H 2x - or -C ⁇ -sulfonyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention provides compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, W1, W2, W3, A and X are as described herein, compositions including the compounds and methods of using the compounds.

Description

AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION
The present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to respiratory syncytial virus (RSV) inhibitors useful for treating RSV infection.
FIELD OF THE INVENTION
Respiratory Syncytial Virus (RSV) belongs to the family of Paramyxoviridae, subfamily of Pneumovirinae. The human RSV is a major cause of acute upper and lower respiratory tract infection in infants and children. Almost all children are infected by RSV at least once by age of three. Natural human immunity against RSV is incomplete. In normal adults and elder children, RSV infection is mainly associated with upper respiratory track symptoms. Severe case of RSV infection often leads to bronchiolitis and pneumonia, which requires hospitalization. High-risk factors for lower respiratory tract infections include premature birth, congenital heart disease, chronic pulmonary disease, and immunocompromised conditions. A severe infection at young age may lead to recurrent wheezing and asthma. For the elderly, RSV-related mortality rate becomes higher with advancing age.
RSV Fusion (F) protein is a surface glycoprotein on the viral envelope which, together with the G surface glycoprotein, mediates viral entry into host cell. The F protein initiates viral penetration by fusing viral and host cellular membranes and subsequently promotes viral spread after infection by melding infected cells to adjacent uninfected cells, resulting in characteristic syncytial formation. By inhibiting viral entry and spread, it is expected that treatment with chemicals described here will decrease the duration and severity of respiratory symptoms and subsequent risk of prolonged hospitalization and complications. It is also expected to limit the ability of individuals to transmit RSV within households, nursing homes and the hospital setting to other hosts potentially at high risk of complications.
FZ / 13.3.2013 There is no RSV vaccine available for human use, despite of many attempts in subunit vaccine and live-attenuated vaccine approaches. Virazole®, the aerosol form of ribavirin, is the only approved antiviral drug for treatment of RSV infection. However, it is rarely used clinically, due to limited efficacy and potential side effects. Two marketed prophylaxis antibodies were developed by Medlmmune (CA, USA).
RSV-IGIV (brand name RespiGam) is polyclonal-concentrated RSV neutralizing antibody administered through monthly infusion of 750 mg/kg in hospital (Wandstrat TL, Ann
Pharmacother. 1997 Jan; 31(l):83-8). Subsequently, the usage of RSV-IGIV was largely replaced by palivizumab (brand name Synagis®), a humanized monoclonal antibody against RSV fusion (F) protein approved for prophylaxis in high-risk infants in 1998. When administered intramuscularly at 15 mg/kg once a month for the duration of RSV season, palivizumab demonstrated 45 - 55% reduction of hospitalization rate caused by RSV infection in selected infants (Pediatrics. 1998 Sep; 102(3):531-7; Feltes TF et al, J Pediatr. 2003 Oct; 143(4):532-40). Unfortunately, palivizumab is not effective in the treatment of established RSV infection. A newer version monoclonal antibody, motavizumab, was designed as potential replacement of palivizumab but failed to show additional benefit over palivizumab in recent Phase III clinical trials (Feltes TF et al, Pediatr Res. 2011 Aug; 70(2): 186-91).
A number of small molecule RSV inhibitors have been discovered. Among them, only a few reached Phase I or II clinical trials. Arrow Therapeutics (now a group in AstraZeneca, UK) completed a five-year Phase II trial of nucleocapsid (N) protein inhibitor, RSV-604, in stem cell transplantation patients by February 2010 (www.clinicaltrials.gov), but has not released the final results. Most of other small molecules were put on hold for various reasons.
RNAi therapeutics against RSV has also been thoroughly studied. ALN-RSV01 (Alnylam Pharmaceuticals, MA, USA) is a siRNA targeting on RSV gene. A nasal spray administered for two days before and for three days after RSV inoculation decreased infection rate among adult volunteers (DeVincenzo J. et al, Proc Natl Acad Sci U S A. 2010 May 1 1 ; 107(19): 8800-5). In another Phase II trial using naturally infected lung transplantation patients, results were not sufficient for conclusion of antiviral efficacy, though certain health benefits have been observed (Zamora MR et al, Am J Respir Crit Care Med. 2011 Feb 15;183(4):531-8). Additional Phase lib clinical trials in similar patient population for ALN-RSV01 are on-going
(www.clinicaltrials.gov).
Nevertheless, safe and effective treatment for RSV disease is needed urgently. SUMMARY OF THE INVENTION
Objects of the present invention are novel compounds of formula I, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I for the treatment or prophylaxis of RS V infection.
DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS
As used herein, the term "Ci- alkyl" alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1 -butyl, 2-butyl, tert-butyl and the like. Particular "Ci-6alkyl" groups are methyl, ethyl, isopropyl and tert-butyl.
The term "CxH2x" alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 2 to 6, particularly 2 to 4 carbon atoms. Particular "CxH2x" groups are saturated, linear alkyl chain containing 2 to 6, particularly 2 to 4 carbon atoms.
The term "CyH2y" alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms. Particular "CyH2y" groups are saturated, linear alkyl chain containing 1 to 6, particularly 1 to 4 carbon atoms.
The term "cycloalkyl", alone or in combination, refers to a saturated carbon ring containing from 3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Particular "cycloalkyl" groups are cyclopropyl, cyclopentyl and cyclohexyl.
The term "Ci-6alkoxy" alone or in combination signifies a group Ci- alkyl-0-, wherein the "Ci-6alkyl" is as defined above; for example methoxy, ethoxy, propoxy, wo-propoxy, n-butoxy, wo-butoxy, 2-butoxy, tert-butoxy and the like. Particular "Ci- alkoxy" groups are methoxy and ethoxy and more particularly methoxy.
The term "cyano" alone or in combination refers to the group -CN.
The term "amino", alone or in combination, refers to primary (-NH2), secondary (-NH-) or
/
— N
tertiary amino ( ).
The term "halogen" means fluorine, chlorine, bromine or iodine. Halogen is particularly fluorine, chlorine or bromine.
The term "hydroxy" alone or in combination refers to the group -OH. The term "carbonyl" alone or in combination refers to the group -C(O)-.
The term "sulfonyl" alone or in combination refers to the group -S(0)2-.
The term "sulfinyl" alone or in combination refers to the group -S(O)-.
The compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Acid-addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as -toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide. The chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of
compounds. It is for example described in Bastin R.J., et ah, Organic Process Research &
Development 2000, 4, 427-435; or in Ansel, H., et ah, In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (1995), pp. 196 and 1456-1457. Particular are the sodium salts of the compounds of formula I.
Compounds of the general formula I which contain one or several chiral centers can either be present as racemates, diastereomeric mixtures, or optically active single isomers. The racemates can be separated according to known methods into the enantiomers. Particularly, diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.
INHIBITORS OF RSV FUSION PROTEIN
The present invention provides (i) novel compounds having the general formula I:
Figure imgf000007_0001
wherein
A is phenyl or pyridinyl, which is unsubstituted or substituted by Ci-6alkyl, Ci-6alkoxy, halogen, trifluoromethyl or cyano;
X is nitrogen, -CH or -CR ; provided that
when X is -CR 7 , R 1 i*s hydrogen, wherein R 7 i ·s C1-6alkylsulfonyl-CyH2y-;
when X is nitrogen or -CH, R1 is Ci-6alkylsulfonylphenyl-CyH2y-, thietan-3-yl-CyH2y-, dioxothietan-3-yl-CyH2y-, oxetan-3-yl-CyH2y-, aminooxetan-3-yl-CxH2x-, hydroxy-CxH2x-, Ci_
Figure imgf000007_0002
C1-6alkyl
6alkylsufmyl-CyH2y-, trifluoromethyl-CyH2y-aminocarbonyl-0-CxH2x-, or
Figure imgf000007_0003
; or -CyH2y-S02R8, wherein R8 is C1-6alkyl, cycloalkyl, Ci_
6alkylcarbonylamino Ci-6alkylamino diCi-6alkylamino, amino, morpholinyl, pyrrolidinyl,
piperazinyl,
Figure imgf000007_0004
; or -CyH2y-CORy, wherein R9 is Ci-6alkoxy, amino, hydroxy, cycloalkylsulfonylamino,
cycloalkylsulfonylamino(Ci-6alkyl) or Ci-6alkylsulfonylamino(Ci-6alkyl); or -CxH2x-NRI0Rn, wherein R10 is hydrogen, R11 is hydrogen, Ci-6alkoxycarbonyl, Ci-6alkylcarbonyl, Ci_
Figure imgf000007_0005
6alkylsulfonyl, hydroxy-CxH2x- or , or R and R , together with the nitrogen atom, to which they are attached, form
Figure imgf000008_0001
Figure imgf000008_0002
, which is unsubstituted or substituted by hydroxy, Q.
6alkylcarbonyl or Ci-6alkylsulfonyl;
2 3
R and RJ are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cycloalkyl;
R6 is hydrogen or halogen;
1 12 1
W is nitrogen or -CR , wherein R is hydrogen or halogen;
W2 is -CH or nitrogen;
3 * · 1 2 3
W is -CH or nitrogen; provided that at most one of W , W and W is nitrogen;
x is 2-6;
y is 1-6;
or pharmaceutically acceptable salt thereof.
Another embodiment of present invention is (ii) a compound of formula I, wherein
A is phenyl, which is unsubstituted or once or twice substituted by Ci-6alkyl, Ci-6alkoxy, halogen, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by Ci_
6alkyl or halogen;
X is nitrogen, -CH or -CR7; provided that
7 1 7
when X is -CR , R is hydrogen, wherein R is Ci- alkylsulfonyl-CyH2y-;
when X is nitrogen or -CH, R1 is Ci-6alkylsulfonylphenyl-CyH2y-, thietan-3-yl-CyH2y-, dioxothietan-3-yl-CyH2y-, oxetan-3-yl-CyH2y-, aminooxetan-3-yl-CxH2x-, hydroxy-CxH2x-, d.
Figure imgf000008_0003
C alkvl
6alkylsufinyl-CyH2y-, trifluoromethyl-CyH2y-aminocarbonyl-0-CxH2x-, 1-6 y or
Figure imgf000009_0001
C1-6alkyl
; or -CyH2y-S02R , wherein R is Ci-6alkyl, cycloalkyl, Ci
6alkylcarbonylamino, Ci-6alkylamino diCi-ealkylamino, amino, morpholinyl, pyrrolidinyl,
piperazinyl,
Figure imgf000009_0002
or or -CyH2y-CORy wherein R is
Figure imgf000009_0003
amino, hydroxy, cycloalkylsulfonylamino,
cycloalkylsulfonylamino(Ci-6alkyl) or Ci-6alkylsulfonylamino(Ci-6alkyl); or -CxH2x-lSl wherein R10 is hydrogen, R1 1 is hydrogen, Ci-6alkoxycarbonyl, Ci_6alkylcarbonyl, C\.
Figure imgf000009_0004
6alkylsulfonyl, hydroxy-CxH2x- or , or R10 and R1 1, together with the nitrogen atom,
Figure imgf000009_0005
to which they are attached, form
Figure imgf000009_0006
alkyl
Figure imgf000009_0007
R2 and R3 are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cycloalkyl;
R6 is hydrogen or halogen;
W1 is nitrogen or -CR12, wherein R12 is hydrogen or halogen;
W2 is -CH or nitrogen;
W3 is -CH or nitrogen; provided that at most one of W1 , W2 and W3 is nitrogen; x is 2-6;
y is 1-6;
or pharmaceutically acceptable salt thereof.
Further embodiment of present invention is (iii) a compound of formula I, wherein
A is phenyl, which is unsubstituted or once or twice substituted by methyl, ethyl, fluoro, chloro, bromo, methoxy, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by methyl or chloro;
X is nitrogen, -CH or -CR7; provided that
7 1 * 7
when X is -CR , R is hydrogen, wherein R is ethylsulfonylethyl, methylsulfonylethyl or methylsulfony lpropyl ;
when X is nitrogen or -CH, R1 is acetylaminoethyl, acetylaminosulfonylpropyl, 4- acetylpiperazin-l-ylethyl, aminocarbonylethyl, amino carbony lpropyl, aminoethyl, 3- aminooxetan-3-ylmethyl, aminosulfonylpropyl, carboxyethyl,
cyclopropylsulfonylaminocarbonylethyl, cyclopropylsulfonylamino(methyl)carbonylethyl, cyclopropylsulfonylethyl, cyclopropylsulfonylpropyl, dimethylaminosulfonylethyl,
dimethylaminosulfonylpropyl, ethoxycarbonylethyl, ethylsulfonylethyl, ethylsulfonylpropyl, hydroxyethylaminopropyl, hydroxypropyl, methoxycarbonylaminopropyl,
methoxycarbonylpropyl, methylaminosulfonylpropyl, methylsulfinylpropyl,
methylsulfonylamino(methyl)carbonylethyl, methylsulfonylaminoethyl,
methylsulfonylaminopropyl, methylsulfonylbutyl, methylsulfonylethyl,
methylsulfonylphenylmethyl, 4-(methylsulfonyl)piperazin- 1 -ylethyl, methylsulfonylpropyl, oxetan-3-ylethyl, oxetan-3-ylmethyl, piperazin-l-ylethyl, piperazin-l-ylsulfonylpropyl, thietan-
3-ylethyl, (2,2,2-trifluoroethyl)carbamoyloxypropyl,
Figure imgf000010_0001
Figure imgf000010_0002
Figure imgf000011_0001
2 3
IC and RJ are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl or cyclopentyl;
R6 is hydrogen, fluoro, chloro or bromo;
W1 is nitrogen, -CH or -CF;
W2 is -CH or nitrogen;
W3 is -CH or nitrogen; provided that at most one of W1, W2 and W3 is nitrogen;
or pharmaceutically acceptable salt thereof.
Another embodiment of present invention is (iv) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein A is phenyl, which is unsubstituted or once or twice substituted by d-6alkyl, Ci^alkoxy, halogen, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by Ci- 6alkyl or halogen;
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is Ci.6alkylsulfonyl-CyH2y-;
when X is nitrogen or -CH, R1 is Ci-6alkylsulfonylphenyl-CyH2y-, thietan-3-yl-CyH2y-, dioxothietan-3-yl-CyH2y-, oxetan-3-yl-CyH2y-, aminooxetan-3-yl-CxH2x-, hydroxy-CxH2x-, C\.
NH
CyH2y-S
6alkylsufinyl-CyH2y-, trifluoromethyl-CyH2y-aminocarbonyl-0-CxH2x- C1-6alkyl or
Figure imgf000012_0001
Ci-6alky' ; or -CyH2y-S02R8, wherein R8 is Ci-6alkyl, cycloalkyl, Ci_
6alkylcarbon lamino, Ci-6alkylamino, diCi-6alkylamino, amino, morpholinyl, pyrrolidinyl,
piperazinyl,
Figure imgf000012_0002
wherein R9 is Ci-6alkoxy, amino, hydroxy, cycloalkylsulfonylamino
cycloalkylsulfonylamino(Ci-6alkyl) or Ci-6alkylsulfonylamino( -6alkyl); or -CxH2x-NR 1i0UrR. l l wherein R10 is hydrogen, R1 1 is hydrogen, Ci-6alkoxycarbonyl,
Figure imgf000012_0003
C
Figure imgf000012_0004
6alkylsulfonyl, hydroxy-CxH2x- or and R1 1, together with the nitrogen atom,
to which they are attached, form
Figure imgf000012_0005
Figure imgf000013_0001
2 3
R and RJ are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cycloalkyl;
R6 is hydrogen;
W1 is -CH;
W is nitrogen;
W3 is -CH;
x is 2-6;
y is 1-6.
Further embodiment of present invention is (v) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
A is phenyl, which is unsubstituted or once or twice substituted by methyl, ethyl, fluoro, chloro, bromo, methoxy, trifluoromethyl or cyano; or pyridinyl; which is unsubstituted or once substituted by methyl or chloro;
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is methylsulfonylethyl or
methylsulfonylpropyl ;
when X is nitrogen or -CH, R1 is acetylaminoethyl, acetylaminosulfonylpropyl, 4- acetylpiperazin-l-ylethyl, aminocarbonylethyl, aminocarbonylpropyl, aminoethyl, 3- aminooxetan-3-ylmethyl, aminosulfonylpropyl, carboxyethyl,
cyclopropylsulfonylaminocarbonylethyl, cyclopropylsulfonylamino(methyl)carbonylethyl, cyclopropylsulfonylethyl, cyclopropylsulfonylpropyl, dimethylaminosulfonylethyl, dimethylaminosulfonylpropyl, ethoxycarbonylethyl, ethylsulfonylethyl, ethylsulfonylpropyl, hydroxyethylaminopropyl, hydroxypropyl, methoxycarbonylaminopropyl,
methoxycarbonylpropyl, methylaminosulfonylpropyl, methylsulfinylpropyl,
methylsulfonylamino(methyl)carbonylethyl, methylsulfonylaminoethyl, methylsulfonylaminopropyl, methylsulfonylbutyl, methylsulfonylethyl,
methylsulfonylphenylmethyl, 4-(methylsulfonyl)piperazin-l -yl ethyl, methylsulfonylpropyl, oxetan-3-ylethyl, oxetan-3-ylmethyl, piperazin-l-ylethyl, piperazin-l-ylsulfonylpropyl, thietan- N
3-ylethyl, (2,2,2-trifluoroethyl)carbamoyloxypropyl,
Figure imgf000014_0001
Figure imgf000014_0002
R2 and R3 are hydrogen or deuterium simultaneously; R4 and R5, with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl or cyclopentyl;
R6 is hydrogen;
W1 is -CH;
W2 is nitrogen;
W3 is -CH.
Still further embodiment of present invention is (vi) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
A is phenyl, which is unsubstituted or once or twice substituted by Ci-6alkyl, Ci_6alkoxy, halogen, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by Ci. alkyl or halogen;
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is Ci- alkylsulfonyl-CyH2y- when X is nitrogen or -CH, R1 is Ci-6alkylsulfonylphenyl-CyH2y-, thietan-3-yl-CyH2y-, dioxothietan-3-yl-CyH2y-, oxetan-3-yl-CyH2y-, aminooxetan-3-yl-CxH2x-, hydroxy-CxH2x-, Ci.
O
NH
— CyH2y— S
C1-6alkyl alkylsufinyl-CyH2y-, trifluoromethyl-CyH2y-aminocarbonyl-0-CxH2x-, or
Figure imgf000015_0001
ci-6alky! ; or -CyH2y-S02R8, wherein R8 is Ci-6alkyl, cycloalkyl, Ci.
6alkylcarbonylamino, Ci-6alkylamino diCi- alkylamino, amino, morpholinyl, pyrrolidinyl,
piperazinyl,
Figure imgf000015_0002
,
wherein R9 is Ci- alkoxy, amino, hydroxy, cycloalkylsulfonylamino,
cycloalkylsulfonylamino(Ci.6alkyl) or Ci-6alkylsulfonylamino(Ci-6alkyl); or -CxH2x-NR10Rn, wherein R10 is hydrogen, R11 is hydrogen, Ci-6alkoxycarbonyl, Ci-6alkylcarbonyl, Ci_
Figure imgf000016_0001
ealkylsulfonyl, hydroxy-CxH2x- or , or R10 and R11, together with the nitrogen atom,
to which the are attached, form
Figure imgf000016_0002
alkyl
Figure imgf000016_0003
2 3
R and R are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cyclopropyl;
R6 is hydrogen;
W1 is -CH;
W is nitrogen;
W3 is -CH;
x is 2-6;
y is 1-6.
More further embodiment of present invention is (vii) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
A is phenyl, which is unsubstituted or once or twice substituted by methyl, ethyl, fluoro, chloro, bromo, methoxy, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by methyl or chloro;
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is methylsulfonylethyl or
methylsulfonylpropyl;
when X is nitrogen or -CH, R1 is acetylaminoethyl, acetylaminosulfonylpropyl, 4- acetylpiperazin-l-ylethyl, aminocarbonylethyl, aminocarbonylpropyl, aminoethyl, 3- aminooxetan-3-ylmethyl, aminosulfonylpropyl, carboxy ethyl,
cyclopropylsulfonylaminocarbonylethyl, cyclopropylsulfonylamino(methyl)carbonylethyl, cyclopropylsulfonylethyl, cyclopropylsulfonylpropyl, dimethylaminosulfonylethyl,
dimethylaminosulfonylpropyl, ethoxycarbonylethyl, ethylsulfonylethyl, ethylsulfonylpropyl, hydroxyethylaminopropyl, hydroxypropyl, methoxycarbonylaminopropyl,
methoxycarbonylpropyl, methylaminosulfonylpropyl, methylsulfmylpropyl,
methylsulfonylamino(methyl)carbonylethyl, methylsulfonylaminoethyl,
methylsulfonylaminopropyl, methylsulfonylbutyl, methylsulfonylethyl,
methylsulfonylphenylmethyl, 4-(methylsulfonyl)piperazin- 1 -yl ethyl, methylsulfonylpropyl, oxetan-3-ylethyl, oxetan-3-ylmethyl, piperazin-l-ylethyl, piperazin-l-ylsulfonylpropyl, thietan-
-ylethyl, (2,2,2-trifluoroethyl)carbamoyloxypropyl,
Figure imgf000017_0001
Figure imgf000017_0002
Figure imgf000018_0001
2 3
Rz and RJ are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cyclopropyl;
R6 is hydrogen;
W1 is -CH;
W2 is nitrog
W3 is -CH.
Still further embodiment of present invention is (viii) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
A is phenyl or pyridinyl, which is once substituted by halogen;
X is -CH;
R1 is Ci-6alkylsulfonyl-CyH2y-;
R2 is hydrogen;
R is hydrogen;
R4 and R5, with the carbon atom to which they are attached, form cyclobutyl or cyclopentyl;
R6 is hydrogen;
W1 is -CH;
W2 is nitrogen;
W3 is -CH;
y is 1-6.
More further embodiment of present invention is (ix) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000019_0001
X is -CH;
R1 is methylsulfonylethyl or methylsulfonylpropyl;
R is hydrogen;
R3 is hydrogen;
R4 and R5, with the carbon atom to which they are attached, form cyclobutyl or cyclopentyl; R6 is hydrogen;
W! is -CH;
W2 is nitrogen;
W3 is -CH.
Another embodiment of present invention is (x) a compound of formula I or a
pharmaceutically acceptable salt thereof, wherein
A is phenyl or pyridinyl, which is once substituted by halogen;
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is Ci.6alkylsulfonyl-CyH2y-;
when X is nitrogen or -CH, R1 is Ci,6alkylsulfonyl-CyH2y- or aminocarbonyl-CyH2y-;
R is hydrogen;
R3 is hydrogen;
R4 and R5, with the carbon atom to which they are attached, form cycloalkyl;
R6 is hydrogen or halogen;
W1 is nitrogen or -CR12, wherein R12 is hydrogen or halogen;
W2 is -CH;
W3 is -CH or nitrogen; provided that W1 and W3 are not nitrogen simultaneously;
x is 2-6;
y is 1-6.
Further embodiment of present invention is (xi) a compound of formula I or a
pharmaceutically acceptable salt thereof, wherein
Figure imgf000020_0001
X is nitrogen, -CH or -CR7; provided that
when X is -CR 7 , R 1 i*s hydrogen, wherein R 7 is ethylsulfonylethyl;
when X is nitrogen or -CH, R1 is ethylsulfonylethyl, methylsulfonylethyl,
methylsulfonylpropyl or aminocarbonylethyl;
R is hydrogen;
R is hydrogen;
R > 44 and R5, with the carbon atom to which they are attached, form cyclopropyl;
R6 is hydrogen, fluoro, chloro or bromo;
W is nitrogen, -CH or -CF;
W2 is -CH;
W3 is -CH or nitrogen;
provided that W and W are not nitrogen simultaneously.
Particular compounds of formula I, including their activity data, NMR data and MS data are summarized in the following Table 1 and 2.
Table 1 : Structure, name and activity data of particular compounds
CPE
Example Long
Structure Name
No. EC50
(μΜ)
r J ° 1 '-({ 1 -[2-(Methylsulfonyl)ethyl]-lH-
1 -1 indol-2-yl } methyl)spiro [cyclopropane - 0.22 l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one r7
Figure imgf000021_0001
l '-({7-Chloro-l-[2- (methylsulfonyl)ethyl] - 1 H-indol-2--7 0.164 yl } methyljspiro [cyclopropane- 1,3'-
Or* pyrrolo[2,3-c]pyridin]-2'(rH)-one
l'-({5-Ethyl-l -[2- (methylsulfonyl)ethyl] - 1 H-indol-2--8 0.22 yl }methyl)spiro [cyclopropane- 1 ,3'- pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one
l'-({5,7-Difluoro-l-[2- (methylsulfonyl)ethyl]-lH-indol-2--9 0.024 yl } methyl)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'( 1 'H)-one
1 '-( { 1 - [2-(Methylsulfonyl)ethyl] -5- (trifluoromethyl)- 1 H-indol-2--10 0.557 yl } methyl)spiro [cyclopropane- 1 ,3'- pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one
l'-({5,6-Difluoro-l-[2- (methylsulfonyl)ethyl] - 1 H-indol-2--1 1 0.935 yl } methyl)spiro [cyclopropane- 1 ,3'- pyrrolo [2,3-c]pyridin] -2'( 1 'H)-one l '-({5-Chloro-7-fluoro-l-[2- (methylsulfonyl)ethyl]- 1 H-indol-2--12 0.0034 yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one
l'-({5-Methyl-l-[2- (methylsulfonyl) ethyl]- 1 H-indol-2--13 0.009 yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(l'H)-one
0.
1 '-({ 1 -[2-(Methylsulfonyl)ethyl]- 1H- pyrrolo [3 ,2-c]pyridin-2--14 0.0778 yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one
l'-({5-Chloro-l-[2- (ethylsulfonyl)ethyl]-17J-indol-2--1 0.00767 yl } methyl)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l' )-one
l'-({5-Chloro-l-[2-
(ethylsulfonyl) ethyl] - 1 H-pyrrolo [2,3 --2 &]pyridin-2- 0.019 yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
l'-({5-Chloro-l-[4-
(methylsulfonyl)butyl]-lH--5 pyrrolo[3,2- )]pyridin-2- 0.0221 yl } methyl)spiro [cyclopropane- 1,3'- r pyrrolo[2,3 -c]pyridin]-2'( 1 'H)-one
l'-({5-Chloro-l-[3-
(cyclopropylsulfonyl)propyl]-lH--6 pyrrolo[3,2- )]pyridin-2- 0.029 yl}methyl)spiro[cyclopropane-l ,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one
Figure imgf000027_0001
l'-({5-Chloro-l-[4-
(methylsulfonyl)butyl]-lH--7 pyrrolo[2,3-c]pyridin-2- 0.027 yl}methyl)spiro[cyclopropane-l,3'- pyrrolo[2,3-c]pyridin]-2'(rH)-one
N-Benzyl-3-{5-chloro-2-[(2'-
7 o oxospiro[cyclopropane-l ,3'--8 pyrrolo[2,3-c]pyridin]-l'(2'H)- 0.7775 yl)methyl]-lH-pyrrolo[2,3-£]pyridin- 1 -yl } -N-methylpropane- 1 -sulfonamide l'-({5-Chloro-l-[3-
(cyclopropylsulfonyl)propyl]-lH--9 pyrrolo[2,3-c]pyridin-2- 0.0487 yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Figure imgf000028_0001
1 '-( { 5 -Chloro- 1 - [2-(thietan-3 -y l)ethy 1] -
1 H-pyrrolo [2 ,3 -c]pyridin-2--10 0.074 yl } methyl)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one
1 '-({5 -Chloro- 1-[2-( 1 ,1 - dioxidothietan-3 -y 1) ethyl] - 1 H--1 1 N- N pyrrolo[2,3-c]pyridin-2- 0.018 yl}methyl)spiro[cyclopropane-l ,3'- pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one
l'-({5-Chloro-l-[3-
(methylsulfonyl)propyl] - 1 H--12 pyrrolo[2,3-6]pyridin-2- 0.05675 yl } methyl) spiro [cyclobutane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Figure imgf000028_0002
l'-({5-Chloro-l-[3-
(methylsulfonyl)propyl]- 1H--13 pyrrolo[2,3-c]pyridin-2- 0.026 yl } methyl)spiro[cyclopropane- 1,3'- pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one
Figure imgf000029_0001
l'-({5-Chloro-l-[2-
(cyclopropylsulfonyl)ethyl]-lH--14 pyrrolo[3,2-¾]pyridin-2- 0.072 cr N ~Y yl }methyl)spiro [cyclopropane- 1,3'-
Cr pyrrolo[2,3-c]pyridin]-2'(l'H)-one
l'-({5-Chloro-l-[3-
(methylsulfonyl)propyl]- 1 H--15 pyrrolo[3,2-£]pyridin-2- 0.018 y 1 } methyl)spiro [cyclopropane- 1,3'- pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one
Figure imgf000029_0002
l'-({5-Chloro-l-[4-
(methylsulfonyl)butyl]-lH--16 pyrrolo[2,3-£]pyridin-2- 0.0549 yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
/ 0 1 '-({5-Chloro- l-[3-(l , 1 -dioxido- 1 ,2- thiazolidin-2-yl)propyl]-lH-indol-2-
7-10 0.029 yl } methyl)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one
1 '- { [5-Chloro- 1 -(3-hydroxypropyl)- lH-indol-2-
8 0.058 yljmethyl } spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one
l '-[{5-Chloro-l-[2- (methylsulfonyl)ethyl] - 1 H-indol-2-
9 0.019 yl } (2H2)methyl] spiro [cyclopropane- l ,3'-pyrrolo[2,3-c]pyridin]-2'(l 'H)-one
0
w
_v / ^ o l '-[{5-Chloro-l-[3- (methylsulfonyl)propyl]- lH-indol-2-
10 0.019 yl } (2H2)methyl] spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin] -2'( 1 'H)-one
Figure imgf000034_0001
NH
I I
0=S^
l '-({5-Chloro-l-[2-(S- methylsulfonimidoyl)ethyl]-l/7-indol--2 0.007
2-yl } methy l)spir o [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one
NH
I I
l'-({5-Chloro-l-[4-(S- methylsulfonimidoyl)butyl] - 1 H--3 pyrrolo [2,3 -b] pyridin-2- 0.074 yl } methyl) spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one
NH
I I
l'-({5-Chloro-l-[2-(S- methy 1 sul f onimi doy 1) ethyl] - 1 H--4 pyrrolo[2,3-¾]pyridin-2- 0.172 yl } methyl) spiro [cyclopropane- 1,3'- r pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one
0
N-[(2-{5-Chloro-2-[(2'-
I I
oxospiro[cyclopropane-l ,3'- pyrrolo [2,3 -c]pyridin] - 1 '(277)-
0.025 yl)methyl]-lH-indol-l- yl } ethyl)(methyl)oxido- 6- ύτ7 sulfanylidene]acetamide
Figure imgf000036_0001
0
- NH2 3-{5-Chloro-2-[(2'- oxospiro[cyclopropane- 1 ,3'--2 pyrrolo [2,3 -ijpyridin] - 1 '(2'H 0.71 1 yl)methyl]-lH-indol-l - yl}propanamide
0
NH2 4-{5-Chloro-2-[(2'- oxospiro [cyclopropane- 1 ,3'--3 0.01 1 pyrrolo[2,3-c]pyridin]-l '(2'H)- yl)methyl] - 1 H-indol- 1 -yl } butanamide
3-{5-Chloro-2-[(2'- oxospirofcyclopropane- 1 ,3'--1 pyrrolo[2,3-c]pyridin]-l '(2'H)- 1.184 yl)methyl] - 1 H-indol- 1 -yl } -N- (cyclopropylsulfonyl)propanamide
Figure imgf000037_0001
3-{5-Chloro-2-[(2'-
O /
0 oxospiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-r(2'H)--2 0.059 yl)methyl]- lH-indol- 1 -yl} -N- (cyclopropylsulfonyl)-N-
0T7 methylpropanamide o 0 3-{5-Chloro-2-[(2'- oxospiro[cyclopropane-l,3'--3 pyrrolo [2,3-c]pyridin] - 1 '(2'H)- 0.047 yl)methy 1] - 1 H-indol- 1 -yl } -JV-methyl-
Or N-(methylsulfonyl)propanamide
H
°=< 1 3-(2-{5-Chloro-2-[(2'- oxospiro[cyclopropane-l ,3'- pyrrolo[2,3-c]pyridin]-r(2'H)- 3.484 yl)methyl] -1 H-indol- 1- yl } ethyl)imidazolidine-2,4-dione
OH r-[(5-Chloro-l-{3-[(3i?)-3- hydroxypyrrolidin- 1 -yl]propyl} - 1 H-
0.544 indol-2-yl)methyl]spiro[cyclopropane- 1 ,3'-pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one
0 u
0 l'-({5-Chloro-l-[3- (ethylsulfonyl)propyl]-lH-indol-2--1 0.003 yl } methyl)spiro [cyclopropane- 1 ,3'- pyrrol o [2 , 3 -c] pyridin] -2 ' ( 1 'H) -one
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
o S-VNH N-[(3-{5-Chloro-2-[(2'- J 0 oxo spiro [cyclopropane- 1 ,3'--2 pyrrolo[2,3-c]pyridin]-l '(2'H)- 1.917 yl)methyl]- 1 H-pyrrolo [2,3 - >]pyridin- 1 -yl } propyl)sulfonyl] acetamide
JV-(2-{5-Chloro-2-[(2'- oxospiro[cyclopropane-l ,3'-
Figure imgf000042_0001
-3 pyrrolo[2,3-c]pyridin]-l '(2'H)- 0.025 yl)methyl]-lH-indol-l - yl } ethyl)acetamide
l '-[(5-Chloro-l -{2-[4- (methylsulfonyl)piperazin- 1 -yl] ethyl } --1 lH-indol-2- 0.006 yl)methyl] spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one
0
H »
N-(2-{5-Chloro-2-[(2'- oxospiro[cyclopropane-l ,3'--2 pyrrolo [2,3 -cjpyridin] - 1 '(2'H)- 0.01 15 yl)methyl]-lH-indol-l - yl } ethyl)methanesulfonamide 0
w
N-(3-{5-chloro-2-[(2'- oxospiro [cyclopropane- 1 ,3'-
27-3 pyrrolo[2,3-c]pyridin]-l '(2'H)- 0.4987 yl)methyl]-l H-indol- 1 - yl } propyl)methanesulfonamide
NH l-(2-{5-Chloro-2-[(2'- oxospiro [cyclopropane- 1 ,3'-
28 0.064
pyrrolo[2,3-c]pyridin]-l '(2'H)- yl)methyl] - 1 H-indol- 1 -yl } ethyl)urea
OH
l'-[(5-Chloro-l -{3-[(2- hydroxy ethyl) amino] propyl } - 1 H-
29 0.244 indol-2-yl)methyl] spiro [cyclopropane - 1 , 3 '-pyrrolo [2, 3 -c]pyridin] -2'( 1 'H)-one
0
Methyl (3-{5-chloro-2-[(2'- oxospiro [cyclopropane- 1 ,3'-
30 pyrrolo [2,3 -c]pyridin] - 1 '(2'H)- 0.02 yl)methyl]-l H-indol- 1 - yl}propyl)carbamate o ρ 3-{5-Chloro-2-[(2'- oxospiro[cyclopropane- 1 ,3'- pyrro lo [2 , 3 -c] pyri din] - 1 ' (2 'H)-
0.052 yl)methyl]-lH-indol-l- yl}propyl(2,2,2- trifluoroethyl)carbamate
r-o T-({6-Chloro-3-[2- (ethylsulfonyl)ethyl]-lH-indol-2-- 1 0.009 yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-0]pyridin]-2'(l'H)-one
l'-({6-Chloro-3-[2- (methylsulfonyl)ethyl]-lH-indol-2--2 0.005 yl } raethyl)spiro [cyclopropane- 1,3'- r pyrrolo[2,3-c]pyridin]-2'(l ' )-one
0 I I
J 0 l'-({6-Chloro-3-[3- (methylsulfonyl)propyl]-lH-indol-2-
0.006 yl}methyl)spiro[cyclopropane-l ,3'- 7 pyrrolo[2,3-c]pyridin]-2'(rH)-one
Figure imgf000045_0001
l'-({5-Chloro-l-[2-
(ethylsulfonyl)ethyl]-lH--5 benzimidazol-2- 0.013 yl } methyl)spiro [cyclopropane- 1,3'- r pyrrolo[2,3-c]pyridin]-2'(rH)-one
l'-({5-Chloro-l-[2-(l,l - dioxidothietan-3 -y l)ethyl] - 1 H- benzimidazol-2- 0.001 1 yl } methyl) spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one
0 I I
l'-({5-Chloro-l-[3-
0 (methylsulfonyl)propyl]- 1H--1 benzimidazol-2- 0.002 yl } methyl)spiro [cyclopropane- 1 ,3'-
CP7 pyrrolo[2,3-c]pyridin]-2'(rH)-one
l'-({5-Chloro-l-[2- (cyclopropylsulfonyl)ethyl] - 1 H--2 benzimidazol-2- 0.008 yl}methyl)spiro[cyclopropane-l,3'-
Cr7 pyrrolo [2 ,3 -c] pyridin] -2' ( 1 'H)-one 1 '-( { 5-Chloro-7-fluoro- 1 - [2- (methyl sulf ony 1) ethyl] - 1 H--1 benzimidazol-2- 0.009 yl}methyl)spiro[cyclopropane-l ,3'- r pyrrolo[2,3-c]pyridin]-2'(l 'H)-one
l '-({5,7-Dichloro-l-[2- (methylsulfonyl)ethyl]- 1 H--2 benzimidazol-2- 0.0168 yl}methyl)spiro[cyclopropane-l ,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one
1 '-{ [5-Chloro- l-(oxetan-3-ylmethyl)- lH-benzimidazol-2--1 0.003 yljmethyl} spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one
1 '-( { 5-Chloro- 1 - [2-(oxetan-3-yl)ethyl]-
1 H-benzimidazol-2--2 0.003 yl } methyl)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one
r7
Figure imgf000048_0001
Table 2: NMR and MS data of particular compounds
Example
Ή NMR data MW data No.
Ή NMR (400 MHz, CD3OD) δ ppm 8.45 - 8.40 (m, 1 H), 7.69 - 7.58 (m, 1 H), 7.54 - 7.52 (m, 1 H), 7.47 - 7.45 (m, 1 H), 7.25 -
MS obsd. (ESI+)
1-1 7.17 (m, 2 H), 7.1 1 - 7.07 (m, 1 H), 6.50 (s, 1 H), 5.42 (s, 2 H),
[(M+H)+] 396 4.81 - 4.78 (t, 2 H), 3.59 - 3.55 (t, 2 H), 2.82 (s, 3 H), 1.94 - 1.90
(m, 4 H)
JH NMR (400 MHz, CDC13) δ ppm 8.47 (s, 1 H), 8.32 - 8.31 (d, J
MS obsd. (ESI+)
1-2 = 4.4 Hz, 1 H), 7.26 - 7.21 (m, 1 H), 7.02 (m, 1 H), 6.92 - 6.89 (m,
[(M+H)+] 426 1 H), 6.84 - 6.83 (m, 1 H), 6.58 (s, 1 H), 5.22 (s, 2 H), 4.75 - 4.72 (t, 2 H), 3.82 (s, 3 H), 3.39 - 3.35 (t, 2 H), 2.74 (s, 3 H), 1.93 - 1.90 (m, 2 H), 1.72 - 1.69 (m, 2 H)
lU NMR (400 MHz, CD3OD) δ ppm 8.19 (s, 1 H), 8.11 - 8.10 (m,
1 H), 7.75 (m, 1 H), 7.33 (m, 2 H), 6.81- 6.80 (m, 1 H), 6.48 (s, 1 MS obsd. (ESI+)-3
H), 5.16 (s, 2 H), 4.68 - 4.64 (t, 2 H), 3.84 - 3.38 (t, 2 H), 2.73 (s, [(M+H)+] 421 3 H), 1.80 - 1.78 (m, 2 H), 1.65 - 1.63 (m, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.42 - 8.39 (m, 1 H), 8.27 - 8.26 (m, 1 H), 7.45 - 7.44 (m, 1 H), 7.44 - 7.20 (m, 2 H), 7.98 - MS obsd. (ESI+)-4
7.01 (m, 1 H), 6.46 (s, 1 H), 5.41 (s, 2 H), 4.81 - 4.78 (t, 2 H), 3.61 [(M+H)+] 414 - 3.58 (t, 2 H), 2.86 (s, 3 H), 1.92 (t, 4 H)
Ή NMR (400 MHz, DMSO- 6) δ ppm 8.38 (s, 1 H), 8.26 - 8.25
(d, J = 4.8 Hz, 1 H), 7.67 (m, 1 H), 7.45 - 7.43 (d, J = 8.8 Hz, 1
H), 7.28 - 7.25 (dd, J = 6.8, 0.8 Hz, 1 H), 7.18 - 7.17 (d, J = 4.8 MS obsd. (ESI+)-5
Hz, 1 H), 6.30 (s, 1 H), 5.34 (s, 2 H), 4.73 - 4.70 (t, 2 H), 3.64 - [(M+H)+] 474 3.60 (t, 2 H), 3.00 (s, 3 H), 1.89 - 1.84 (m, 2 H), 1.74 - 1.72 (m, 2
H)
Ή NMR (400 MHz, CDC13) δ ppm 8.54 (s, 1 H), 8.37 (d, J = 4.8
Hz, 1 H), 7.27 (s, 1 H), 7.18 (m, 2 H), 6.88 (d, J = 4.8 Hz, 1 H),
MS obsd. (ESI+)-6 6.81 (s, 1 H), 5.29 (s, 2 H), 4.81 (t, J = 6.0 Hz, 2 H), 3.41 (t, J =
[(M+H)+] 430 7.2 Hz, 2 H), 2.85 (s, 3 H), 1.97 (t, J = 4.8 Hz, 2 H), 1.76 (t, J =
3.0 Hz, 2 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.43 (s, 1 H), 8.40 - 8.30 (d, J
= 4.8 Hz, 1 H), 7.50 - 7.40 (d, J =7.6 Hz, 1 H), 7.22 - 7.16 (d, J =
12 Hz, 1 H), 7.10 - 7.00 (t, J = 8.0 Hz, 1 H), 6.90 - 6.82 (d, J = MS obsd. (ESI"*)-7
4.8 Hz,l H), 6.60 (s,l H), 5.30 (s, 2 H), 5.15 - 5.08 (t, J = 6.8 Hz, [(M+H)+] 430 2 H), 3.52 - 3.42 (t, J = 7.2 Hz , 2 H), 2.86 (s, 3 H), 2.00 - 1.96 (m,
2 H), 1.65 - 1.60 (m, 2 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.49 (s, 1 H), 8.40 - 8.30 (d, J
= 4.8 Hz, 1 H), 7.39 (s, 1 H), 7.24 (s, 1 H), 7.15 - 7.10 (dd, J =
8.4, 1.6 Hz, 1 H), 6.90 - 6.80 (d, J = 4.8 Hz, 1 H), 6.61 (s,l H), MS obsd. (ESI+)-8
5.24 (s, 2 H), 4.80 - 4.70 (t, J= 7.2 Hz, 2 H), 3.42 - 3.32 (t, J= 6.8 [(M+H)+] 424 Hz , 2 H), 2.80 - 2.60 (m, 5 H), 2.00 - 1.90 (m, 2 H), 1.75 - 1.68
(m, 2 H), 1.30 - 1.20 (t, J= 7.6 Hz , 3 H) Ή NMR (400 MHz, CDC13) δ ppm 8.41 (s, 1 H), 8.40 - 8.30 (d, J = 4.8 Hz, 1 H), 7.10 - 6.98 (d, J = 2.0 Hz, 1 H), 6.90 - 6.80 (d, J =
MS obsd. (ESI+)-9 4.8 Hz, 1 H), 6.80 - 6.70 (t, J = 1 1.6 Hz, 1 H), 6.54 (s,l H), 5.28
[(M+H)+] 432 (s, 2 H), 4.90 - 4.80 (t, J= 6.8 Hz, 2 H), 3.50 - 3.38 (t, J= 6.8 Hz ,
2 H), 2.83 (s, 3 H), 2.00 - 1.90 (m, 2 H), 1.80 - 1.68 (m, 2 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.45 (s, 1 H), 8.40 - 8.30 (d, J
= 4.8 Hz, 1 H), 7.87 (s, 1 H), 7.52 - 7.38 (m, 2 H), 6.90 - 6.80 (d, J
MS obsd. (ESI+)-10 = 4.8 Hz, 1 H), 6.75 (s, 1 H), 5.28 (s, 2 H), 4.90 - 4.78 (t, J =7.2
[(M+H)+] 464 Hz, 2 H), 3.42 - 3.38 (t, J = 7.2 Hz , 2 H), 2.83 (s, 3 H), 2.00 - 1.90 (m, 2 H), 1.75 - 1.65 (m, 2 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.44 (s, 1 H), 8.40 - 8.30 (d, J
= 4.8 Hz, 1 H), 7.40 - 7.28 (t, J = 8.0 Hz, 1 H), 7.20 - 7.10 (dd, J =
MS obsd. (ESI+)-1 1 6.8, 4.0 Hz, 1 H), 6.90 - 6.80 (t, J = 0.8 Hz, 1 H), 6.60 (s, 1 H),
[(M+H)+] 432 5.23 (s, 2 H), 4.75 - 4.68 (t, J= 6.8 Hz, 2 H), 3.40 - 3.30 (t, J= 7.2
Hz , 2 H), 2.83 (s, 3 H), 2.00 - 1.90 (m, 2 H), 1.75 - 1.68 (m, 2 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.39 (s, 1 H), 8.40 - 8.30 (d, J
= 4.8 Hz, 1 H), 7.35 - 7.28 (d, J= 1.6 Hz, 1 H), 7.00 - 6.90 (dd, J
= 12.4, 1.6 Hz ,1 H), 6.90 - 6.80 (d, J = 4.8 Hz, 1 H), 6.52 (s, 1 MS obsd. (ESI+)-12
H), 5.27 (s, 2 H), 4.90 - 4.80 (t, J= 7.2 Hz, 2 H), 3.45 - 3.35 (t, J = [(M+H)+] 448 6.8 Hz , 2 H), 2.83 (s, 3 H), 2.00 - 1.90 (m, 2 H), 1.72 - 1.60 (m, 2
H)
Ή NMR (400 MHz, CDC13) δ ppm 8.49 (s, 1 H), 8.32 (d, J = 3.2
Hz, 1 H), 7.37 (s, 1 H), 7.24 - 7.22 (dd, J = 10.4, 8.4 Hz, 1 H),
7.09 - 7.07 (d, J = 8.8 Hz, 1 H), 6.84 - 6.82 (d, J = 4.4 Hz, 1 H), MS obsd. (ESI+)-13
6.59 (s, 1 H), 5.24 (s, 2 H), 4.77 - 4.73 (q, J = 6.8 Hz, 2 H), 3.52 - [(M+H)+] 410 3.39 (q, J = 6.8 Hz, 2 H), 2.75 (s, 3 H), 2.42 (s, 3 H), 1.94 - 1.91
(m, 2 H), 1.72 - 1.69 (m, 2 H)
Ή NMR (400 MHz, DMSO-c/6) δ ppm 8.72 (s, 1 H), 8.39 (s, 1 H),
8.25 (d, J= 4.8 Hz, 1 H), 8.21 (d, J= 5.6 Hz, 1 H), 7.48 (d, J= 5.6
MS obsd. (ESI+)-14 Hz, 1 H), 7.18 (d, J = 4.8 Hz, 1 H), 6.44 (s, 1 H), 5.36 (s, 2 H),
[(M+H)+] 397 4.75 - 4.72 (m, 2 H), 3.67 - 3.64 (m, 2 H), 3.02 (s, 3 H), 1.85 - 1.72 (m, 4 H)
-1 Ή NMR (400 MHz, CD3OD) δ ppm 8.43 - 8.33 (m, 1 H), 8.30 - MS obsd. (ESI+) 8.20 (m, 1 H), 7.51 (s, 1 H), 7.49 - 7.40 (m, 1 H), 7.17 (d, J = 4.80 [(M+H)+] 444 Hz, 2 H), 6.44 (s, 1 H), 5.41 (s, 2 H), 4.80 - 4.73 (m, 2 H), 3.54 (t,
J- 6.69 Hz, 2 H), 2.93 (q, J = 7.58 Hz, 2 H), 1.96 - 1.85 (m, 4 H),
1.26 (t, J = 7.45 Hz, 3 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.39 (s, 1 H), 8.28 (d, J =
5.05 Hz, 1 H), 8.24 (d, J = 2.02 Hz, 1 H), 7.92 (d, J = 2.27 Hz, 1
MS obsd. (ESI+)-2 H), 7.21 (d, J = 4.80 Hz, 1 H), 6.39 (s, 1 H), 5.47 (s, 2 H), 4.84 (t,
[(M+II)+] 445 J = 6.57 Hz, 2 H), 3.72 (t, J = 6.57 Hz, 2 H), 3.07 - 2.96 (m, 2 H),
1.99 - 1.88 (m, 4 H), 1.28 (t, J = 7.45 Hz, 3 H)
[H NMR (400 MHz, DMSO-<4) δ ppm 8.20 - 8.10 (m, 1 H), 7.58 - 7.45 (m, 3 H), 7.17 (dd, J = 8.84, 1.77 Hz, 1 H), 7.05 (dd, J =
MS obsd. (ESI+)-3 7.20, 5.43 Hz, 1 H), 6.30 (s, 1 H), 5.24 (s, 2 H), 4.87 (t, J = 6.95
[(M+H)+] 444 Hz, 2 H), 3.66 (t, J = 7.07 Hz, 2 H), 3.10 (q, J = 7.49 Hz, 2 H),
1.83 - 1.73 (m, 2 H), 1.71 - 1.61 (m, 2 H), 1.26 - 1.13 (m, 3 H)
lH NMR (400 MHz, CDC13) δ ppm 8.56 - 8.46 (m, 1 H), 8.42 (s, 1
H), 8.24 (d, J= 2.27 Hz, 1 H), 7.80 (d, J = 2.27 Hz, 1 H), 7.68 (d,
MS obsd. (ESI+)-4 J = 5.05 Hz, 1 H), 6.35 (s, 1 H), 5.36 - 5.24 (m, 2 H), 4.88 - 4.75
[(M+H)+] 445 (m, 2 H), 3.75 (t, J = 6.19 Hz, 2 H), 2.87 - 2.70 (m, 5 H), 2.55 - 2.29 (m, 4 H)
Ή NMR (400 MHz, DMSO-d6) δ ppm 8.16 (dd, J = 5.05, 1.52
Hz, 1 H), 7.56 - 7.45 (m, 3 H), 7.16 (dd, J = 8.72, 2.15 Hz, 1 H),
MS obsd. (ESI+)-5 7.05 (dd, J = 7.33, 5.31 Hz, 1 H), 6.31 (s, 1 H), 5.24 (s, 2 H), 4.87
[(M+H)+] 430 (t, J = 7.07 Hz, 2 H), 3.70 (t, J = 7.20 Hz, 2 H), 3.01 (s, 3 H), 1.81
- 1.74 "(m, 2 H), 1.69 - 1.62 (m, 2 H)
Ή NMR (400 MHz, DMSO-c¾) δ ppm 8.40 (s, 1 H), 8.33 - 8.25
(m, 2 H), 8.04 (d, J = 2.27 Hz, 1 H), 7.21 (dd, J = 4.80, 0.51 Hz, 1
MS obsd. (ESI+)-6 H), 6.30 (s, 1 H), 5.41 (s, 2 H), 4.79 (t, J = 6.95 Hz, 2 H), 3.74 (t,
[(M+H)+] 431 J = 6.95 Hz, 2 H), 3.08 (s, 3 H), 1.92 - 1.85 (m, 2 H), 1.80 - 1.73
(m, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.27 (d, J = 2.27 Hz, 1 H),
7.96 (d, J = 2.27 Hz, 1 H), 7.15 (d, J = 4.30 Hz, 1 H), 6.95 (d, J = MS obsd. (ESI+)-7
8.34 Hz, 2 H), 6.38 (s, 1 H), 5.40 (s, 2 H), 4.87 (t, J = 6.82 Hz, 2 [(M+H)+] 448 H), 3.75 (t, J = 6.82 Hz, 2 H), 3.01 (s, 3 H), 1.85 - 1.73 (m, 4 H) Ή NMR (400 MHz, CD3OD) δ ppm 8.34 - 8.31 (m, 2 H), 8.24 (d, J = 2.27 Hz, 1 H), 7.92 (d, J = 2.27 Hz, 1 H), 7.46 (dd, J = 4.80,
MS obsd. (ESI+)-8 0.76 Hz, 1 H), 6.33 (s, 1 H), 5.38 (s, 2 H), 4.86 - 4.83 (m, 2 H),
[(M+H)+] 459 3.82 (t, J = 6.57 Hz, 2 H), 2.95 (s, 3 H), 2.29 - 2.19 (m, 2 H), 2.13
(d, J = 7.33 Hz, 4 H), 2.06 - 1.96 (m, 2 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.46 (s, 1 H), 8.38 (d, J = 4.80
Hz, 1 H), 7.69 (d, J = 8.59 Hz, 1 H), 7.20 (d, J = 8.59 Hz, 1 H),
MS obsd. (ESI+)-9 6.88 (d, J = 4.80 Hz, 1 H), 6.80 (s, 1 H), 5.34 - 5.17 (m, 2 H), 4.80
[(M+H)+] 431 (t, J = 7.07 Hz, 2 H), 3.42 (t, J= 7.07 Hz, 2 H), 2.88 (s, 3 H), 2.00
- 1.93 (m, 2 H), 1.76 (q, J= 4.38 Hz, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.35 (d, J = 5.3 Hz, 1 H),
8.13 (s, 1 H), 7.53 - 7.42 (m, 2 H), 7.29 (d, J = 5.6 Hz, 1 H), 7.20
MS obsd. (ESI+)-1 (dd, J = 8.8, 1.8 Hz, 1 H), 6.41 (s, 1 H), 5.38 (s, 2 H), 4.81 (t, J =
[(M+H)+] 430 6.8 Hz, 2 H), 3.57 - 3.65 (m, 2 H), 2.86 (s, 3 H), 1.88 (d, J = 1 1.1
Hz, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.37 - 8.28 (m, 2 H), 7.53 - 7.40 (m, 3 H), 7.20 (dd, J = 8.7, 1.9 Hz, 1 H), 6.37 (s, 1 H), 5.33 MS obsd. (ESf)-2
(s, 2 H), 4.80 (t, J= 6.7 Hz, 2 H), 3.67 (t, J = 6.7 Hz, 2 H), 2.86 (s, [(M+H)+] 458 3 H), 2.26 - 1.96 (m, 8 H)
JH NMR (400 MHz, CDCI3) δ ppm 8.45 (s, 1 H), 8.34 (d, J= 4.8
Hz, 1 H), 7.55 (d, J = 1.6 Hz, 1 H), 7.27 (d, J = 6.0 Hz, 1 H), 7.21
MS obsd. (ESf )-3 (d, J = 6.0 Hz, 1 H), 6.84 (d, J = 5.2 Hz, 1 H), 6.61 (s, 1 H), 5.24
[(M+H)+] 430 (s, 2 H), 4.77 (t, J= 7.2 Hz, 2 H), 3.38 (t, J= 7.0 Hz, 2 H), 2.80 (s,
3 H), 1.93 (q, J= 4 Hz, 2 H), 1.72 (q, J= 4 Hz, 2 H)
!H NMR (400 MHz, CD3OD) δ ppm 8.37 (s, 1 H), 8.25 (d, J =
4.80 Hz, 1 H), 7.52 (d, J = 2.02 Hz, 1 H), 7.41 (d, J = 8.59 Hz, 1 MS obsd. (ESI+)-1
H), 7.20 - 7.1 1 (m, 2 H), 6.59 (s, 1 H), 5.33 (s, 2 H), 4.30 (t, J = [(M+H)+] 458 7.33 Hz, 2 H), 3.17 - 3.07 (m, 2 H), 1.95 - 1.76 (m, 8 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.39 (s, 1 H), 8.16 (d, J = 4.80
Hz, 1 H), 7.68 (d, J = 1.77 Hz, 1 H), 7.48 (d, J = 8.34 Hz, 2 H),
MS obsd. (ESI+)-2 7.21 - 7.08 (m, 2 H), 7.00 (s, 1 H), 6.85 (d, J= 4.80 Hz, 1 H), 6.63
[(M+H)+] 493 (d, J = 8.08 Hz, 2 H), 5.63 (s, 2 H), 5.33 (s, 2 H), 3.03 (s, 3 H),
1.46 (d, J= 3.28 Hz, 4 H) Ή NMR (400 MHz, DMSO-c/6) δ ppm 8.43 (s, 1 H), 8.31 - 8.23 (m, 2 H), 8.06 (d, J = 2.27 Hz, 1 H), 7.20 (d, J = 4.80 Hz, 1 H),
MS obsd. (ESI+)-3 6.48 (s, 1 H), 5.34 (s, 2 H), 4.44 (t, J = 7.33 Hz, 2 H), 3.22 - 3.09
[(M+H)+] 445 (m, 2 H), 2.98 (s, 3 H), 2.09 (q, J = 7.71 Hz, 2 H), 1.91 - 1.84 (m,
2 H), 1.80 - 1.74 (m, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.38 (s, 1 H), 8.26 (d, J =
4.80 Hz, 1 H), 8.14 (d, J = 1.26 Hz, 1 H), 7.73 (s, 1 H), 7.17 (d, J
MS obsd. (ESI+)-4 = 5.05 Hz, 1 H), 6.38 (s, 1 H), 5.44 (s, 2 H), 4.82 (t, J= 6.69 Hz, 2
[(M+H)+] 41 1 H), 3.72 (t, J = 6.69 Hz, 2 H), 2.89 (s, 3 H), 2.42 (s, 3 H), 1.98 - 1.85 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.36 (s, 1 H), 8.27 (d, J =
5.05 Hz, 1 H), 7.97 (d, J = 8.59 Hz, 1 H), 7.27 - 7.15 (m, 2 H), MS obsd. (ESI+)-5
6.64 (s, 1 H), 5.40 (s, 2 H), 4.38 (t, J = 6.95 Hz, 2 H), 3.17 (t, J = [(M+H)+] 459 6.95 Hz, 2 H), 2.96 (s, 3 H), 1.94 (s, 4 H), 1.91 - 1.79 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.37 (s, 1 H), 8.28 (d, J =
5.05 Hz, 1 H), 8.00 (d, J = 8.59 Hz, 1 H), 7.24 (d, J = 8.59 Hz, 1
MS obsd. (ESI+)-6 H), 7.18 (d, J = 4.80 Hz, 1 H), 6.63 (s, 1 H), 5.41 (s, 2 H), 4.55 - [(M+H)+] 471 4.45 (m, 2 H), 3.22 (t, J = 7.45 Hz, 2 H), 2.68 - 2.56 (m, 1 H),
2.29 - 2.14 (m, 2 H), 2.00 - 1.85 (m, 4 H), 1.19 - 1.00 (m, 5 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.66 - 8.58 (m, 1 H), 8.33 (s,
1 H), 8.28 (d, J = 4.80 Hz, 1 H), 7.57 (s, 1 H), 7.18 (d, J = 5.05 MS obsd. (ESI+)-7
Hz, 1 H), 6.61 (s, 1 H), 5.39 (s, 2 H), 4.44 (br. s., 2 H), 3.23 - 3.12 [(M+H)+] 459 (m, 2 H), 2.96 (s, 3 H), 2.00 - 1.84 (m, 8 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.38 (d, J = 0.76 Hz, 1 H),
8.27 (d, J = 5.05 Hz, 1 H), 8.22 (d, J = 2.27 Hz, 1 H), 7.99 (d, J =
MS obsd. (ESI+)-8 2.27 Hz, 1 H), 7.29 (s, 5 H), 7.20 - 7.16 (m, 1 H), 6.62 (s, 1 H),
[(M+H)+] 550 5.38 (s, 2 H), 4.55 - 4.44 (m, 2 H), 4.26 (s, 2 H), 3.14 - 3.04 (m, 2
H), 2.70 (s, 3 H), 2.22 - 2.09 (m, 2 H), 1.99 - 1.88 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.66 (s, 1 H), 8.36 (s, 1 H),
8.28 (s, 1 H), 7.57 (d, J = 0.76 Hz, 1 H), 7.19 (d, J = 5.05 Hz, 1
MS obsd. (ESI+)-9 H), 6.60 (s, 1 H), 5.40 (s, 2 H), 4.57 (t, J = 7.58 Hz, 2 H), 3.25 (t,
[(M+H)+] 471 J = 8.08 Hz, 2 H), 2.69 - 2.59 (m, 1 H), 2.26 (quin, J = 7.71 Hz, 2
H), 1.99 - 1.90 (m, 4 H) Ή NMR (400 MHz, CD3OD) δ ppm 8.57 (s, 1 H), 8.32 (s, 1 H), 8.28 (d, J = 5.05 Hz, 1 H), 7.56 (d, J = 0.76 Hz, 1 H), 7.19 (d, J
MS obsd. (ESI+)-10 = 4.29 Hz, 1 H), 6.60 (s, 1 H), 5.37 (s, 2 H), 4.33 (t, J = 7.58
[(M+H)+] 425 Hz, 2 H), 3.16 (t, J = 8.84 Hz, 2 H), 3.01 (t, J = 8.84 Hz, 2 H),
2.07 - 1.97 (m, 3 H), 1.97 - 1.89 (m, 4 H)
1H NMR (400 MHz, CD3OD) δ ppm 8.62 (s, 1 H), 8.36 (s, 1 H),
8.28 (d, J = 5.31 Hz, 1 H), 7.58 (d, J = 0.76 Hz, 1 H), 7.18 (d, J
MS obsd. (ESf)-1 1 = 5.31 Hz, 1 H), 6.65 (s, 1 H), 5.38 (s, 2 H), 4.48 - 4.38 (m, 2
[(M+H)+] 457 H), 4.29 - 4.19 (m, 2 H), 3.91 (dd, J = 14.65, 6.32 Hz, 2 H), 2.73
- 2.60 (m, 1 H), 2.22 - 2.12 (m, 2 H), 1.99 - 1.86 (m, 4 H)
Ή NMR (400 MHz, DMSO-i¾) δ ppm 8.39 (d, J = 4.55 Hz, 1 H),
8.34 (s, 1 H), 8.25 (d, J = 2.27 Hz, 1 H), 8.04 (d, J = 2.02 Hz, 1
H), 7.76 (d, J = 4.80 Hz, 1 H), 6.40 (s, 1 H), 5.23 (s, 2 H), 4.45 (t, MS obsd. (ESf)-12
J = 7.33 Hz, 2 H), 3.23 - 3.13 (m, 2 H), 2.98 (s, 3 H), 2.61 - 2.53 [(M+H)+] 459 (d, J = 9.09 Hz, 2 H), 2.47 - 2.38 (m, 2 H), 2.36 - 2.24 (m, 2 H),
2.20 - 2.05 (m, 2 H)
Ή NMR (400 MHz, DMSO-<¾) δ ppm 8.74 (s, 1 H), 8.40 (s, 1 H),
8.29 (d, J = 4.80 Hz, 1 H), 7.57 (s, 1 H), 7.21 (d, J = 4.80 Hz, 1
MS obsd. (ESf)-13 H), 6.44 (s, 1 H), 5.34 (s, 2 H), 4.49 (t, J = 7.58 Hz, 9 H), 3.24 - [(M+H)+] 445 3.14 (m, 2 H), 3.00 (s, 3 H), 2.14 - 2.05 (t, J= 7.33 Hz, 2 H), 1.93
- 1.81 (m, 2 H), 1.81 - 1.66 (m, 2 H)
Ή NMR (400 MHz, DMSO-i¼) δ ppm 8.41 (s, 1 H), 8.29 (d, J =
4.80 Hz, 1 H), 7.99 (d, J = 8.59 Hz, 1 H), 7.29 - 7.13 (m, 2 H),
MS obsd. (ESf)- 14 6.43 (s, 1 H), 5.41 (s, 2 H), 4.81 (t, J = 6.82 Hz, 2 H), 3.71 (t, J =
[(M+H)+] 457 6.82 Hz, 2 H), 2.75 - 2.64 (m, 1 H), 1.93 - 1.85 (m, 2 H), 1.82 - 1.66 (m, 2 H), 1.00 (d, J= 6.32 Hz, 4 H)
Ή NMR (400 MHz, DMSO-i 6) δ ppm 8.44 (s, 1 H), 8.28 (d, J =
4.80 Hz, 1 H), 8.04 (d, J = 8.59 Hz, 1 H), 7.27 - 7.13 (m, 2 H),
MS obsd. (ESf)-15 6.61 (s, 1 H), 5.34 (s, 2 H), 4.41 (t, J = 7.45 Hz, 2 H), 3.19 - 3.09
[(M+H)+] 445 (m, 2 H), 2.98 (s, 3 H), 2.01 (q, J = 7.64 Hz, 2 H), 1.90 - 1.83 (m,
2 H), 1.80 - 1.71 (m, 2 H)
Ή NMR (400 MHz, DMSO- ) δ ppm 8.39 (s, 1 H), 8.28 (d, J = MS obsd. (ESf)-16
4.80 Hz, 1 H,) 8.25 (d, J = 2.27 Hz, 1 H), 8.06 (d, J = 2.27 Hz, 1 [(M+H)+] 459 H), 7.20 (d, J = 4.80 Hz, 1 ¾), 6.52 (s, 1 ¾), 5.34 (s, 2 H , 4.34 (t,
J = 6.69 Hz, 2 ¾), 3.14 (t, J = 7.07 Hz, 2 ¾), 2.94 (s, 3 H), 1.93 - 1.86 (m, 2 ¾), 1.79 - 1.63 (m, 6 H)
lU NMR (400 MHz, CDC13) δ ppm 8.53 (s, 1 H), 8.35 (d, J= 5.05
Hz, 1 U), 7.52 (d, J = 1.77 Hz, 1 ¾), 7.32 - 7.12 (m, 1 HI, 6.99 (d,
MS obsd. (ESI+)-1 J= 5.05 Hz, 1 ¾), 6.57 (s, 1 H), 5.27 (s, 1 H), 4.40 (t, J= 7.45 Hz,
[(M+H)+] 428 2 H , 2.76 - 2.60 (m, 2 H), 2.56 (s, 3 ¾), 2.18 (dq, J = 14.97, 7.56
Hz, 2 H), 2.1 1 - 1.96 (m, 2 ¾), 1.84 (d, J= 4.04 Hz, 2 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.54 (s, 1 U), 8.47 - 8.34 (m, 2
U), 7.49 (s, 1 U), 6.92 (d, J= 4.55 Hz, 1 ¾), 6.54 (s, 1 R), 5.33 (s,
MS obsd. (ESI+)-2 2 Hj, 4.89 (t, J = 6.69 Hz, 2 Hj, 3.52 (t, J = 6.57 Hz, 2 HI, 2.89 (s,
[(M+H)+] 431 2 H), 2.00 (q, J = 3.96 Hz, 2 ¾), 1.78 (q, J = 4.38 Hz, 2 ¾), 1.28
(s, 1 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.39 (s, 1 Hj, 8.29 (d, J =
4.80 Hz, 1 U), 8.00 (d, J = 8.59 Hz, 1 ¾), 7.25 (d, J = 8.59 Hz, 1
MS obsd. (ESI+) Hj, 7.19 (d, J = 4.80 Hz, 1 Hj, 6.45 (s, 1 ¾), 5.49 (s, 2 HI, 3.63 (t,
[(M+H)+] 445 J = 6.57 Hz, 2 ¾), 3.04 (q, J = 7.33 Hz, 2 ¾), 2.06 (s, 3 ¾), 1.93
(s, 3 HJ, 1.31 (t, J= 7.45 Hz, 3 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.43 - 8.21 (m, 2 H), 7.54
(d, J = 1.8 Hz, 1 H), 7.45 (d, J = 8.8 Hz, 1 H), 7.24 - 7.08 (m, 2
MS obsd. (ESI+)-1 H), 6.59 (s, 1 H), 5.33 (s, 2 H), 4.46 - 4.33 (m, 2 H), 3.08 - 2.98
[(M+H)+] 473 (m, 2 H), 2.82 (s, 6 H), 2.07 (t, J = 7.7 Hz, 2 H), 1.97 - 1.86 (m, 4
H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.37 (s, 1 H), 8.23 (d, J= 2.0
Hz, 2 H), 7.98 (d, J = 2.3 Hz, 1 H), 7.17 (d, J = 4.8 Hz, 1 H), 6.60 MS obsd. (ESI+)-2
(s, 1 H), 5.38 (s, 2 H), 4.49 (t, J = 7.5 Hz, 2 H), 3.11 - 3.00 (m, 2 [(M+H)+] 474 H), 2.81 (s, 6 H), 2.14 (br. s., 2 H), 1.93 (d, J= 6.8 Hz, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.37 (s, 1 H), 8.26 (d, J =
5.1 Hz, 1 H), 7.51 (d, J = 2.0 Hz, 1 H), 7.42 (d, J = 8.6 Hz, 1 H), MS obsd. (ESI+)-3
7.25 - 7.13 (m, 2 H), 6.44 (s, 1 H), 5.39 (s, 2 H), 4.74 (t, J = 6.9 [(M+H)+] 459 Hz, 2 H), 3.40 - 3.36 (m, 2 H), 2.82 (s, 6 H), 1.98 - 1.86 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.38 (s, 1 H), 8.26 (d, J = 5.1 MS. obsd.-4
Hz, 1 H), 7.54 (d, J = 1.8 Hz, 1 H), 7.45 (d, J = 8.8 Hz, 1 H), 7.23 (ESI+) [(M+H)+] - 7.12 (m, 2 H), 6.59 (s, 1 H), 5.33 (s, 2 H), 4.47 - 4.36 (m, 2 H), 515
3.73 - 3.64 (m, 4 H), 3.23 - 3.15 (m, 4 H), 3.1 1 - 3.00 (m, 2 H),
2.09 (t, J= 7.6 Hz, 2 H), 1.99 - 1.83 (m, 4 H)
Ή NMR (400 MIIz, CD3OD) δ ppm 8.38 (s, 1 H), 8.26 (d, J =
4.8 Hz, 1 H), 7.53 (d, J = 2.0 Hz, 1 H), 7.45 (d, J = 8.8 Hz, 1 H),
MS obsd. (ESI+)-5 7.21 - 7.12 (m, 2 H), 6.59 (s, 1 H), 5.32 (s, 2 H), 4.48 - 4.33 (m, 2
[(M+H)+] 499 H), 3.26 (t, J = 6.7 Hz, 4 H), 3.09 - 3.02 (m, 2 H), 2.13 - 2.03
(m, 2 H), 1.96 - 1.85 (m, 8 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.42 - 8.35 (m, 1 H), 8.29 - 8.24 (m, 1 H), 7.57 - 7.51 (m, 1 H), 7.48 - 7.42 (m, 1 H), 7.22 - 7.13 (m, 2 H), 6.61 - 6.55 (m, 1 H), 5.36 - 5.29 (m, 2 H), 4.45 - MS obsd. (ESf )-6
4.36 (m, 2 H), 3.91 - 3.85 (m, 2 H), 3.50 - 3.44 (m, 2 H), 3.39 - [(M+H)+] 528 3.34 (m, 2 H), 3.18 - 3.1 1 (m, 2 H), 2.15 - 2.04 (m, 2 H), 1.97 - 1.87 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.34 (d, J = 0.76 Hz, 1 H),
8.27 (d, J = 5.05 Hz, 1 H), 7.53 - 7.45 (m, 2 H), 7.21 - 7.12 (m, 2
MS obsd. (ESf)-7 H), 6.39 (s, 1 H), 5.38 (s, 2 H), 4.48 (t, J = 6.06 Hz, 2 H), 3.37 (t,
[(M+H)+] 471 J = 6.06 Hz, 2 H), 3.20 - 3.08 (m, 2 H), 2.88 (t, J = 6.82 Hz, 2 H),
2.20 (dd, J= 8.34, 6.82 Hz, 2 H), 1.92 (s, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.34 (s, 1 H), 8.25 (d, J =
4.80 Hz, 1 H), 7.50 (d, J = 1.77 Hz, 1 H), 7.41 (d, J = 8.84 Hz, 1
MS obsd. (ESf)-8 H), 7.19 - 7.07 (m, 2 H), 6.54 (d, J = 0.51 Hz, 1 H), 5.31 (s, 2 H),
[(M+H)+] 499 4.25 (d, J = 8.08 Hz, 2 H), 3.21 - 3.07 (m, 4 H), 2.94 (t, J = 6.69
Hz, 2 H), 2.33 - 2.21 (m, 2 H), 1.74 - 1.54 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.35 - 8.41 (m, 1 H), 8.30 - 8.24 (m, 1 H), 7.55 - 7.47 (m, 2 H), 7.24 - 7.15 (m, 2 H), 6.46 -
MS obsd. (ESf)-9 6.41 (m, 1 H), 5.46 - 5.41 (m, 2 H), 4.84 - 4.78 (m, 2 H), 3.72 - [(M+H)+] 499 3.64 (m, 2 H), 3.26 - 3.17 (m, 4 H), 2.92 - 2.80 (m, 4 H), 2.1 1 - 2.01 (m, 2 H), 1.95 - 1.88 (m, 4 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.40 (s, 1 H), 8.33 (d, J= 4.77
Hz, 1 H), 7.54 (d, J = 1.76 Hz, 1 H), 7.26 (s, 1 H), 7.17 (dd, J = MS obsd. (ESf)-10
8.78, 2.01 Hz, 1 H), 6.84 (d, J = 4.77 Hz, 1 H), 6.55 (s, 1 H), 5.23 [(M+H) ] 486 (s, 2 H), 4.39 - 4.28 (m, 2 H), 3.27 - 3.13 (m, 4 H), 3.02 (t, J = 6.53 Hz, 2 H), 2.36 (dd, J= 8.41, 7.15 Hz, 2 H), 2.08 - 1.98 (m, 2
H), 1.94 (q, J = 4.02 Hz, 2 H), 1.72 (q, J = 4.35 Hz, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.32 (s, 1 H), 8.24 (d, J = 5.6
Hz, 1 H), 7.48 (d, J= 2.0 Hz, 1 H), 7.41 (d, J= 8.8Hz, 1 H), 7.16 -
MS obsd. (ESf ) 7.10 (m, 2 H), 6.46 (s, 1 H), 5.33 (s, 2 H), 4.34 (t, J = 7.2Hz, 2 H),
[(M+H)+] 382 4.20 (m, 1 H), 3.54 (t, J= 6.4 Hz, 2 H), 1.91 (m, 4 H), 1.86 - 1.82
(m, 2 H)
]H NMR (400 MHz, DMSO-c¾) δ ppm 8.40 (s, 1 H), 8.27 (d, J =
4.80 Hz, 1 H), 7.55 (d, J = 1.77 Hz, 1 H), 7.51 (d, J = 8.84 Hz, 1
MS obsd. (ESf) H), 7.22-7.14 (m, 2 H), 6.34 (s, 1 H), 4.74 (t, J = 6.82 Hz, 2 H),
[(M+H)+] 432 3.64 (t, J = 6.95 Hz, 2 H), 3.01 (s, 3 H), 1.90 - 1.83 (m, 2 H), 1.79
- 1.71 (m, 2 H)
Ή NMR (400 MHz, DMSO-c/6) δ ppm 8.41 (s, 1 H), 8.27 (d, J =
4.80 Hz, 1 H), 7.64 - 7.45 (m, 2 H), 7.25 - 7.1 1 (m, 2 H), 6.50 (s, 1
MS obsd. (ESI+) H), 4.37 (t, J = 7.58 Hz, 2 H), 3.21 - 3.10 (m, 2 H), 2.98 (s, 3 H),
[(M+H)+] 446 1.99 (q, J = 7.71 Hz, 2 H), 1.92 - 1.82 (m, 2 H), 1.82 - 1.68 (m, 2
H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.34 (s, 1 H), 8.26 (d, J =
5.05 Hz, 1 H), 7.49 (d, J = 2.02 Hz, 1 H), 7.39 (d, J = 8.59 Hz, 1
MS obsd. (ESI+) H), 7.20 - 7.12 (m, 2 H), 6.45 (s, 1 H), 5.39 (s, 2 H), 4.56 (t, J =
[(M+H)+] 424 7.07 Hz, 2 H), 4.08 (q, J = 7.16 Hz, 2 H), 2.70 (t, J = 7.07 Hz, 2
H), 1.91 (d, J= 1.77 Hz, 4 H), 1.17 (t, J= 7.20 Hz, 3 H)
]H NMR (400 MHz, CD3OD) δ ppm 8.37 (br. s., 1 H), 8.24 (s, 1
H), 8.28 (s, 1 H), 7.97 (br. s., 1 H), 7.18 (br. s., 1 H), 6.61 (br. s., 1
MS obsd. (ESf) H), 5.37 (br. s., 2 H), 4.41 (br. s., 2 H), 4.17 (d, J = 9.85 Hz, 2 H),
[(M+H)+] 457 3.86 (br. s., 2 H), 2.55 (br. s., 1 H), 2.06 (br. s., 2 H), 1.93 (br. s., 4
H)
Ή NMR (400MHz, OUSO-d6) δ ppm 8.37 (s, 1 H), 8.27 (d, J =
4.8 Hz, 1 H), 7.47 - 7.38 (m, 1 H), 7.20 (d, J = 4.8 Hz, 1 H), 7.10
(dd, J= 1.6, 12.5 Hz, 1 H), 6.47 (d, J= 1.8 Hz, 1 H), 5.33 (s, 2 H), MS obsd. (ESf) 4.58 (t, J = 7.2 Hz, 2 H), 4.1 1 - 3.98 (m, 2 H), 2.72 (t, J = 7.2 Hz, [(M+H)+] 442 2 H), 1.91 - 1.82 (m, 2 H), 1.73 (q, J = 4.0 Hz, 2 H), 1.17 - 1.08
(m, 3 H) Ή NMR (400 MHz, DMSO-d6) δ ppm 8.41 (s, 1 Η), 8.27 (d, J = 4.55 Hz, 1 H), 7.58 (br. s., 2 H), 7.26 - 7.09 (m, 2 H), 6.48 (s, 1
MS obsd. (ESI+)-1 H), 6.21 - 5.94 (m, 1 H), 5.29 (br. s., 2 H), 4.39 (br. s., 2 H), 3.77
[(M+H)+] 443 (br. s., 1 H), 3.14 - 3.02 (br.s., 2 H), 2.96 - 2.80 (m, 5 H), 2.09 - 1.93 (br. s., 2 H), 1.86 (br. s., 2 H), 1.77 (d, J = 3.54 Hz, 2 H)
Ή NMR (400 MHz, DMSO- 6) δ ppm 8.42 (s, 1 H), 8.28 (d, J =
4.80 Hz, 1 H), 7.61 - 7.48 (m, 2 H), 7.26 - 7.00 (m, 2 H), 6.33 (s, 1 MS obsd. (ESI+)-2
H), 5.38 (s, 2 H), 4.77 - 4.57 (m, 2 H), 3.99 (s, 1 H), 3.64 - 3.41 [(M+H)+] 429 (m, 2 H), 2.91 (s, 3 H), 1.92 - 1.84 (m, 2 H), 1.81 - 1.70 (m, 2 H)
*H NMR (400 MHz, DMSO-i¾) δ ppm 8.39 (s, 1 H), 8.31 - 8.20
(m, 2 H), 8.06 (d, J = 2.27 Hz, 1 H), 7.20 (d, J = 4.80 Hz, 1 H),
MS obsd. (ESI+)-3 6.51 (s, 1 H), 5.34 (s, 2 H), 4.33 (br. s., 2 H), 3.59 (s, 1 H), 3.05
[(M+H)+] 458 (br. s., 2 H), 2.86 (s, 3 H), 1.92 - 1.85 (m, 2H), 1.80 - 1.64 (m, 6
H)
Ή NMR (400 MHz, DMSO- 6) δ ppm 8.42 (s, 1 H), 8.32 - 8.23
(m, 2 H), 8.03 (d, J = 2.27 Hz, 1 H), 7.21 (d, J = 4.80 Hz, 1 H),
MS obsd. (ESI+)-4 6.30 (s, 3 H), 5.44 (s, 2 H), 4.76 (t, J = 6.95 Hz, 2 H), 3.96 (s, 1
[(M+H)+] 430 H), 3.65 (t, J = 6.95 Hz, 2 H), 2.94 (s, 3 H), 1.93 - 1.86 (m, 2 H),
1.80 - 1.71 (m, 2 H)
1H NMR (400 MHz, DMSO- 6) δ ppm 8.42 (s, 1 H), 8.28 (d, J =
4.80 Hz, 1 H), 7.60 - 7.48 (m, 2 H), 7.26 - 7.10 (m, 2 H), 6.34 (s, 1 MS obsd. (ESI+) H), 5.36 (s, 2 H), 4.91 - 4.65 (m, 2 H), 4.09 - 3.88 (m, 2 H), 1.96 - [(M+H)+] 471 1.91 (m, 3 H), 1.89 - 1.85 (m, 2 H), 1.79 - 1.67 (m, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.49 - 8.40 (m, 2 H), 7.59 (d,
J = 5.56 Hz, 1 H), 7.50 (d, J = 1.77 Hz, 1 H), 7.43 (d, J = 8.59 Hz,
MS obsd. (ESI+)-1 1 H), 7.17 (dd, J= 8.84, 2.02 Hz, 1 H), 6.49 (s, 1 H), 5.45 (s, 2 H),
[(M+H)+] 396 4.55 (t, J = 6.95 Hz, 2 H), 2.71 (t, J = 7.07 Hz, 2 H), 2.19 - 2.09
(m, 4 H)
1H NMR (400MHz, DMSO- 6) δ ppm 12.56 - 12.42 (m, 1 H),
8.37 (s, 1 H), 8.27 (d, J = 4.5 Hz, 1 H), 7.42 (d, J = 1.3 Hz, 1 H),
MS obsd. (ESI+)-2 7.20 (d, J = 4.5 Hz, 1 H), 7.10 (d, J = 12.4 Hz, 1 H), 6.44 (s, 1 H),
[(M+H)+] 414 5.35 (s, 2 H), 4.53 (t, J = 7.1 Hz, 2 H), 2.65 (t, J = 7.1 Hz, 2 H),
1.92 - 1.83 (m, 2 H), 1.80 - 1.69 (m, 2 H) Ή NMR (400 MHz, DMSO-rf6) δ ppm 8.40 (s, 1 H), 8.26 (d, J = 4.55 Hz, 1 H), 7.61 - 7.44 (m, 2 H), 7.21 - 7.10 (m, 2 H), 6.51 (s, 1 MS obsd. (ESI+) H), 5.27 (s, 2 H), 4.30 - 4.16 (m, 2 H), 2.36 (t, J = 7.33 Hz, 2 H), [(M+H)+] 424 1.89 - 1.82 (m, 2 H), 1.81 - 1.68 (m, 4 H)
1H NMR (400 MHz, CD3OD) δ ppm 8.30 (s, 1 H), 8.26 (d, J =
4.80 Hz, 1 H), 7.46 (d, J = 1.77 Hz, 1 H), 7.43 (d, J = 8.84 Hz, 1
MS obsd. (ESI+)-1 H), 7.17 (d, J = 4.80 Hz, 1 H), 7.14 (dd, J = 8.84, 2.02 Hz, 1 H),
[(M+H)+] 395 6.34 (s, 1 H), 5.38 (s, 2 H), 4.57 (t, J = 7.07 Hz, 2 H), 2.64 (t, J =
6.95 Hz, 2 H), 1.95 - 1.88 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.17 (d, J = 4.3 Hz, 1 H),
7.45 - 7.36 (m, 3 H), 7.14 - 7.03 (m, 2 H), 6.28 (s, 1 H), 5.31 (s, 2 MS obsd. (ESI+)-2
H), 4.72 (t, J = 7.1 Hz, 2 H), 2.72 (t, J = 6.9 Hz, 2 H), 1.78 (d, J = [(M+H)+] 395 7.8 Hz, 4 H)
Ή NMR (400 MHz, DMSO-<¼) δ ppm 8.40 (s, 1 H), 8.26 (d, J =
4.80 Hz, 1 H), 7.57 (d, J = 2.02 Hz, 1 H), 7.51 (d, J = 8.84 Hz, 1
H), 7.33 (br. s„ 1 H), 7.18 (d, J = 4.80 Hz, 1 H), 7.14 (dd, J = MS obsd. (ESI+)-3
8.84, 2.02 Hz, 1 H), 6.80 (br. s., 1 H), 6.51 (s, 1 H), 5.27 (s, 2 H), [(M+H)+] 409 4.28 - 4.12 (m, 2 H), 2.20 - 2.04 (m, 3 H), 1.89 - 1.80 (m, 2 H),
1.79 - 1.60 (m, 4 H)
]H NMR (400 MHz, CD3OD) δ ppm 8.43 - 8.20 (m, 2 H), 7.51 - 7.35 (m, 2 H), 7.22 - 7.06 (m, 2 H), 6.40 (s, 1 H), 5.38 (s, 2 H),
MS obsd. (ESI+)-1 4.58 (t, J = 6.95 Hz, 2 H), 2.92 - 2.78 (m, 1 H), 2.70 (t, J = 6.95
[(M+H)+] 499 Hz, 2 H), 1.99 - 1.83 (m, 4 H), 1.17 - 1.06 (m, 2 H), 1.00 - 0.92
(m, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.42 - 8.30 (m, 1 H), 8.24
(br. s., 1 H), 7.46 (d, J= 1.52 Hz, 1 H), 7.40 (d, J = 8.59 Hz, 1 H),
MS obsd. (ESI+)-2 7.25 - 7.05 (m, 2 H), 6.45 (s, 1 H), 5.37 (s, 2 H), 4.60 (t, J - 6.69
[(M+H)+] 513 Hz, 2 H), 3.21 - 3.12 (m, 3 H), 3.1 1 - 3.03 (m, 2 H), 2.73 - 2.63
(m, 1 H), 1.88 (s, 4 H), 1.10 - 1.01 (m, 2 H), 0.96 - 0.85 (m, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.39 - 8.28 (m, 1 H), 8.27 - 8.18 (m, 1 H), 7.45 (d, J = 1.77 Hz, 1 H), 7.39 (d, J = 8.84 Hz, 1 MS obsd. (ESI+)-3
H), 7.20 - 7.05 (m, 2 H), 6.42 (s, 1 H), 5.35 (s, 2 H), 4.56 (t, J = [(M+H)+] 487 6.95 Hz, 2 H), 3.20 - 3.09 (m, 6 H), 3.05 (t, J = 6.82 Hz, 2 H), 1.87 (s, 4 H)
1H NMR (400 MHz, CDC13) δ ppm 8.44 (s, 1 H), 8.34 - 8.32 (d, J
= 4.8 Hz, 1 H), 7.49 - 7.48 (d, J = 2 Hz, 1 H), 7.24 (s, 1 H), 7.12
(d, J = 2 Hz, 1 H), 6.84 - 6.83 (d, J =4.8 Hz, 1 H), 6.52 (s, 1 H), MS obsd. (ESI+) 5.24 (s, 2 H), 5.07 (s, 1 H), 4.49 - 4.46 (q, J = 6 Hz, 2 H), 3.90 - [(M+H)+] 450 3.86 (q, J = 6.4 Hz, 2 H), 3.65 (s, 32H), 1.95 - 1.93 (m, 2 H), 1.72
- 1.69 (m, 2 H)
1H NMR (400 MHz, CD3OD) δ ppm 8.33 (s, 1 H), 8.26 (d, J= 4.8
Hz, 1 H), 7.51 (d, J = 2.0 Hz, 1 H), 7.43 (d, J = 8.8 Hz, 1 H), 7.17
MS obsd. (ESI+) - 7.12 (m, 2 H), 6.53 (s, 1 H), 5.35 (s, 2 H), 4.33 (m, 3 H), 2.67
[(M+H)+] 451 (m, 2 H), 2.40 (m, 2 H), 1.96 - 1.85 (m, 6 H), 1.31 (m, 2 H), 0.89
(m, 2 H)
Ή NMR (400MHz, DMSO-i¾ ): δ ppm 8.45 - 8.38 (m, 1 H), 8.27
(d, J = 4.8 Hz, 1 H), 7.61 - 7.51 (m, 2 H), 7.23 - 7.12 (m, 2 H),
MS obsd. (ESI+)-1 6.49 (s, 1 H), 5.28 (s, 2 H), 4.38 (t, J = 7.7 Hz, 2 H), 3.1 1 (q, J =
[(M+H)+] 458 7.6 Hz, 4 H), 1.98 (q, J= 7.7 Hz, 2 H), 1.89 - 1.82 (m, 2 H), 1.79 - 1.72 (m, 2 H), 1.19 (t, J= 7.5 Hz, 3 H)
Ή NMR (400 MHz, DMSO- 6) δ ppm 8.15 (dd, J = 5.31 , 1.52
Hz, 1 H), 7.60 - 7.45 (m, 3 H), 7.25 - 6.93 (m, 3 H), 6.25 (s, 1 H),
MS obsd. (ESI+)-2 5.20 (s, 2 H), 4.49 (t, J = 7.45 Hz, 2 H), 3.26 - 3.15 (m, 2 H), 3.00
[(M+H)+] 444 (s, 3 H), 2.19 - 2.04 (m, 2 H), 1.84 - 1.74 (m, 2 H), 1.71 - 1.62 (m,
2 H)
Ή NMR (400 MHz, DMSO-J6) δ ppm 8.42 (s, 1 H), 8.27 (d, J =
4.80 Hz, 1 H), 7.63 - 7.49 (m, 2 H), 7.23 - 7.1 1 (m, 2 H), 6.49 (s, 1
MS obsd. (ESI+)-3 H), 5.28 (s, 2 H), 4.38 (t, J = 7.83 Hz, 2 H), 3.22 - 3.1 1 (m, 2 H),
[(M+H)+] 444 2.99 (s, 3 H), 2.06 - 1.92 (m, 2 H), 1.91 - 1.83 (m, 2 H), 1.79 - 1.73 (m, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.37 (s, 1 H), 8.27 (d, J =
4.80 Hz, 1 H), 8.23 (d, J = 2.27 Hz, 1 H), 7.97 (d, J = 2.27 Hz, 1
MS obsd. (ESI+) H), 7.17 (dd, J = 5.05, 0.76 Hz, 1 H), 6.60 (s, 1 H), 5.38 (s, 2 H),
[(M+H)+] 459 4.51 (t, J = 7.33 Hz, 2 H), 3.18 - 3.00 (m, 4 H), 2.18 (t, J = 7.83
Hz, 2 H), 1.99 - 1.86 (m, 4 H), 1.30 (t, J = 7.45 Hz, 3 H)
-1 Ή NMR (400 MHz, CDC13) δ ppm 8.38 (s, 1 H), 8.30 (d, J = 4.8 MS obsd. (ESI+) Hz, 1 H), 7.50 (s, 1 H), 7.20 (d, J = 8.8 Hz, 1 H), 7.14 (d, J = 8.8 [(M+H)+] 436 Hz, 1 H), 6.83 (d, J = 4.0 Hz, 1 H), 6.81 (s, 1 H), 5.24 (s, 2 H),
4.30 (t, J = 6.8 Hz, 2 H), 2.88 (m, 4 H), 2.53 (t, J = 6.8 Hz, 4 H),
2.43 (s, 3 H), 1.93 (m, 2 H), 1.71 (m, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.37 (d, J = 0.76 Hz, 1 H),
8.26 (d, J = 4.80 Hz, 2 H), 7.53 (d, J = 2.02 Hz, 1 H), 7.44 (d, J =
MS obsd. (ESI+)-2 8.84 Hz, 1 H), 7.21 - 7.12 (m, 2 H), 6.58 (d, J = 0.51 Hz, 1 H),
[(M+H)+] 514 5.32 (s, 2 H), 4.40 (s, 2 H), 3.23 - 3.15 (m, 4 H), 3.08 - 2.99 (m, 2
H), 2.90 - 2.83 (m, 4 H), 2.15 - 2.02 (m, 2 H), 1.98 - 1.87 (m, 4 H)
1H NMR (400 MHz, CD3OD) δ ppm 8.37 (d, J = 0.51 Hz, 1 H),
8.26 (d, J = 4.80 Hz, 1 H), 7.53 (d, J = 2.02 Hz, 1 H), 7.47 - 7.41
(m, 1 H), 7.20 - 7.14 (m, 2 H), 6.57 (s, 1 H), 5.32 (s, 2 H), 4.45 -
MS obsd. (ESI+)-3 4.38 (m, 2 H), 4.32 - 4.27 (m, 1 H), 3.82 - 3.76 (m, 1 H), 3.38 - [(M+H)+] 526 3.34 (m, 1 H), 3.25 - 3.20 (m, 1 H), 3.1 1 - 3.01 (m, 3 H), 2.93 - 2.89 (m, 1 H), 2.13 - 2.06 (m, 2 H), 1.94 - 1.90 (m, 4 H), 1.76 - 1.72 (m, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.40 - 8.36 (m, 1 H), 8.27 - 8.22 (m, 1 H), 7.53 - 7.51 (m, 1 H), 7.43 - 7.39 (m, 1 H), 7.16 (s, 2
MS obsd. (ESI+)-4 H), 6.61 - 6.59 (m, 1 H), 5.31 (s, 2 H), 4.32 - 4.24 (m, 2 H), 3.53 - [(M+H)+] 464 3.48 (m, 4 H), 3.42 - 3.37 (m, 2 H), 3.14 - 3.09 (m, 2 H), 2.02 - 1.95 (m, 2 H), 1.91 (d, J= 6.57 Hz, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.40 - 8.31 (m, 1 H), 8.28 - 8.21 (m, 1 H), 7.55 - 7.38 (m, 3 H), 7.15 (s, 2 H), 6.55 - 6.46 (m, 1 MS obsd. (ESI+)-5
H), 5.34 (s, 2 H), 4.40 - 4.28 (m, 2 H), 2.93 - 2.81 (m, 2 H), 1.98 - [(M+H)+] 367 1.86 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.36 (s, 1 H), 8.26 (d, J =
4.80 Hz, 1 H), 8.22 (d, J = 2.27 Hz, 1 H), 7.97 (d, J = 2.27 Hz, 1 MS obsd. (ESI+)-1
H), 7.16 (s, 1 H), 6.60 (s, 1 H), 5.38 (s, 2 H), 4.49 (s, 2 H), 3.06 (s, [(M+H)+] 460 2 H), 2.65 (s, 3 H), 2.20 - 2.08 (m, 2 H), 1.99 - 1.85 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.41 - 8.34 (m, 1 H), 8.29 - 8.20 (m, 1 H), 7.56 - 7.51 (m, 1 H), 7.48 - 7.42 (m, 1 H), 7.20 - MS obsd. (ESI+)-2
7.1 1 (m, 2 H), 6.63 - 6.52 (m, 1 H), 5.33 (s, 2 H), 4.47 - 4.34 (m, 2 [(M+H)+] 459 H), 3.1 1 - 3.00 (m, 2 H), 2.65 (s, 3 H), 2.13 - 2.01 (m, 2 H), 1.92 (d, J= 7.58 Hz, 4 H)
Ή NMR (400 MHz, DMSO-J6) δ ppm 8.44 - 8.39 (m, 1 H), 8.26
(s, 2 H), 8.07 (s, 1 H), 7.24 - 7.16 (m, 1 H), 6.81 (s, 2 H), 6.51 (s, MS obsd. (ESI+)-3
1 H), 5.33 (s, 2 H), 4.48 - 4.37 (m, 2 II), 3.08 - 2.94 (m, 2 H), 2.17 [(M+H)+] 446 - 2.01 (m, 2 H), 1.92 - 1.84 (m, 2 H), 1.81 - 1.72 (m, 2 H)
Ή NMR (400 MHz, DMSO-J6) δ ppm 8.32 (s, 1 H), 8.25 (d, J =
4.0 Hz, 1 H), 7.51 (s, 1 H), 7.46 (d, J = 8.8 Hz, 1 H), 7.18 (d, J =
MS obsd. (ESI+)-1 4.8 Hz, 1 H), 7.10 (dd, J= 8.8, 2.0 Hz, 1 H), 6.32 (s, 1 H), 5.32 (s,
[(M+H)+] 478 2 H), 4.35 (t, J = 6.0 Hz, 2 H), 2.48 (s, 6 H), 2.33 (m, 4 H), 1.94
(s, 3 H), 1.86 (m, 2 H), 1.73 (m, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.38 - 8.34 (m, 1 H), 8.28 - 8.25 (m, 1 H), 8.24 - 8.21 (m, 1 H), 7.98 - 7.94 (m, 1 H), 7.19 -
MS obsd. (ESI+)-2 7.15 (m, 1 H), 6.59 - 6.56 (m, 1 H), 5.37 (s, 2 H), 4.54 - 4.43 (m, 2
[(M+H)+] 488 H), 3.42 - 3.35 (m, 2 H), 2.25 - 2.14 (m, 2 H), 2.00 (s, 3 H), 1.94
(d, J= 12.38 Hz, 4 H)
Ή NMR (400 MHz, DMSO-d6) δ ppm 8.36 (s, 1 H), 8.27 (d, J =
4.77 Hz, 1 H), 8.1 1 - 8.03 (m, 1 H), 7.53 (d, J = 2.01 Hz, 2 H),
MS obsd. (ESI+)-3 7.20 (d, J= 5.02 Hz, 1 H), 7.17 - 7.1 1 (m, 1 H), 6.28 (s, 1 H), 5.25
[(M+H)+] 409 (s, 2 H), 4.32 (s, 2 H), 3.33 - 3.28 (m, 2 H), 1.86 (s, 2 H), 1.80 - 1.72 (m, 5 H)
Ή NMR (400 MHz, DMSO-J6) δ ppm 8.34 (s, 1 H), 8.25 (s, 1 H),
7.47 (m, 2 H), 7.17 (m, 2 H), 6.34 (s, 1 H), 5.31 (s, 2 H), 4.35 (s, 2 MS obsd. (ESI+)-1
H), 3.06 (s, 6 H), 2.83 (s, 3 H), 2.65 (m, 4 H), 1.85 (m, 2 H), 1.73 [(M+H)+] 514 (m, 2 H).
Ή NMR (400 MHz, DMSO-d6) δ ppm 8.42 - 8.33 (m, 1 H), 8.31 - 8.24 (m, 1 H), 7.59 - 7.49 (m, 1 H), 7.24 - 7.08 (m, 2 H), 6.32 - MS obsd. (ESI+)-2
6.21 (m, 1 H), 5.39 - 5.24 (m, 2 H), 4.43 - 4.31 (m, 2H), 3.30 - [(M+H)+] 445 3.19 (m, 2 H), 2.77 (s, 3 H), 1.92 - 1.70 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.40 - 8.32 (m, 1 H), 8.28 - 8.23 (m, 1 H), 7.56 - 7.47 (m, 1 H), 7.45 - 7.36 (m, 1 H), 7.21 -
MS obsd. (ESI+)-3 7.10 (m, 2 H), 6.60 - 6.49 (m, 1 H), 5.39 - 5.26 (m, 2 H), 4.34 - [(M+H)+] 459 4.29 (m, 4 H), 2.94 (s, 3 H), 1.71 - 1.65 (m, 2 H), 1.46 - 1.40, 2
H), 1.05 (s, 4 H) 1H NMR (400 MHz, CD3OD) δ ppm 8.40 - 8.31 (m, 1 H), 8.29 - 8.21 (m, 1 H), 7.56 - 7.40 (m, 2 H), 7.15 (s, 2 H), 6.55 - 6.45 (m, 1 MS obsd. (ESI+) H), 5.34 (s, 2 H), 4.43 - 4.24 (m, 2 H), 2.93 - 2.78 (m, 2 H), 1.98 - [(M+H)+] 409 1.83 (m, 4 H)
Ή NMR (400 MHz, DMSO-c/6) δ ppm 8.47 - 8.21 (m, 2 H), 7.56
(s, 2 H), 7.11 (s, 2 H), 6.45 (s, 1 H), 5.29 (s, 2 H), 4.35 - 4.20 (m, MS obsd. (ESI+) 2 H), 3.52 - 3.39 (m, 2 H), 2.55 (s, 6 H), 1.86 (s, 2 H), 1.77 - 1.62 [(M+H)+] 425 (m, 2 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.47 (s, 1 H), 8.34 (d, J= 4.80
Hz, 1 H), 7.56 (d, J = 1.01 Hz, 1 H), 7.23 - 7.13 (m, 2 H), 6.90 - 6.79 (m, 1 H), 6.62 (s, 1 H), 5.20 (s, 2 H), 4.29 - 4.19 (m, 2 H), MS obsd. (ESI+) 4.14 (q, J = 7.24 Hz, 1 H), 3.71 (s, 3 H), 3.26 (d, J = 5.81 Hz, 2 [(M+H)+] 439 H), 1.98 (q, J = 4.13 Hz, 2 H), 1.90 (dt, J = 14.21, 6.92 Hz, 2 H),
1.73 (d, J= 3.79 Hz, 2 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.33 (s, 1 H), 8.25 (d, J= 5.1
Hz, 1 H), 7.51 (d, J=1.5 Hz, 1 H), 7.38 (d, J= 8.6 Hz, 1 H), 7.22 -
MS obsd. (ESf ) 7.08 (m, 2 H), 6.54 (s, 1 H), 5.33 (s, 2 H), 4.36 (t, J = 7.3 Hz, 2
[(M+H)+] 507 H), 4.27 - 4.21 (m, 1 H), 4.07 (t, J = 5.9 Hz, 2 H), 3.82 (d, J = 9.3
Hz, 2 H), 2.09 - 1.84 (m, 5 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.28 - 8.21 (m, 1 H), 7.55 - 7.47 (m, 1 H), 7.42 - 7.27 (m, 2 H), 7.09 -6.96 (m, 2 H), 5.24 (s, 2 MS obsd. (ESf)-1
H), 3.43 (d, J = 3.54 Hz, 4 H), 3.10 (d, J = 7.58 Hz, 2 H), 1.83 - [(M+H)+] 444 1.66 (m, 4 H), 1.44 - 1.17 (m, 3 H)
1H NMR (400 MHz, CD3OD) δ ppm 8.28 - 8.19 (m, 1 H), 8.15 (s,
1 H), 7.59 - 7.48 (m, 1 H), 7.33 (d, J = 1.52 Hz, 1 H), 7.15 (d, J = MS obsd. (ESI+)-2
4.80 Hz, 1 H), 7.10 - 7.00 (m, 1 H), 5.27 (s, 2 H), 2.93 (s, 3 H), [(M+H)+] 430 1.92 (s, 2 H), 1.90 - 1.83 (m, 2 H)
JH NMR (400 MHz, DMSO-c/6) δ ppm 1 1.24 - 1 1.10 (m, 1 H),
8.29 - 8.17 (m, 2 H), 7.55 (d, J = 8.59 Hz, 1 H), 7.37 (d, J = 1.77
MS obsd. (ESf) Hz, 1 H), 7.16 (d, J = 4.80 Hz, 1 H), 7.02 (dd, J = 8.59, 1.77 Hz, 1
[(M+H)+] 444 H), 5.15 (s, 2 H), 3.01 - 3.13 (m, 2 H), 2.97 - 2.86 (m, 5 H), 1.96 - 1.86 (m, 2 H), 1.85 - 1.79 (m, 2 H), 1.77 - 1.70 (m, 2 H)
-1 Ή NMR (400 MHz, CD3OD) δ ppm 8.41 (s, 1 H) 8.28 (d, J = MS obsd. (ESf) 5.05 Hz, 1 H), 7.63 (d, J = 9.09 Hz, 1 H), 7.59 (d, J = 1.52 Hz, 1 [(M+H)+] 433 H), 7.36 (dd, J = 8.72, 1.89 Hz, 1 H), 7.18 (dd, J = 4.80, 0.76 Hz,
1 H), 5.54 (s, 2 H), 4.94 (t, J = 6.44 Hz, 2 H), 3.79 (t, J = 6.44 Hz,
2 H), 3.03 (s, 3 H), 1.87 - 1.95 (m, 4 H)
Ή NMR (400 MHz, DMSO-c/6) δ ppm 7.67 (s, 1.5 H), 7.64 (s, 0.5
H), 7.32 (d, J = 8.4 Hz, 1 H), 7.24 (dd, J = 14, 7.6 Hz, 1 H), 7.03
MS obsd. (ESI+)-2 (d, J = 8.0 Hz, 1 H), 6.85 (t, J = 9.2 Hz, 1 H), 5.41 (s, 2 H), 4.83
[(M+H)+] 449 (t, J = 6.4 Hz, 2 H), 3.77 (t, J = 6.4 Hz, 2 H), 3.09 (s, 3 H), 1.92
(d, J = 3.2 Hz, 2 H), 1.62 (d, J= 3.2 Hz, 2 H)
Ή NMR (400 MHz, DMSO-c¾ δ ppm 7.66 (m, 2 H), 7.32 (dd, J
= 8.8, 2.0 Hz, 1 H), 7.23 (t, J = 8.0 Hz, 1 H), 7.15 (d, J = 7.2 Hz,
MS obsd. (ESI+)-3 1 H), 7.03 (dd, J = 8.4, 0.8 Hz, 1 H), 5.41 (s, 2 H), 4.83 (t, J = 6.8
[(M+H)+] 465 Hz, 2 H), 3.77 (t, J = 6.4 Hz, 2 H), 3.09 (s, 3 H), 1.92 (dd, J = 8.0,
4.0 Hz, 2 H), 1.56 (dd, J= 8.0, 4.0 Hz, 2 H)
Ή NMR (400 MHz, DMSO-c¾ δ ppm 7.66 (m, 2 H), 7.32 (dd, J
= 8.8, 2.0 Hz, 1 H), 7.20 - 7.15 (m, 3 H), 5.41 (s, 2 H), 4.83 (t, J = MS obsd. (ESI+)-4
6.8 Hz, 2 H), 3.77 (t, J = 6.4 Hz, 2 H), 3.09 (s, 3 H), 2.28 (dd, J = [(M+H)+] 509 7.6, 4.0 Hz, 2 H), 1.52 (dd, J= 7.6, 3.6 Hz, 2 H)
1H NMR (400 MHz, CD3OD) δ ppm 8.41 (s, 1 H), 8.28 (d, J = 5.1
Hz, 1 H), 7.68 - 7.54 (m, 2 H), 7.40 - 7.31 (m, 1 H), 7.18 (d, J =
MS obsd. (ESI+)-5 4.8 Hz, 1 H), 5.55 (s, 2 H), 4.94 (d, J = 6.6 Hz, 2 H), 3.73 (t, J =
[(M+H)+] 445 6.3 Hz, 2 H), 3.12 (q, J = 7.6 Hz, 2 H), 1.92 (m, 4 H), 1.34 (t, J =
7.3 Hz, 3 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.47 (s, 1 H), 8.28 (d, J =
4.80 Hz, 1 H), 7.64 (d, J = 1.26 Hz, 1 H), 7.59 (d, J = 8.84 Hz, 1
H), 7.35 (dd, J = 8.84, 1.77 Hz, 1 H), 7.17 (d, J = 5.05 Hz, 1 H), MS obsd. (ESI+) 5.42 (s, 2 H), 4.46 - 4.37 (m, 2 H), 4.27 (dd, J = 13.89, 9.60 Hz, 2 [(M+H)+] 457 H), 3.95 (dd, J = 14.02, 6.44 Hz, 2 H), 2.73 - 2.62 (m, 1 H), 2.20
(q, J = 7.75 Hz, 2 H), 1.99 - 1.86 (m, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.43 (s, 1 H), 8.28 (d, J = 5.1
Hz, 1 H), 7.68 - 7.58 (m, 2 H), 7.40 - 7.30 (m, 1 H), 7.17 (d, J = MS obsd. (ESI+)-1
4.8 Hz, 1 H), 5.45 (s, 2 H), 4.57 (t, J = 7.7 Hz, 2 H), 3.28 (t, J = [(M+H)+] 445 7.3 Hz, 2 H), 3.02 (s, 3 H), 2.30 (br. s, 2 H), 1.92 (m, 4 H) 'Η NMR (400 MHz, CD3OD) δ ppm 8.41 (d, J = 0.51 Hz, 1 H), 8.28 (d, J= 4.80 Hz, 1 H), 7.63 (d, J- 8.34 Hz, 1 H), 7.59 (d, J =
1.77 Hz, 1 H), 7.37 (d, J = 2.02 Hz, 1 H), 7.18 (dd, J = 5.05, 0.76 MS obsd. (ESI+)-2
Hz, 1 H), 5.55 (s, 2 H), 4.99 - 4.90 (m, 2 H), 3.79 (t, J = 6.57 Hz, [(M+H)+]459 2 H), 2.65 - 2.54 (m, 1 H), 1.92 (d, J = 2.27 Hz, 4 H), 1.14 (br. s.,
2 H), 1.09 - 1.00 (m, 2 H)
Ή NMR (400 MHz, DMSO-<¾) δ ppm 8.34 (s, 1 H), 8.25 (d, J =
4.8 Hz, 1 H), 7.55 (d, J = 1.6 Hz, 1 H), 7.30 (dd, J = 11.2, 1.6 Hz,
MS obsd. (ESI+)-1 1 H), 7.17 (d, J= 1.6 Hz, 1 H), 5.46 (s, 2 H), 4.87 (d, J= 6.8 Hz, 2
[(M+H)+] 448 H), 3.81 (d, J= 6.8 Hz, 2 H), 3.1 1 (s, 3 H), 1.85 (m, 2 H), 1.72 (m,
2 H)
Ή NMR (400 MHz, DMSO-t¾) δ ppm 8.35 (s, 1 H), 8.25 (d, J =
4.8 Hz, 1 H), 7.70 (d, J = 1.6 Hz, 1 H), 7.43 (d, J = 2.0 Hz, 1 H),
MS obsd. (ESI+)-2 7.17 (d, J = 4.8 Hz, 1 H), 5.49 (s, 2 H), 5.02 (t, J = 6.0 Hz, 2 H),
[(M+H)+] 464 3.84 (t, J = 6.0 Hz, 2 H), 3.15 (s, 3 H), 1.85 (m, 2 H), 1.72 (m, 2
H)
Ή NMR (400 MHz, CDC13) δ ppm 8.78 (s, 1 H), 8.36 - 8.34 (br.s,
J = 4.8 Hz, 1 H), 7.75 (s, 1 H), 7.29 - 7.24 (m, 2 H), 6.82 - 6.81 MS obsd. (ESI+)-1
(m, 1 H), 5.32(s, 2 H), 4.71 - 4.63 (m, 4 H), 4.44 - 4.41 (m, 2 H), [(M+H)+] 395 3.42 - 3.35 (m, 1 H), 1.94 - 1.91 (m, 2 H), 1.73 - 1.70 (m, 2 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.79 (s, 1 H), 8.34 (d, J = 4.8
Hz, 1 H), 7.77 (d, J = 2.0 Hz, 1 H), 7.28 (m, l H), 7.20 (d, J= 8.8
MS obsd. (ESI+)-2 Hz, 1 H), 6.81 (d, J = 5.2 Hz, 1 H), 5.30 (s, 2 H), 4.77 (t, J = 7.6
[(M+H)+] 409 Hz, 2 H), 4.32 (t, J = 6.0 Hz, 2 H), 4.22 (t, J = 7.6 Hz, 2 H), 3.02
(m, 1 H), 2.08 (q, J = 7.6 Hz, 2 H), 1.92 (m, 2 H), 1.70 (m, 2 H)
JH NMR (400 MHz, CD3OD) δ ppm 8.42 (s, 1 H), 8.29 (d, J =
5.02 Hz, 5 H), 7.44 (d, J = 1.51 Hz, 1 H), 7.20 - 7.14 (m, 2 H),
MS obsd. (ESI+)-3 5.44 (s, 2 H), 4.85 (d, J = 7.28 Hz, 2 H), 4.80 (t, J = 6.50 Hz, 2 H),
[(M+H)+] 413 4.57 (t, J = 6.27 Hz, 2 H), 3.65 (m, J = 7.40, 6.15 Hz, 1 H), 1.91
(s, 4 H)
Ή NMR (400 MHz, CD3OD) δ ppm 8.34 (s, 1 H), 8.27 (d, J =
MS obsd. (ESI+)-1 5.02 Hz, 1 H), 7.72 (d, J = 8.78 Hz, 1 H), 7.57 (d, J = 1.76 Hz, 1
[(M+H)+] 410 H), 7.34 (dd, J = 8.78, 1.76 Hz, 1 H), 7.17 (d, J = 4.77 Hz, 1 H), 5.55 (s, 2 H), 4.76 (s, 2 H), 4.70 (d, J= 6.78 Hz, 2 H), 4.48 (d, J =
6.78 Hz, 2 H), 1.90 (s, 4 H)
Ή NMR (400 MHz, CDC13) δ ppm 8.36 (s, 1 H), 8.28 - 8.27 (d, J
= 4.8 Hz, 1 H), 7.42 (s, 1 H), 7.19 - 7.14 (m, 2 H), 5.56 (s, 2 H), MS obsd. (ESI+)
39-2
4.92 - 4.91 (m, 1 H), 4.71 - 4.70 (d, J = 7.2 Hz, 1 H), 4.49 - 4.47 [(M+H)+] 428 (d, J= 6.8 Hz, 1 H), 1.91 - 1.90 (m, 4 H)
More particular compounds of formula I include the following:
1 '-( { 5-Bromo- 1 -[2-(methylsulfonyl)ethyl]- 1 H-indol-2-yl } methyl)spiro [cyclopropane- 1 ,3 '- pyrrolo[2,3-c]pyridin]-2'(rH)-one;
1 '-( { 5 -Chloro-7-fluoro- 1 - [2-(methy lsulfony l)ethy 1] - 1 H-indol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] -2'( 1 /)-one;
1 '-( { 5-Methyl- 1 - [2-(methylsulfonyl)ethyl] - 1 H-indol-2-yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'( 1 'H)-one;
l'-({ 5 -Chloro-1 - [2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
l'-({5-Chloro-l-[2-(ethylsulfonyl)ethyl]-lH-pyrrolo[2,3-b]pyridin-2- yljmethy^spirofcyclopropane-l ^'-pyrrolop^-cJpyridinJ^ HJ-one;
1 '-( { 5 -^Chloro- 1 - [2-(methy lsulfony l)ethyl] - 1 H-indol-2-y 1 } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(rH)-one;
1 '-( { 5-Chloro- 1 - [4-(methylsulfonyl)butyl]- 1 H-indol-2-yl } methyl)spiro [cyclopropane- 1 ,3 '- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
l'-({5-Chloro-l-[2-(l,l -dioxidothietan-3-yl)ethyl]- lH-pyrrolo[2,3-c]pyridin-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( {5-Chloro- 1 -[3 -(methylsulfonyl)propyl] - lH-pyrrolo [3 ,2-¾]pyridin-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
1 '-({ 5-Chloro- 1 - [3 -(methylsulfinyl)propyl]- 1 H-indol-2-yl} methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(rH)-one;
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)-yl)methyl]- 1 H-indol- 1 -yl } -N,7V-dimethylpropane- 1 -sulfonamide;
l'-({5-Chloro-l-[3-(morpholin-4-ylsulfonyl)propyl]-lH-indol-2- yl } methyl)spiro[cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one; 1 '-( { 5-Chloro- 1 -[3 -(pyrrolidin- 1 -ylsulfonyl)propyl]- 1 H-indol-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one;
1 '- [(5 -Chloro- 1 - { 3 - [(3 -oxopiperazin- 1 -yl)sulfonyl] propyl } - 1 H-indol-2- yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5 -Chloro- 1 - [4-( 1 , 1 -dioxido- 1 ,2-thiazolidin-2-y l)butyl] - 1 H-indol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
1 '- [ { 5 -Chloro- 1 - [2-(methylsulfonyl)ethyl] - 1 H-indol-2-yl } (2H2)methy 1] spiro [cyclopropane- l ,3'-pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
1 '- [ { 5 -Chloro- 1 - [3 -(methylsulfony l)propyl] - 1 H-indol-2- yl } ( H2)methyl] spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] -2'(l 'H)-one;
Ethyl 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- (2'H)- yl)methyl]- 1 H-indol- 1 -yl }propanoate;
Ethyl 3-{5-chloro-7-fluoro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- 1 '(2'H)-yl)methyl] - 1 H-indol- 1 -yl }propanoate;
1 '-( { 5 -Chloro- 1 - [3 -(S-methylsulfonimidoyl)propy 1] - 1 H-indol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3-c]pyridin]-2'( 1 'H)-one;
l'-CiS-Chloro-l -P-C.S-methylsulfonimidoy ethyll-lH-indol^- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
Methyl 4-{5-chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- (2'H)- yl)methyl] - 1 H-indol- 1 -y 1 } butanoate;
3 - { 5-Chloro-2-[(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin]- 1 '(2'H)-yl)methyl] - 1 H-indol- 1 -yl } propanamide;
4-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyiTolo[2,3-c]pyridin]-l '(2'H)-yl)methyl]- 1 H-indol- 1 -yl }butanamide;
1 '-( { 5 -Chloro- 1 - [3 -(ethy lsulfony l)propy 1] - 1 H-indol-2-y 1 } methy l)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(rH)-one;
1 '-( { 5 -Chloro- 1 - [3 -(methylsulfony l)propyl] - 1 H-indol-2-yl } methy l)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
1 '-( { 5-Chloro- 1 -[3 -(piperazin- 1 -ylsulfonyl)propyl]- 1 H-indol-2- yl } methy l)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
l'-[(5-Chloro- l -{3-[(li?,4i?)-2,5-diazabicyclo[2.2.1]hept-2-ylsulfonyl]propyl}-lH-indol-2- yl)methyl]spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one; 3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)-yl)methyl]- 1 H-indol- 1 -yl } -N-methylpropane- 1 -sulfonamide;
1 '- [(5 -Chloro- 1 - { 2- [4-(methylsulfonyl)piperazin- 1 -yl] ethyl } - 1 H-indol-2- yl)methyl]spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
N-(2-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- (2'H)- yl)methyl]- 1 H-indol- 1 -yl} ethyl)methanesulfonamide;
Methyl (3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-r(2'H)- yl)methyl]-lH-indol-l-yl}propyl)carbamate;
l'-({6-Chloro-3-[2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane-l,3'- pyrrolo[2,3-0]pyridin]-2'(l 'H)-one;
r-({6-Chloro-3-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane-l,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
r-({6-Chloro-3-[3-(methylsulfonyl)propyl]-lH-indol-2-yl}methyl)spiro[cyclopropane-l,3'- pyrrolo[2,3-c]pyridin]-2'(l'H)-one;
1 '-( { 5 -Chloro- 1 - [2-(methylsulfonyl)ethyl] - 1 H-benzimidazol-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2-yl}methyl)-4'- fluorospiro [cyclopropane- 1 ,3 '-indol] -2'( 1 'H)-one;
l'-({5-Chloro-l-[2-(ethylsulfonyl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-({5-Chloro- l-[2-(l , 1 -dioxidothietan-3-yl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
r-({5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5-Chloro- 1 - [2-(cyclopropylsulfonyl)ethyl]- 1 H-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
r-({5-Chloro-7-fluoro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- y 1 } methy l)spiro [cy cloprop ane- 1 , 3 '-pyrrolo [2,3 -c]pyridin] -2 '( 1 'H)-one;
l'-({5,7-Dichloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro [cyclopropane- 1 , 3 '-pyrrolo [2,3 -c]pyridin] -2'(1 'H)-one;
l'-{ [5-Chloro- l-(oxetan-3-ylmethyl)-lH-benzimidazol-2-yl]methyl}spiro[cyclopropane- l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one; l '-({5-Chloro- l-[2-(oxetan-3-yl)ethyl]-lH-benzimidazol-2-yl}methyl)spiro[cyclopropane- 1 ,3'-pyrrolo[2,3-c]pyridin]-2'(l 'H)-one; and
l '-({ l -[(3-Aminooxetan-3-yl)methyl]-5-chloro-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one.
Compound with favorable pharmacokinetics is more likely to be efficacious and safe. It is very important for a drug to have a moderate or low clearance and a long half-life, as this often lead to a good oral bioavailability and high exposure in systemic exposure. Reducing the clearance and increasing half-life time of a compound or drug could reduce the daily dose required for efficacy and therefore give a better efficacy and safety profile. From the examples below, it has been found a good SDPK profiling of this invention: good exposure at low dose, longer t 1/2 (more than 1 hour), low to moderate clearance and good bioavailability (see Table 3).
The single dose PK in male ICR mouse was performed to assess their pharmacokinetic properties. Two groups of animals were dosed via either bolus intravenous (IV) or oral gavage (PO) of the respective compound. The animals for oral administration were fasted overnight prior to dosing and food was resumed 4 hours postdose. Blood samples (approximately 400 μϋ,) were collected via cardiac puncture after euthanasia by carbon dioxide inhalation at 2 minutes, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, and 24 hours postdose for IV group, and at 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, and 24 hours postdose for PO group. Blood samples were placed into tubes containing sodium heparin and centrifuged at 8000 rpm for 6 minutes at 4°C to separate plasma from the samples.
Following centrifugation, the resulting plasma was transferred to clean tubes for
bioanalysis on LC/MS/MS. The pharmacokinetic parameters were calculated using non- compartmental module of WinNonlin® Professional 5.2.
Table 3. Selected Pharmacokinetics Parameters of Compounds in Male ICR Mice
Following Intravenous and Oral Administration
Figure imgf000069_0001
Example 2-6
μg/L*hr hr mL/min/kg % IV (5 mg/kg) 3510 0.724 23.7 NA*
PO i25 mg/kg) 10200 0.701 NA* 58.3
Figure imgf000070_0001
Example 34-1
μg/L*hr hr mL/min/kg %
IV fl.45 mg/Kg) 373 10.2 64.8 NA*
PO (25 mg/kg) 3280 2.98 NA* 51.0
Figure imgf000070_0002
Example 37-1
μg L*hr hr mL/min/kg %
IV (2 mg/kg) 751 0.976 44.4 NA*
PO (25 mg/kg) 9290 3.74 NA* 99
In the above Table 3, the abbreviations have the following meanings:
AUC(o-t): area under the curve from 0 to t hour;
ti/2z: terminal half-life
CLz: clearance;
F: bioavailability;
IV: intravenous;
PO: oral gavage.
NA: not applicable
SYNTHESIS
The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R1 to R6, W1 to W3, A and X are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.
General synthetic route for Compound Iaa (Scheme 1) Scheme 1
Figure imgf000071_0001
Compound of interest Iaa can be prepared according to Scheme 1.
Hydroxymethyl indole IVa can be prepared by reduction of Ci^alkyl ester Ila. The conversion can be carried out by treating Ci-6alkyl ester Ila with lithium aluminum hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours.
Sulfone Via can be prepared by coupling of hydroxymethyl indole IVa and (C\.
6alkylsulfonyl)ethene Va. The reaction can be carried out with a suitable base such as cesium carbonate in a suitable organic solvent such as acetonitrile or N,N-dimethylformamide at a temperature between room temperature and 50 °C for several hours. Intermediate Vila can be prepared by treating hydroxy Via with thionyl chloride or methanesulfonyl chloride. When L3 is chloride, the reaction can be carried out by treating hydroxy Via with thionyl chloride in dichloromethane at a temperature between room temperature and 60 °C for 30 minutes to several hours. When L3 is methanesulfonate, the reaction can be carried out by treating hydroxy Via with methanesulfonyl chloride in the presence of an organic base such as triethylamine or diisopropylethylamine in dichloromethane at a temperature between 0 °C and room temperature for one to several hours.
Compound of interest Iaa can be prepared by Mitsunobu reaction of hydroxy Via and amide III. The reaction can be carried out in the presence of a phosphine reagent such as triphenylphosphine or tributylphosphine, and an azidocarbonyl reagent such as diethyl azodicarboxylate, diisopropyl azodicarboxylate, l, l-(azodicarbonyl)dipiperidine or Ν,Ν,Ν,Ν- tetramethylazodicarboxamide in an inert organic solvent such as tetrahydrofuran, diethyl ether, acetonitrile or toluene at a temperature between room temperature and 80 °C for several hours.
Compound of interest Iaa can also be prepared by reaction of intermediate Vila and amide III. The reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium fert-butoxide in an organic solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 0 °C to room temperature for one to several hours.
General synthetic route for Compound lab (Scheme 2)
Scheme 2
Figure imgf000073_0001
Vllb lab
X1 is chloro, bromo, iodo, 4-methylbenzenesulfonate or hydroxy;
L is alkyl;
L3 is chloro or -OS02CH3.
Compound of interest lab can be prepared according to Scheme 2.
N-Substituted indole Villa can be prepared by reaction of Ila and Vb. When X1 is chloro, bromo, iodo or 4-methylbenzenesulfonate, the reaction can be carried out in the presence of a base such as potassium carbonate or cesium carbonate in a suitable solvent such as acetonitrile or N,N-dimethylformamide at a temperature between 70 °C and 100 °C for several hours. When X1 is hydroxy, The reaction can be carried out in the presence of a phosphine reagent such as triphenylphosphine or tributylphosphine and an azidocarbonyl reagent such as diethyl azodicarboxylate, diisopropyl azodicarboxylate, l,l-(azodicarbonyl)dipiperidine or Ν,Ν,Ν,Ν- tetramethylazodicarboxamide in an inert organic solvent such as tetrahydrofuran, diethyl ether, acetonitrile or toluene at a temperature between room temperature and 80 °C for several hours.
Hydroxy VIb can be prepared by reduction of Ci-6alkyl ester Villa in the presence of lithium aluminum hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours.
Intermediate Vllb can be prepared by treating hydroxy VIb with thionyl chloride or methanesulfonyl chloride. When L is chloro, the reaction can be carried out by treating hydroxy Via with thionyl chloride in dichloromethane at a temperature between room temperature and 60 °C for 30 minutes to several hours. When L3 is methanesulfonate, the reaction can be carried out by treating hydroxy Via with methanesulfonyl chloride in the presence of an organic base such as triethylamine or diisopropylethylamine in dichloromethane at a temperature between 0 °C and room temperature for one to several hours.
Compound of interest lab can be prepared by reaction of intermediate Vllb and amide III. The reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium teri-butoxide in an organic solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
General synthetic route for Compound lac (Scheme 3)
Scheme 3
Figure imgf000075_0001
Xllla lac
X2 is chloro, bromo, iodo or 4-methylbenzenesulfonate;
L is C^e alkyl.
Compound of interest lac can be prepared according to Scheme 3.
N-protected indole IX can be prepared by reaction of indole Ila and benzenesulfonyl chloride. The reaction can be carried out in the presence of sodium hydride in N,N- dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
Hydroxy Xa can be prepared by reduction of ester IX in the presence of lithium aluminum hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours. Chloride XI can be prepared by treating hydroxy Xa with thionyl chloride. The reaction can be carried out in dichloromethane at a temperature between room temperature and 60 °C for 30 minutes to several hours.
Compound XII can be prepared by reaction of chloride XI and amide III. The reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium tert- butoxide in an organic solvent such as acetonitrile or N,N-dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
Key intermediate Xllla can be prepared by deprotection of benzenesulfonyl XII. The reaction can be carried out in the presence of tetrabutylammonium fluoride in tetrahydrofuran at room temperature for several hours.
Compound of interest lac can be prepared by substitution reaction of intermediate Xllla and intermediate Vc. The reaction can be carried out in the presence of a base such as potassium carbonate or cesium carbonate in a suitable solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 70 °C and 100 °C for several hours.
Figure imgf000076_0001
X2 is chloro, bromo, iodo or 4-met ylbenzenesulfonate;
L3 is chloro or -OS02CH3.
Compound of interest lad can be prepared according to Scheme 4. Silyloxy XV can be prepared by reaction of hydroxy IVa and tert- butyl(chloro)dimethylsilane. The reaction can be carried out in the presence of imidazole in dichloromethane at room temperature for several hours.
N-Substituted indole XVI can be prepared by substitution reaction of indole XV and intermediate Vc. The reaction can be carried out in the presence of a base such as potassium carbonate or cesium carbonate in a suitable solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 70 °C and 100 °C for several hours.
Hydroxy VIb can be prepared by deprotection of silyloxy XVI. The reaction can be carried out by treating silyloxy XVI with tetrabutylammonium fluoride in tetrahydrofuran at room temperature for several hours.
Compound of interest lad can be prepared in analogy to Compound lab in Scheme 3 starting with hydroxy VIb and amide III.
General synthetic route for Compounds Iae and Iaf (Scheme 5)
Scheme 5
Figure imgf000078_0001
Figure imgf000078_0002
L1 is C^ alkyl.
Compounds of interest Iae and Iaf can be prepared according to Scheme 5.
ethylsulfanyl XVII can be prepared by reaction of indole Ila and bromide Vd and then followed by the reaction with sodium methanethiolate. The reaction of indole Ila and bromide Vd can be carried out in the presence of a base such as potassium carbonate or cesium carbonate in a suitable solvent such as acetone, acetonitrile or N, N-dimethylformamide at a temperature between 55 °C and 80 °C for several hours. The reaction of bromide with sodium methanethiolate can be carried out in ethanol at room temperature for several hours.
Hydroxymethyl indole XVIII can be prepared by reduction of ester XVII in the presence of lithium aluminum hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours.
ethylsulfoxide XIX can be prepared by reaction of hydroxymethyl indole XVIII and tert- butyl(chloro)dimethylsilane and then followed by oxidation of methylsulfanyl. The reaction of hydroxy XVIII with tert-butyl(chloro)dimethylsilane can be carried out in the presence of 4- dimethylaminopyridine and triethylamine in dichloromethane at a temperature between 0 °C and room temperature for several hours. Oxidation reaction can then be carried out with 3- chlorobenzene-l-carboperoxoic acid in dichloromethane at room temperature for several hours. Trifluoroacetyl sulfonimidoyl XX can be prepared by reaction of methylsulfoxide XIX and trifluoroacetamide. The reaction can be carried out in the presence of magnesium oxide and rhodium(II) acetate in an organic solvent such as dichloromethane at room temperature for several hours or overnight. Sulfonimidoyl Vic can be generated by removal of trifluoroacetyl and ½rt-butyl(dimethyl)silyl of trifluoroacetyl sulfonimidoyl XX in the presence of
tetrabutylazanium fluoride and concentrated hydrochloric acid in a mixture of tetrahydrofuran and ethanol at a temperature between 50 °C and 80 °C for several hours or overnight.
Chloromethyl indole VIIc can be prepared by treating hydroxy Vic with thionyl chloride. The reaction can be carried out in dichloromethane at room temperature for several hours.
Compound of interest lae can be prepared by reaction of chloromethyl indole VIIc and amide III. The reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium teri-butoxide in an organic solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
Compound of interest Iaf can be prepared by acetylation of sulfonimidoyl Compound lae. The reaction can be carried out by treating sulfonimidoyl lae with acyl chloride in the presence of a base such as triethylamine at room temperature for several hours.
General synthetic route for Compounds Iah, Iai, Iaj and Iak (Scheme 6)
Scheme 6
Figure imgf000080_0001
Compounds of interest Iah, lai, Iaj and Iak can be prepared according to Scheme 6.
Ester lag can be prepared according to Scheme 4.
Amide Iah can be prepared by ammonolysis of ester lag in the presence of ammonia in an organic solvent such as methanol or ethanol at a temperature about 70 °C for several days.
Carboxylic acid lai can be prepared by hydrolysis of ester lag. The reaction can be carried out in the presence of a suitable base such as sodium hydroxide, potassium hydroxide or lithium hydroxide in a mixture of tetrahydrofuran and water at a temperature between room temperature and 80 °C for several hours.
Methyl ester Iaj can be prepared by reaction of carboxylic acid lai in methanol. The reaction can be carried out in the presence of thionyl chloride in methanol at a temperature between 50 °C and 65 °C for several hours.
N-(Ci-6alkylsulfonyl)Ci-6alkylamide Iak can be prepared by reaction of carboxylic acid lai and sulfonamide XXI. The reaction can be carried out in the presence of N-[3- (dimethylamino)propyl]-N1-ethylcarbodiimide hydrochloride and 4-dimethylamiopryidine in dichloromethane at room temperature for several hours.
General synthetic route for Compounds lam and Ian (Scheme 7)
Figure imgf000081_0001
Compounds of interest lam and Ian can be prepared according to Scheme 7.
Xlllb can be prepared in analogy to XHIa in Scheme 3.
Bromide XXII can be prepared by reaction of Xlllb with dibromoalkane Vd. The reaction can be carried out in the presence of a suitable base such as potassium carbonate or cesium carbonate in an organic solvent such as acetonitrile or acetone at a temperature between 60 °C and 80 °C for several hours to several days.
Compound of interest lam can be prepared by reaction of bromide XXII with
imidazolidine-2,4-dione. The reaction can be carried out in the presence of a suitable base such as potassium carbonate or cesium carbonate and tetrabutylamine fluoride in an organic solvent such as tetrahydrofuran, acetonitrile or acetone at room temperature for several hours to several days.
Compound of interest Ian can be prepared by reaction of bromide XXII with (3R)- pyrrolidin-3-ol. The reaction can be carried out in the presence of a suitable base such as potassium carbonate or cesium carbonate in an organic solvent such as N.N-dirnethylformamide, acetonitrile or acetone at a temperature between 60 °C and 80 °C for several hours.
General synthetic route for Compound lao (Scheme 8)
Scheme 8
Figure imgf000082_0001
VId VI Id
L3 is chloro or -OS02CH3;
L6 is C^alkyl.
Compound of interest lao can be prepared according to Scheme 8.
BromoCi-6alkyl indole XXIII can be prepared in analogy to bromide XXII in Scheme 7 by reaction of indole lib with dibromoalkane Vd.
(Ci.6alkylsufonyl)Ci-6alkyl indole VHIb can be prepared by reaction of bromide XXIII and sodium Ci-6alkylsulfinate XXIV. The reaction can be carried out in N,N-dimethylformamide at a temperature between 50 °C and 100 °C for several hours.
Hydroxymethyl indole VId can be prepared by reduction of ethyl ester VHIb in the presence of lithium aluminum hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours.
Intermediate Vlld can be prepared by treating hydroxy VId with thionyl chloride or methanesulfonyl chloride. When L3 is chloro, the reaction can be carried out by treating hydroxy Vld with thionyl chloride in dichloromethane at a temperature between room temperature and 60 °C for 30 minutes to several hours. When L3 is methanesulfonate, the reaction can be carried out by treating hydroxy VId with methanesulfonyl chloride in an organic base such as triethylamine or diisopropylethylamine in dichloromethane at a temperature between 0 °C and room
temperature for one to several hours.
Compound of interest Iao can be prepared by reaction of intermediate Vlld with amide III. The reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium teri-butoxide in an organic solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
General synthetic route for Compound lap (Scheme 9)
Scheme 9
Figure imgf000083_0001
X3 is chloro or bromo;
V is -CxH2x;
L8 is hydrogen or C,_6alkyl;
or L7 and L8, together with the nitro en to which the are attached form
Figure imgf000083_0002
Compound of interest lap can be prepared according to Scheme 9.
Intermediate XXVI can be prepared by reaction of indole Xlllb and halide Ve. The reaction can be carried out in the presence of a suitable base such as cesium carbonate, potassium carbonate or potassium rt-butoxide in an organic solvent such as acetone, acetonitrile or N,N- dimethylformamide at a temperature between room temperature and 0 °C for one to several hours. Compound of interest lap can be prepared by removal of tert-b ty\ carboxylate of Compound XXVI. The conversion can be achieved by treating of XXVI with hydrochloride in ethyl acetate or trifluoroacetic acid in dichloromethane at room temperature for several hours.
General synthetic route for Compounds lar and las (Scheme 10)
Scheme 10
Figure imgf000084_0001
when L9 is p-methoxybenzyl, L10 is p-methoxybenzyl
or when L9 isC^alky, L 0 is benzyl.
Compounds of interest lar and las can be prepared according to Scheme 10.
Iaq can be prepared in analogy to lab in Scheme 2.
Compound las can be prepared by removal of benzyl group of Compound Iaq wherein L9 is Ci-6alkyl and L10 is benzyl. The conversion can be achieved by treating N-benzyl sulfonamides Iaq with concentrated sulfuric acid at 0 °C for several minutes to 1 hour.
Compound lar can be prepared by removal of p-methoxybenzyl group of Compound Iaq wherein both L9 and L10 are p-methoxybenzyl. The conversion can be achieved by treating sulfonamides Iaq with trifluoroacetic acid at room temperature for several hours.
General synthetic route for Compounds Iau, lav, law, lax and lay (Scheme 1 1) Scheme 11
-84-
Figure imgf000086_0001
L11 is -CxH2x- or -C^ -sulfonyl;
L12 is hydrogen or C 6alkyl;
or L 1 and L 2, together with the nitrogen to which they are attached, form
Figure imgf000087_0001
Compounds of interest Iau, lav, law, lax and lay can be prepared according to Scheme 1 1.
Amine Iat can be prepared in analogy to amine lap in Scheme 9 or in analogy to
sulfonamides Iar and las in Scheme 10.
Compound Iau can be prepared by reaction of amine Iat and methanesulfonyl chloride. The reaction can be carried out in the presence of a suitable base such as triethylamine in an organic solvent such as dichloromethane or N, N-dimethylformamide at a temperature between 0 °C and room temperature for several hours.
Compound lav can be prepared by acetylation of amine Iat. The reaction can be carried out by treating amine Iat with acetic anhydride or acetyl chloride in the presence of a suitable base such as triethylamine or ethyldiisopropylamine in an organic solvent such as dichloromethane or N, N-dimethylformamide at a temperature between room temperature and 80 °C for several hours.
Compound law can be prepared by reaction of amine Iat and methyl carbonochloridate. The reaction can be carried out in the presence of a base such as triethylamine in N,N- dimethylformamide at room temperature for several hours.
Compound lax can be prepared by reaction of amine Iat and 2-bromoefhanol. The reaction can be carried out in the presence of a suitable base such as cesium carbonate in an organic solvent such as acetonitrile or N, N-dimethylformamide at room temperature for several hours.
Compound lay can be prepared by reaction of amine Iat and methyl carbamimidothioate. The reaction can be carried out in the presence of sulfuric acid in a mixture of ethanol and water at a temperature between 70 °C and 100 °C overnight.
General synthetic route for Compound Iba (Scheme 12)
Scheme 12
Figure imgf000088_0001
Compound of interest Iba can be prepared according to Scheme 12.
Hydroxy laz can be prepared in analogy to Compound lac in Scheme 3.
Imidazol XXVII can be prepared by reaction of hydroxy laz with di-lH-imidazol-1- ylmethanone. The reaction can be carried out in the presence of a base such as cesium carbonate in tetrahydrofuran at room temperature for several hours or overnight.
Compound of interest Iba can be prepared by reaction of imidazol XXVII and trifluoroethanamine. The reaction can be carried out in the presence of a base such as cesium carbonate in tetrahydrofuran at room temperature for several hours or overnight.
General synthetic route for Compound Ibb (Scheme 13)
Scheme 13
Figure imgf000089_0001
Figure imgf000089_0002
L3 is chloro or -OS02CH3;
L13 is C^galkoxycarbonyl or C^galkylsulfonyl.
Compound of interest Ibb can be prepared according to Scheme 13.
Hydroxy Xb can be prepared in analogy to Xa in Scheme 3.
3-Ethenyl indole XXIX can be prepared via reaction of hydroxy Xb with ethene XXVIII. The reaction can be carried out in the presence of 2-dicyclohexylphosphino-2',6'-dimethoxy-l,l '- biphenyl, allylpalladium chloride dimmer and sodium acetate in a suitable solvent such as N,N- dimethylacetamide or N, N-dimethylformamide at a temperature between 100 °C and 150 °C under microwave irradiation for 15 minutes to several hours.
3-Ethyl indole XXX can be prepared by reduction of 3-ethenyl indole XXIX. The reaction can be carried out in the presence of sodium borohydride and nickel(II) chloride in methanol at 0 °C for several hours.
Intermediate XXXI can be prepared by treating hydroxy XXX with thionyl chloride or methanesulfonyl chloride. When L is chloro, the reaction can be carried out by treating hydroxy XXX with thionyl chloride in dichloromethane at a temperature between room temperature and 60 °C for 30 minutes to several hours. When L3 is methanesulfonate, the reaction can be carried out by treating hydroxy XXX with methanesulfonyl chloride in the presence of an organic base such as triethylamine or diisopropylethylamine in dichloromethane at a temperature between 0 °C and room temperature for one to several hours.
Compound XXXII can be prepared by reaction of intermediate XXXI and amide III. The reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium fer/-butoxide in an organic solvent such as acetronitrile or N,N-dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
Compound of interest Ibb can be prepared by removal of benzenesulfonyl of XXXII in the presence of tetrabutylammonium fluoride solution in tetrahydrofuran at room temperature for several hours.
General synthetic route for Compound Ibc (Scheme 14)
Scheme 14
Figure imgf000091_0001
Figure imgf000091_0002
XXXV χχχνΐ XXXVII
Figure imgf000091_0003
XXXVIII XXXIX I be
Compound of interest Ibc can be prepared according to Scheme 14.
3-(Methylsulfanyl)propanoyl indole XXXIII can be prepared by reaction of indole Ila with chloride Vf . The reaction can be carried out in the presence of ferric trichloride in 1 ,2- dichloroethane at 0 °C for several hours.
3-(Methylsulfanyl)propyl indole XXXIV can be prepared by reduction of 3- (methylsulfanyl)propyl XXXIII to l-hydroxy-3-(methylsulfanyl)propyl and then followed by treating hydroxy with triiluoroacetic acid in triethylsilane. The reduction reaction can be carried out in the presence of sodium borohydride in methanol at room temperature for one to several hours. Then 3-(methylsulfanyl)propyl indole XXXIV can be generated by treating hydroxy with trifluoroacetic acid in triethylsilane. The reaction can be carried out at 0 °C for several hours.
N-Substituted indole XXXV can be prepared by reaction of indole XXXIVwith
benzenesulfonyl chloride. The reaction can be carried out in the presence of a base such as sodium hydride in N, N-dimethylformamide at a temperature between 0 °C and room temperature for several hours.
Hydroxymethyl indole XXXVI can be prepared by reduction of ester XXXV. Reduction reaction can be carried out by treating ester with lithium aluminium hydride or lithium aluminum deuteride in tetrahydrofuran at a temperature between 0 °C and room temperature for several hours or overnight.
Methylsulfone XXXVII can be prepared by oxidation of methylsulfanyl XXXVI. The reaction can be carried out by treating methylsulfanyl XXXVI with 3-chloro-peroxybenzoic acid in dichloromethane at a temperature between 0 °C and room temperature for several hours or overnight.
Methane sulfonate XXXVIII can be prepared by reaction of hydroxy XXXVII with methanesulfonyl chloride. The reaction can be carried out in the presence of a suitable base such as triethylamine in dichloromethane at 0 °C for one to several hours.
Intermediate XXXIX can be prepared by reaction of methanesulfonate XXXVIII and amide III. The reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or sodium tert-butoxide in an organic solvent such as acetonitrile or N,N- dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
Compound of interest Ibc can be prepared by removal of benzenesulfonyl of intermediate XXXIX in the presence of tetrabutylammonium fluoride in tetrahydrofuran at room temperature for several hours or overnight.
General synthetic route for Compound Ibd (Scheme 15)
Scheme 15
Figure imgf000093_0001
Figure imgf000093_0002
Compound of interest Ibd can be prepared according to Scheme 15.
N-Substituted aniline XLIa can be prepared by reaction of o-fluoro nitrobenzene XLa or o- nitrophenyl trifluoromethanesulfonate XLb with amine Vg. The reaction can be carried out in the presence of a suitable base such as triethylamine, N-ethyl-N-(propan-2-yl)propan-2-amine or potassium phosphate in an organic solvent such as tetrahydrofuran or acetonitrile at room temperature for several hours to several days.
N-Substituted aniline XLIa can also be prepared by reaction of o-nitro aniline XLc and p- methylbenzenesulfonate Vh. The reaction can be carried out in the presence or absence of tetrabutylamine iodide with a suitable base such as cesium carbonate or potassium carbonate in an organic solvent such as acetone or acetonitrile at a temperature between 50 °C and 80 °C for several hours to several days.
N-Substituted aniline XLIb can be prepared by reaction of N-Boc protected o-nitro aniline XLd and />-methylbenzenesulufonate Vh. The reaction can be carried out in the presence or absence of tetrabutylamine iodide with a suitable base such as cesium carbonate or potassium carbonate in an organic solvent such as acetone or acetonitrile at a temperature between 50 °C and 80 °C for several hours to several days.
Diamine XLIIa and XLIIb can be prepared by reduction of o-nitro aniline XLIa and o- nitro aniline XLIb separately. The reaction can be carried out in the presence of Raney nickel and hydrazine hydrate in an organic solvent such as methanol or ethanol at a temperature between room temperature and 80 °C for 10 minutes to several hours.
2-(Chloromethyl)benzimidazole XLIIIa can be prepared by reaction of diamine XLIIa or XLIIb with bromoacetic acid. The reaction can be carried out in an aqueous solution of hydrochloric acid at a concentration between 4 N and 12 N at a temperature between 100 °C and 150 °C for several hours to several days.
2-(Chloromethyl)benzimidazole XLIIIa also can be prepared by reaction of diamine
XLIIa or XLIIb with 2-chloro-l, l, l-trimethoxyethane or 2-chloro-l, l, l-triethoxyethane. The reaction can be carried out by heating diamine XLIIa or XLIIb with 2-chloro- 1 ,1,1- trimethoxyethane or 2-chloro- 1 , 1 , 1 -triethoxyethane in the presence or absence of 4- methylbenzenesulfonic acid with or without ethanol at a temperature between 50 °C and 80 °C for several hours. The reaction can also be carried out by heating the mixture of diamine XLIIa or XLIIb and 2-chloro- 1 , 1 , 1 -trimethoxyethane or 2-chloro- 1 ,1 ,1 -triethoxyethane with or without ethanol at a temperature between 100 °C and 120 °C for one to several hours under microwave irradiation.
Compound of interest Ibd can be prepared by reaction of 2-(chloromethyl)benzimidazole XLIIIa and amide III. The reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or potassium tert-butoxide in an organic solvent such as acetonitrile or N,N-dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
General synthetic route for Compound Ibe (Scheme 16)
Scheme 16
Figure imgf000095_0001
Figure imgf000095_0002
XLVI XLIIIb Ibe
L2 is alkyl.
Compound of interest Ibe can be prepared according to Scheme 16.
N-substituted aniline XLIV and o-nitro-N-substituted aniline XLV can be prepared by Michael addition of anilins XLc or XLe with (Ci-6alkylsulfonyl)ethene Va. This Michael addition can be carried out in the presence of a base such as cesium carbonate in an organic solvent such as acetonitrile at about 80 °C for several hours or overnight.
o-Nitro-N-substituted aniline XLV can also be prepared by nitrification of N-substituted aniline XLIV. The conversion can be achieved by treating aniline XLIV with sulfuric acid and nitric acid at 0 °C for one to several hours.
Diamine XL VI can be prepared by reduction of nitro group of o-nitro-N-substituted aniline XLII. The reaction can be carried out in the presence of aney nickel and hydrazine hydrate in an organic solvent such as methanol or ethanol at a temperature between room temperature and 80 °C for 10 minutes to several hours.
2-(Chloromethyl)benzimidazole XLIIIb can be prepared by reaction of diamine XL VI and bromoacetic acid. The reaction can be carried out in an aqueous solution of hydrochloric acid at a concentration between 4 N and 12 Nat a temperature between 100 °C and 150 °C for several hours to several days.
2-(Chloromethyl)benzimidazole XLIIIb also can be prepared by reaction of diamine XL VI and 2-chloro- l, l, l -trimethoxyethane or 2-chloro- 1 , 1, 1-triethoxyethane. The reaction can be carried out by heating the mixture of diamine and 2-chloro- 1 , 1 , 1 -trimethoxyethane or 2-chloro- 1 , 1 ,1-triethoxyethane in the presence or absence of 4-methylbenzenesulfonic acid with or without ethanol at a temperature between 50 °C and 80 °C for several hours. The reaction also can be carried out by heating diamine with 2-chloro- 1 ,1 ,1 -trimethoxyethane or 2-chloro- 1,1,1- triethoxyethane with or without ethanol at a temperature between 100 °C and 120 °C for one to several hours under microwave irradiation.
Compound of interest Ibe can be prepared by reaction of 2-(chloromethyl)benzimidazole XLIIIb and amide HI. The reaction can be carried out in the presence of a base such as cesium carbonate, sodium hydride or potassium tert-butoxide in an organic solvent such as acetonitrile or N,N-dimethylformamide at a temperature between 0 °C and room temperature for one to several hours.
General synthetic route for Compound Ibg (Scheme 17)
Scheme 17
Figure imgf000096_0001
Ibf Ibg
Compound of interest Ibg can be prepared according to Scheme 17. Compound Ibf can be prepared in analogous to Compound Ibd in Scheme 15. Treating Compound Ibf with an acid generates Compound of interest Ibg. The reaction can be carried out in the presence of trifluoroacetic acid in dichloromethane at room temperature for several hours.
This invention also relates to a process for the preparation of a compound of formula I comprising the reaction of
(a) a compound of formula (A)
ine reagent and an azidocarbonyl reagent;
Figure imgf000097_0001
(c) a compound of formula (C)
Figure imgf000097_0002
with XZ-R' in the presence of a base;
(d) a compound of formula (D)
Figure imgf000098_0001
with acyl chloride in the presence of a
(e) a compound of formula (E)
Figure imgf000098_0002
the presence of a base;
a compound of formula (F)
Figure imgf000098_0003
with thionyl chloride;
(g) a compound of formula (F)
Figure imgf000098_0004
with sulfonamide in the presence of N-[3-(dimethylamino)propyl]-N,-ethylcarbodiimide hydrochloride and 4-dimethylamiopryidine;
(h) a compound of formula (G)
Figure imgf000099_0001
with imidazolidine-2,4-dione in the presence of a base;
(j) a compound of formula (G)
Figure imgf000099_0002
with (3i?)-pyrrolidin-3-ol in the presence of a
k) a compound of formula (J)
Figure imgf000099_0003
with hydrochloride or trifluoroacetic acid;
(1) a compound of formula (K)
Figure imgf000100_0001
with concentrated sulfuric acid;
(m) a compound of formula (M)
Figure imgf000100_0002
with trifluoroacetic acid;
(n) a compound of formula (N)
Figure imgf000100_0003
with methanesulfonyl chloride in the presence of a base;
(o) a compound of formula (N)
Figure imgf000100_0004
with acetic anhydride or acetyl chloride in the presence of a base; p) a compound of formula (N)
Figure imgf000101_0001
with methyl carbonochloridate in the presence of a base;
(q) a compound of formula (N)
Figure imgf000101_0002
with 2-bromoethanol in the presence of a base;
(r) a compound of formula (N)
Figure imgf000101_0003
with methyl carbamimidothioate in the presence of an acid; (s) a compound of formula (P)
Figure imgf000101_0004
H2N
with F in the presence of a base;
t) a compound of formula (Q)
Figure imgf000102_0001
with tetrabutylammonium fluoride;
wherein R1 to R6, W1 to W3, X, A, x and y are defined above unless otherwise indicated; X is chloro, bromo, iodo or 4-methylbenzenesulfonate; L1 is Ci-6alkyl; L2 is Ci-6alkyl; L3 is chloro or -OS02CH3; L7 is -CxH2x; L8 is h drogen or C^alkyl; or L7 and L8, to ether with the nitrogen,
to which the are attached, form
Figure imgf000102_0002
or
Figure imgf000102_0003
; L is -CxH2x- or -CxH2x-sulfonyl; L is hydro en or Ci-6alkyl; or L and
Figure imgf000102_0004
L12 together with the nitrogen, to which they are attached, form L, 4 is
Figure imgf000102_0005
or ; L is Ci-6alkoxycarbonyl-CxH2x- or
C i .6alkylsulfonyl-CxH2x- . In step (a), the phosphine reagent can be for example triphenylphosphine or tributylphosphine; the azidocarbonyl reagent can be for example diethyl azodicarboxylate, diisopropyl azodicarboxylate, 1 , 1 -(azodicarbonyl)dipiperidine or N,N,jV,iV- tetramethylazodicarboxamide;
In step (b), the base can be for example cesium carbonate, sodium hydride or sodium tert- butoxide;
In step (c), (h), (j), (q) or (s), the base can be for example potassium carbonate or cesium carbonate;
In step (d), (n), (p) or (o), the base can be for example triethylamine or
ethyldiisopropylamine;
In step (e), the base can be for example ammonia, sodium hydroxide, potassium hydroxide or lithium hydroxide;
In step (r), the acid can be for example sulfuric acid.
A compound of formula I when manufactured according to the above process is also an object of the invention.
PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION
The invention also relates to a compound of formula I for use as therapeutically active substance.
Another embodiment provides pharmaceutical compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments. In one example, compounds of formula (I) may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about 3 to about 8. In one example, a compound of formula (I) is formulated in an acetate buffer, at pH 5. In another embodiment, the compounds of formula (I) are sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.
Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The "effective amount" of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to inhibit RSV fusion protein. For example, such amount may be below the amount that is toxic to normal cells, or the mammal as a whole.
In one example, the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.1 to about 50 mg/kg, alternatively about 0.1 to about 20 mg/kg of patient body weight per day, with the typical initial range of compound used being about 0.3 to about 15 mg/kg/day. In another embodiment, oral unit dosage forms, such as tablets and capsules, preferably contain from about 25 to about 100 mg of the compound of the invention.
The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.
A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C, et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004;
Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
An example of a suitable oral dosage form is a tablet containing about 25 mg to about 500 mg of the compound of the invention compounded with about 90 to about 30 mg anhydrous lactose, about 5 to about 40 mg sodium croscarmellose, about 5 to about 30 mg
polyvinylpyrrolidone (PVP) K30, and about 1 to about 10 mg magnesium stearate. The powdered ingredients are first mixed together and then mixed with a solution of the PVP. The resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment. An example of an aerosol formulation can be prepared by dissolving the compound, for example 5 mg to 400 mg), of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired. The solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.
An embodiment, therefore, includes a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. In a further embodiment includes a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.
INDICATIONS AND METHODS OF TREATMENT The compounds of the invention can be utilized to inhibit RSV fusion protein, therefore prevent the virus cell syncytial function. Accordingly, the compounds of the invention are useful for the treatment or prophylaxis of RSV infection.
The invention relates to the use of a compound of formula I for the treatment or prophylaxis of respiratory syncytial virus infection.
The use of a compound of formula I for the preparation of medicaments useful in the treatment or prophylaxis diseases that are related to RSV infection is an object of the invention.
The invention relates in particular to the use of a compound of formula I for the preparation of a medicament for the treatment or prophylaxis of RSV infection.
Another embodiment includes a method of treating or preventing RSV infection in a mammal in need of such treatment, wherein the method comprises administering to said mammal a therapeutically effective amount of a compound of Formula I, a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof.
COMBINATION THERAPY
The compounds of the invention can be used in combination with other antiviral ingredients for the treatment or prophylaxis of RSV infection.
EXAMPLES
The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.
Abbreviations used herein are as follows:
μΐ^: microliter
μιη: micrometer
μΜ: micromoles per liter
AUC: area under the curve
CD3OD: deuterated methanol
CDCI3: deuterated chloroform DMSO- 6: deuterated dimethylsulfoxide
EC50: the concentration of a compound where 50% of its maximal protection effect against viral induced CPE is observed
g: gram
HPLC: high performance liquid chromatography
Hz: Hertz
ICR: imprinting control region
J: coupling constants
LC/MS: Liquid chromatography/mass spectrometry
LongStrain: an A subtype RSV strain obtained from ATCC with catalog number VR-
26
mg: milligram
MHz: megahertz
mL: milliliter
mm: millimeter
mmol: millimole
MS (ESI): mass spectroscopy (electron spray ionization)
NMR: nuclear magnetic resonance
obsd.: observed
PK: Pharmacokinetics
SDPK: single dose pharmacokinetics
Prep HPLC: preparative high performance liquid chromatography
TLC: thin layer chromatography
δ: chemical shift
ppm: parts per million
General Experimental Conditions
Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SPl system and the Quad 12/25 Cartridge module, ii) ISCO combi-flash chromatography instrument. Silica gel Brand and pore size: i) KP-SIL 60 A, particle size: 40-60 μΜ; ii) CAS registry NO: Silica Gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore: 200-300 or 300-400. Intermediates and final compounds were purified by preparative HPLC on reversed phase column using X Bridge™ Perp Ci8 (5 μιη, OBD™ 30 χ 100 mm) column or SunFire™ Perp Ci8 (5 μιτι, OBD™ 30 x 100 mm) column.
LC/MS spectra were obtained using a MicroMass Plateform LC (Waters™ alliance 2795- ZQ2000). Standard LC/MS conditions were as follows (running time 6 minutes):
Acidic condition: A: 0.1% formic acid in H20; B: 0.1% formic acid in acetonitrile;
Basic condition: A: 0.01% ΝΗ3Ή20 in H20; B: acetonitrile;
Neutral condition: A: H20; B: acetonitrile.
Mass spectra (MS): generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion (M+H)+.
The microwave assisted reactions were carried out in a Biotage Initiator Sixty.
NMR Spectra were obtained using Bruker Avance 400MHz.
All reactions involving air-sensitive reagents were performed under an argon atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.
The following examples were prepared by the general methods outlined in the schemes above. They are intended to illustrate the meaning of the present invention but should by no means represent a limitation within the meaning of the present invention.
PREPARATIVE EXAMPLES
Example 1-1
l'-({l-[2-(Methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane-l,3'- pyrrolo [2,3-c] pyridin] -2'(1 'H)-one
Step 1: Preparation of lH-indol-2-ylmethanol
Figure imgf000108_0001
To a slurry of lithium aluminum hydride (1.00 g, 26.3 mmol) in anhydrous tetrahydrofuran (50 mL) which was cooled to 0 °C was added a solution of ethyl lH-indole-2-carboxylate (3.80 g, 20.0 mmol) in tetrahydrofuran (50 mL) dropwise at 0 °C while stirring. The temperature of the mixture was then warmed naturally to room temperature and the mixture was stirred at room temperature overnight. The resulting mixture was quenched with methanol, and then filtered through a celite pad. The filtrate was concentrated in vacuo to afford 1.5 g of lH-indol-2- ylmethanol. Step 2: Preparation of {l-[2-(methylsulfon l)ethyl]-lH-indol-2-yl}methanol
Figure imgf000109_0001
To a cooled mixture of lH-indol-2-ylmethanol (450 mg, 3.0 mmol), cesium carbonate (1.80 g, 6.0 mmol) in N.N-dimethylformamide (25 mL) was added (methylsulfonyl)ethene (293 mg, 3.0 mmol) in portions at 0 °C. The reaction mixture was heated with stirring at 50 °C overnight. The resulting mixture was poured into ice-water (25 mL) and then extracted with ethyl acetate (30 mL x 3). The combined organic layer was washed with brine (50 mL x 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 150 mg of the crude { 1 - [2-(methylsulfonyl)ethyl] - 1 H-indol-2-yl } methanol .
Step 3: Preparation of l'-({l-[2-(methylsulfonyl)ethyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
To a solution of { l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methanol (253 mg, 1.0 mmol), spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one (160 mg, 1.0 mmol) and
triphenylphosphane (800 mg, 3.0 mmol) in tetrahydrofuran (50 mL) was added diisopropyl azodicarboxylate (600 mg, 3.0 mmol) dropwise in an ice-water bath under nitrogen atmosphere. The reaction mixture was stirred at room temperature overnight. The resulting mixture was purified by preparative HPLC to afford 26 mg of the title product.
Example 1-2
l'-({5-Methoxy-l-[2-(methylsuIfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3 ' -pyrrolo [2,3-c] pyridin] -2' (1 'H)-one
The title compound was prepared in analogy to Example 1-1 according to Scheme 1 by using ethyl 5-methoxy-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Example 1-3
l-[2-(MethyIsulfonyl)ethyl]-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- 1 ' (2 'H)-yl) methyl] -lH-indole-5-carbonitriIe
The title compound was prepared in analogy to Example 1-1 according to Scheme 1 by using ethyl 5-cyano-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate. Example 1-4
l'-({5-Fluoro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3 ' -pyrrolo [2 ,3-c] py ridin] -2 ' (1 'H)-one
The title compound was prepared in analogy to Example 1 -1 according to Scheme 1 by using ethyl 5-fluoro-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Example 1-5
l'-({5-Bromo-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3' -pyrrolo [2 ,3-c] py ridin] -2 ' (1 'H)-one
The title compound was prepared in analogy to Example 1-1 according to Scheme 1 by using ethyl 5-bromo-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Example 1-6
l'-({4-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3 ' -pyrrolo [2,3-c] pyridin] -2 ' (1 'H)-one
The title compound was prepared in analogy to Example 1-1 according to Scheme 1 by using methyl 4-chloro-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Example 1-7
l'-({7-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3'-pyrrolo [2,3-c] pyridin] -2' (1 'H)-one
The title compound was prepared in analogy to Example 1 -1 according to Scheme 1 by using methyl 7-chloro-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Example 1-8
l'-({5-Ethyl-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3' -pyrrolo [2,3-c] pyridin] -2 ' (1 'H)-one
The title compound was prepared in analogy to Example 1 -1 according to Scheme 1 by using methyl 5-ethyl-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Example 1-9
l'-({5,7-Difluoro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one The title compound was prepared in analogy to Example 1-1 according to Scheme 1 by using methyl 5,7-difluoro-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Example 1-10
l'-({l-[2-(Methylsulfonyl)ethyl]-5-(trifluoromethyl)-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 1 -1 according to Scheme 1 by using methyl 5-(trifluoromethyl)-lH-indole-2-carboxylate instead of ethyl lH-indole-2- carboxylate.
Example 1- 11
l'-({5,6-Difluoro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 1-1 according to Scheme 1 by using methyl 5,6-difluoro- lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Example 1-12
l'-({5-Chloro-7-fluoro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2- ylJmethy^spirofcyclopropane-ljS'-pyrrolo^jS-clpyridinj^ l'HJ-one
The title compound was prepared in analogy to Example 1-1 according to Scheme 1 by using methyl 5-chloro-7-fluoro-lH-indole-2-carboxylate instead of ethyl lH-indole-2- carboxylate.
Example 1-13
l'-({5-Methyl-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3 '-pyrrolo [2,3-c] pyridin] -2!(1 'H)-one
The title compound was prepared in analogy to Example 1-1 according to Scheme 1 by using methyl 5 -methyl- lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Example 1-14
l'-({l-[2-(Methylsulfonyl)ethyl]-lH-pyrrolo[3,2-c]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one The title compound was prepared in analogy to Example 1 -1 according to Scheme 1 by using methyl lH-pyrrolo[3,2-c]pyridine-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Example 2-1
l'-({5-Chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3 ' -pyrrolo [2 ,3-c] py ridin] -2 ' ( 1 'H)-one
Step 1: Preparation of {5-chloro-l- 2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methanol
Figure imgf000112_0001
{5-Chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methanol was prepared in analogy to { l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methanol in Example 1-1 according to Scheme 1 by using ethyl 5-chloro-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate. MS obsd. (ESI+) [(M+H)+] 302.
Step 2: Preparation of {5-chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methyl methanesulfonate
Figure imgf000112_0002
To a solution of {5-chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methanol (240 mg, 0.80 mmol) and triethylamine (0.34 mL, 2.4 mmol) in dichloromethane (20 mL) was added methanesulfonyl chloride (0.15 mL, 2.0 mmol) dropwise in an ice-water bath. After being stirred at 0 °C for 1 hour, the resulting mixture was neutralized with a saturated aqueous solution of sodium bicarbonate and then extracted with dichloromethane (20 mL x 2). The combined organic layer was washed with a saturated aqueous solution of sodium bicarbonate (20 mL x 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 303 mg of {5- chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methyl methanesulfonate as a brown solid, which was used for next step without further purification.
Step 3: Preparation of l'-({5-chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2- yl} methyl)spiro [cyclopropane-l,3'-pyn"olo [2,3-c] pyridin] -2 ' (1 'H)-one A mixture of {5-chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methyl methanesulfonate (303 mg, 0.80 mmol), cesium carbonate (521 mg, 1.6 mmol) and spiro [cyclopropane- 1,3 '- pyrrolo[2,3-c]pyridin]-2'(rH)-one (128 mg, 0.80 mmol) in acetonitrile (20 mL) was heated with stirring at 85 °C for 2 hours. The resulting mixture was filtered and washed with acetonitrile (10 mL x 2). The filtrate was concentrated in vacuo. The residue was purified by preparative HPLC to afford 130 mg of the product as a white solid.
Example 2-2
l'-({5-Chloro-l-[2-(ethylsulfonyl)ethyl]-lH-pyrrolo[2,3-A]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 2-1 according to Scheme 1 by using methyl 5-chloro-lH-pyrrolo[2,3-6]pyridine-2-carboxylate instead of ethyl 5-chloro-lH- indole-2-carboxylate.
Example 2-3
l'-({5-Chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3'-pyrrolo [2,3- >] pyridin] -2* (1 'H)-one
The title compound was prepared in analogy to Example 2-1 according to Scheme 1 by using spiro[cyclopropane-l ,3'-pyrrolo[2,3-b]pyridin]-2'(l'H)-one instead of spiro [cyclopropane- 1 ,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one.
Example 2-4
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3- >]pyridin-2- yl}methyl)spiro[cyclobutane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 2-1 according to Scheme 1 by using methyl 5-chloro-lH-pyrrolo[2,3-6]pyridine-2-carboxylate and spiro [cyclobutane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(rH)-one instead of ethyl 5-chloro-lH-indole-2-carboxylate and spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3-c]pyridin] -2'( 1 'H)-one.
Example 2-5
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- l,3'-pyrrolo[2,3-6]pyridin]-2'(ri?)-one The title compound was prepared in analogy to Example 2-1 according to Scheme 1 by using (methyl sulfonyl)ethene and spiro[cyclopropane-l ,3'-pyrrolo[2,3-b]pyridin]-2'(l'H)-one instead of (ethylsulfonyl)ethane and spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one.
Example 2-6
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3-b]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 2-1 according to Scheme 1 by using methyl 5-chloro-lH-pyrrolo[2,3-fr]pyridine-2-carboxylate and (methylsulfonyl)ethene instead of ethyl 5-chloro-lH-indole-2-carboxylate and (ethylsulfonyl)ethane.
Example 2-7
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3-6]pyridin-2-yl}methyl)-5'- fluorospiro[cyclopropane-l,3'-indol]-2'(l'H)-one
Step 1: Preparation of {5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3- 6]pyridin-2-yl}methyl methanesulfonate
Figure imgf000114_0001
{5-Chloro- 1 - [2-(methylsulfonyl)ethyl] - 1 H-pyrrolo [2,3 -fr]pyridin-2-yl} methyl
methanesulfonate was prepared in analogy to{5-chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2- yljmethyl methanesulfonate in Example 2-1 by using methyl 5-chloro-lH-pyrrolo[2,3- fr]pyridine-2-carboxylate and (methylsulfonyl)ethene instead of ethyl 5-chloro-lH-indole-2- carboxylate and (ethylsulfonyl)ethane.
Step 2: Preparation of l'-({5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3- ^Ipyridin^-ylJmethy^-S'-fluorospirotcyclopropane-l^'-indolJ^ l'Hi-one
A mixture of {5-chloro-l -[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3-0]pyridin-2-yl}methyl methanesulfonate (183 mg, 0.50 mmol), cesium carbonate (325 mg, 1.0 mmol) and 5'- fluorospiro[cyclopropane-l ,3'-indol]-2'(rH)-one (79 mg, 0.50 mmol) in A^N-dimethylformamide (5 mL) was heated with stirring at 60 °C for 30 minutes. The resulting mixture was purified by preparative HPLC to afford the title product. Example 2-8
1 '-({5-Chloro-l - [2-(methylsulfonyl)ethyl] -lH-pyrrolo [2,3-b] pyridin-2- yl}methyl)spiro [cyclopentane-1 ,3'-pyrrolo [2,3-c] py ridin] -2' (1 'H)-one
The title compound was prepared in analogy to Example 2-7 according to Scheme 1 by using spiro[cyclopentane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one instead of 5'- fluorospiro [cyclopropane- 1 ,3 '-indol] -2'( 1 )-one.
Example 2-9
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[3,2-0]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of {5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[3,2- b] pyridin-2-yl} methyl methanesulfonate
Figure imgf000115_0001
{ 5 -Chloro- 1 - [2-(methylsulfonyl)ethyl] - 1 H-pyrrolo [3 ,2-b]pyridin-2-yl } methyl
methanesulfonate was prepared in analogy to{5-chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2- yljmethyl methanesulfonate in Example 2-1 by using methyl 5-chloro-lH-pyrrolo[3,2- &]pyridine-2-carboxylate instead of methyl 5-chloro-lH-pyrrolo[2,3-&]pyridine-2-carboxylate.
Step 2: Preparation of l'-({5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[3,2- b] pyridin-2-yl} methyl)spiro [cyclopropane-1 ,3'-pyrrolo [2,3-c]pyridin]-2' (1 'H)-one
A mixture of {5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[3,2-b]pyridin-2-yl}methyl methanesulfonate (376 mg, 1.03 mmol), sodium /e -butoxide (105 mg, 1.09 mmol) and spiro [cyclopropane- 1 , 3 '-pyrrolo [2,3 -c]pyridin]-2'(r/ )-one (165 mg, 1.03 mmol) m N,N- dimethylformamide (4 mL) was heated with stirring at 60 °C for 2 hours. The resulting mixture was purified by preparative HPLC to afford 130 mg of the title product as a white solid.
Example 3-1
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- l,3'-pyrrolo[3,2-c]pyridin]-2'(l'H)-one Step 1: Preparation of {5-chloro-l-[2-(meth lsulfonyl)ethyl]-lH-indol-2-yl}methanol
Figure imgf000116_0001
{5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methanol was prepared in analogy to [l-(2-methanesulfonyl-ethyl)-lH-indol-2-yl] -methanol in Example 1-1 according to Scheme 1 by using ethyl 5-chloro-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate. MS obsd. (ESf ) [(M+H)+] 288.
Step 2: Preparation of 5-chloro-2-(chloromethyl)-l-[2-(methylsulfonyl)ethyl]-lH- indole
Figure imgf000116_0002
To a solution of {5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methanol (230 mg, 0.80 mmol) in dichloromethane (10 mL) was added thionyl chloride (0.2 mL) dropwise. After being stirred at room temperature for 2 hours, the resulting mixture was neutralized with a saturated aqueous solution of sodium bicarbonate and then extracted with dichloromethane (20 mL x 2). The combined organic layer was washed with a saturated aqueous solution of sodium bicarbonate (20 mL χ 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford the crude 5-chloro-2-(chloromethyl)-l-[2-(methylsulfonyl)ethyl]-lH-indole as a brown solid which was used for next step without further purification.
Step 3: Preparation of l'-({5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2- yl}methyl)spiro [cyclopropane-1 ,3 '-pyrrolo [3,2-c]pyridin] -2 '(1 'H)-one
A mixture of 5-chloro-2-(chloromethyl)-l-[2-(methylsulfonyl)ethyl]-lH-indole (140 mg, 0.46 mmol), cesium carbonate (200 mg, 0.62 mmol) and spiro [cyclopropane- 1 ,3 '-pyrrolo [3,2- c]pyridin]-2'(l 'H)-one (50 mg, 0.31 mmol) in N, N-dimethylformamide (4 mL) was heated with stirring at 80 °C for 1 hour. The resulting mixture was purified by preparative HPLC to afford 17 mg of the title product.
Example 3-2 -({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopentane- l,3'-pyrrolo [2,3-c] pyridin] -2'(1 'H)-one
The title compound was prepared in analogy to Example 3-1 according to Scheme 1 by using spiro[cyclopentane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one instead of spiro[cyclopropane- 1 , 3 '-pyrrolo [3 ,2-c]pyridin] -2'( 1 'H)-one.
Example 3-3
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3 ' -p rrolo [2,3-c] pyridin] -2' (1 'H)-one
The title compound was prepared in analogy to Example 3-1 according to Scheme 1 by using spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one instead of spiro[cyclopropane- 1,3 '-pyrrolo [3 ,2-c]pyridin]-2'(l'H)-one.
Example 4-1
l*-({5-Chloro-l-[4-(inethylsulfonyl)butyl]-lH-indol-2-yl}inethyl)spiro[cyclopropane- 1 ,3'-py rrolo [2,3-c] pyridin] -2' (1 'H)-one
Step 1: Preparation of ethyl 5-chloro-l-[4-(methylsulfonyl)butyl]-lH-indole-2- carboxylate
Figure imgf000117_0001
A mixture of ethyl 5-chloro-lH-indole-2-carboxylate (2.23 g, 10 mmol), 4- (methylsulfonyl)butyl 4-methylbenzenesulfonate (3.06 g, 10 mmol) and potassium carbonate (2.76 g, 20 mmol) in acetonitrile (30 mL) was heated with stirring at 80 °C overnight. The reaction mixture was diluted with water and then extracted with dichloromefhane (30 mL x 3). The combined organic layer was washed with water, and then dried over sodium sulfate and concentrated in vacuo. The residue was crystallized from ethyl acetate to afford 3.0 g of ethyl 5- chloro-l-[4-(methylsulfonyl)butyl]-lH-indole-2-carboxylate.
Step 2: Preparation of {5-chloro-l-[4-(methylsulfonyl)butyl]-lH-indol-2-yl}methanol
Figure imgf000118_0001
{5-Chloro-l-[4-(methylsulfonyl)butyl]-lH-indol-2-yl}methanol was prepared in analogy to lH-indol-2-ylmethanol in Example 1-1 according to Scheme 1 by using ethyl 5-chloro-l-[4- (methylsulfonyl)butyl]-lH-indole-2-carboxylate instead of ethyl lH-indole-2-carboxylate.
Step 3: Preparation of 5-chloro-2-(chloromethyl)-l-[4-(methylsulfonyl)butyl]-lH- indole
Figure imgf000118_0002
A solution of {5-chloro-l -[4-(methylsulfonyl)butyl]-lH-indol-2-yl}methanol (1.0 g, 3.17 mmol) in anhydrous dichloromethane was stirred with thionyl chloride (465 μί, 6.35 mmol) at room temperature for 2 hours. The resulting mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (60 mL). The solution was washed with a saturated aqueous solution of sodium bicarbonate (30 mL x 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 900 mg of 5-chloro-2-(chloromethyl)-l-[4- (methylsulfonyl)butyl]-lH-indole as a yellow solid which was used for the next step without any purification.
Step 4: Preparation of l'-({5-chloro-l-[4-(methylsulfonyl)butyl]-lH-indol-2- ylJmethy^spirofcyclopropane-l^'-pyrroloPjS-clpyridinl- ^l'HJ-one
A mixture of 5-chloro-2-(chloromethyl)-l -[4-(methylsulfonyl)butyl]-lH-indole (900 mg, 2.7 mmol), spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one (480 mg 3.0 mmol) and cesium carbonate (1.95 g, 6.0 mmol) in anhydrous acetonitrile (20 mL) was heated with stirring at 70 °C for 2 hours. The resulting mixture was diluted with brine (30 mL) and then extracted with ethyl acetate (30 mL x 3). The organic layers were combined, and then washed with brine (10 mL x 2), then dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 200 mg of the title product as a white solid. Example 4-2
r-({5-Chloro-l-[4-(methylsulfonyl)benzyl]-lH-indol-2-yl}methyl)spiro[cycIopropane- l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 4-1 according to Scheme 2 by using l-(bromomethyl)-4-(methylsulfonyl)benzene instead of 4-(methylsulfonyl)butyl 4- methylbenzenesulfonate.
Example 4-3
l'-({5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-pyrroIo[2,3-6]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 4-1 according to Scheme 2 by using methyl 5-chloro-lH-pyrrolo[2,3-6]pyridine-2-carboxylate and 3-(methylsulfonyl)propyl 4- methylbenzenesulfonate instead of ethyl 5-chloro-lH-indole-2-carboxylate and 4- (methylsulfonyl)butyl 4-methylbenzenesulfonate.
Example 4-4
l'-({5-Methyl-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3-6]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 4-1 according to Scheme 2 by using methyl 5-methyl-lH-pyrrolo[2,3-&]pyridine-2-carboxylate and 2-(methylsulfonyl)ethyl 4- methylbenzenesulfonate instead of ethyl 5-chloro-lH-indole-2-carboxylate and 4- (methylsulfonyl)butyl 4-methylbenzenesulfonate.
Example 4-5
l'-({5-Chloro-l-[4-(methylsulfonyl)butyl]-lH-pyrrolo[3,2-6]pyridin-2- yl}methyl)spiro [cyclopropane-1,3 '-pyrrolo [2,3-c] pyridin] -2 *(1 'H)-one
The title compound was prepared in analogy to Example 4-1 according to Scheme 2 by using methyl 5-chloro-lH-pyrrolo[3,2-&]pyridine-2-carboxylate and (methylsulfonyl)butyl 4- methylbenzenesulfonate instead of ethyl 5-chloro-lH-indole-2-carboxylate and 4- (methylsulfonyl)butyl 4-methylbenzenesulfonate.
Example 4-6 l'-({5-Chloro-l-[3-(cyclopropylsulfonyl)propyl]-lH-pyrrolo[3,2-6]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 4-1 according to Scheme 2 by using methyl 5-chloro-lH-pyrrolo[3,2-Z>]pyridine-2-carboxylate and 3- (cyclopropylsulfonyl)propyl 4-methylbenzenesulfonate instead of ethyl 5-chloro-lH-indole-2- carboxylate and 4-(methylsulfonyl)butyl 4-methylbenzenesulfonate.
Example 4-7
l'-({5-Chloro-l-[4-(methylsulfonyl)butyl]-lH-pyrrolo[2,3-c]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 4-1 according to Scheme 2 by using ethyl 5-chloro-lH-pyrrolo[2,3-c]pyridine-2-carboxylate and (methylsulfonyl)butyl 4- methylbenzenesulfonate instead of ethyl 5-chloro-lH-indole-2-carboxylate and 4- (methylsulfonyl)butyl 4-methylbenzenesulfonate.
Example 4-8
N-Benzyl-3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- l'(2'H)-yl)methyl]-lH-pyrrolo[2,3-6]pyridin-l-yl}-N-methylpropane-l-sulfonamide
The title compound was prepared in analogy to Example 4-1 according to Scheme 2 by using methyl 5-chloro-lH-pyrrolo[2,3-0]pyridine-2-carboxylate and N-benzyl-3-chloro-N- methylpropane-1 -sulfonamide instead of ethyl 5-chloro-lH-indole-2-carboxylate and 4- (methylsulfonyl)butyl 4-methylbenzenesulfonate.
Example 4-9
l'-({5-Chloro-l-[3-(cyclopropylsulfonyl)propyl]-lH-pyrrolo[2,3-c]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of 5-chloro-2-(chloromethyl)-l-[3-(cyclopropylsulfonyl)propyl]- lH-pyrrolo [2,3-c] pyridine
Figure imgf000120_0001
5-Chloro-2-(chloromethyl)- 1 -[3 -(cyclopropylsulfonyl)propyl]- 1 H-pyrrolo [2,3 -cjpyridine was prepared in analogy to 5-chloro-2-(chloromethyl)-l-[4-(methylsulfonyl)butyl]-lH-indole in Example 4-1 according to Scheme 2 by using ethyl 5-chloro-lH-pyrrolo[2,3-c]pyridine-2- carboxylate and 3-(cyclopropylsulfonyl)propyl 4-methylbenzenesulfonate instead of ethyl 5- chloro-lH-indole-2-carboxylate and 4-(methylsulfonyl)butyl 4-methylbenzenesulfonate.
Step 2: Preparation of l'-({5-chloro-l-[3-(cyclopropylsulfonyl)propyl]-lH- pyrrolo [2,3-c] py ridin-2-yl} methyI)spiro[cyclopropane-l ,3'-py rrolo [2,3-c] pyridin] -2'(17/)- one
To a cooled solution of 5-chloro-2-(chloromethyl)-l-[3-(cyclopropylsulfonyl)propyl]-lH- pyrrolo[2,3-c]pyridine (782 mg, 2.26 mmol) and spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- 2'(l ' /)-one (362 mg, 2.26 mmol) in N,N-dimethylformamide (10 mL) in an ice water bath was added sodium hydride (270 mg, 6.75mmol) in portions. After the addition, the temperature was allowed to arise to room temperature and the mixture was stirred at room temperature overnight. The resulting mixture was purified by preparative HPLC to afford the title product.
Example 4-10
1 '-({5-Chloro-l- [2-(thietan-3-yl)ethyl] -lH-pyrrolo [2,3-c] pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of ethyl thieta -3-ylideneacetate
Figure imgf000121_0001
To a solution of thietane-3-one (5.0 g, 56.73 mmol) in dichloromethane (280 mL) was added ethyl 2-tri(phenyl)phosphoranylideneacetate (21.74 g, 62.41 mmol) in portions. After the mixture was stirred at room temperature for 24 hours, the solvent was removed in vacuo. The residue was purified by flash column chromatography (eluting with 0 - 30% ethyl acetate in petroleum ether) to give 7.8 g of ethyl thietan-3-ylideneacetate as colorless oil.
Step 2: Preparation of ethyl thietan-3-ylacetate
Figure imgf000121_0002
To a mixture of ethyl thietan-3-ylideneacetate (10 g, 63.2 mmol) and nickel (II) chloride hexahydrate (15.0 g, 63.2 mmol) in methanol (250 mL) was added sodium borohydride (12 g, 316.0 mmol) in portions at 0 °C. After being stirred at room temperature for 30 minutes, the reaction mixture was filtered through a pad of silica gel. The filtrate was concentrated in vacuo. The residue was purified by column chromatography (eluting with 0 - 30% ethyl acetate in petroleum ether) to give 600 mg of ethyl thietan-3-ylacetate.
Step 3: Preparation of 2-(thietan-3-yl)ethanol
Figure imgf000122_0001
To a cooled solution of lithium aluminum hydride in tetrahydrofuran (5.0 mL, 1 M) was added a solution of ethyl thietan-3-ylacetate (784 mg, 4.9 mmol) in dry tetrahydrofuran (15 mL) dropwise at 0 °C. The mixture was stirred for 2 hours while the temperature was allowed to arise to room temperature. The reaction was quenched by addition of water (10 mL). The resulting mixture was stirred for 10 minutes and then extracted with ethyl acetate (20 mL x 3). The combined organic layer was washed with brine (40 mL x 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 410 mg of 2-(thietan-3-yl)ethanol.
Step 4: Preparation of ethyl 5-chloro-l-[2-(thietan-3-yl)ethyl]-lH-pyrrolo[2,3- c] pyridine-2-carboxylate
Figure imgf000122_0002
To a solution of 2-(thietan-3-yl)ethanol (200 mg, 1.69 mmol), tris(butyl)phosphine (6.84g, 10% in hexane, 3.38 mmol) and 1 , l '-(azodicarbonyl)dipiperidine (860 mg, 3.38 mmol) in anhydrous tetrahydrofuran (20 mL) was added ethyl 5-chloro-lH-pyrrolo[2,3-c]pyridine-2- carboxylate (380 mg, 1.69 mmol) under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 3 hours. The resulting mixture was then concentrated in vacuo. The residue was purified by flash column (gradient eluting with 0 - 25% ethyl acetate in petroleum ether) to afford 400 mg of ethyl 5-chloro-l-[2-(thietan-3-yl)ethyl]-lH-pyrrolo[2,3-c]pyridine-2- carboxylate as a white solid. Step 5: Preparation of 5-chloro-2-(chloromethyl)-l-[2-(thietan-3-yl)ethyl]-lH- pyrrolo[2,3-c]pyridine
Figure imgf000123_0001
5-Chloro-2-(chloromethyl)-l-[2-(thietan-3-yl)ethyl]-lH-pyrrolo[2,3-c]pyridine was prepared in analogy to 5-chloro-2-(chloromethyl)-l-[4-(methylsulfonyl)butyl]-lH-indole in Example 4-1 according to Scheme 2 by using ethyl 5-chloro-l-[2-(thietan-3-yl)ethyl]-lH- pyrrolo[2,3-c]pyridine-2-carboxylate instead of ethyl 5-chloro-l-[4-(methylsulfonyl)butyl]-lH- indole-2-carboxylate.
Step 6: Preparation of l'-({5-chloro-l-[2-(thietan-3-yl)ethyl]-lH-pyrrolo[2,3- c]pyridin-2-yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one
The title compound was prepared in analogy to Example 4-9 according to Scheme 2 by using 5-chloro-2-(chloromethyl)-l -[2-(thietan-3-yl)ethyl]-lH-pyrrolo[2,3-c]pyridine instead of 5- chloro-2-(chloromethyl)- 1 - [3 -(cyclopropylsulfonyl)propyl] - 1 H-pyrrolo [2,3 -cjpyridine.
Example 4-1 1
1 '-( {5-Chloro- 1- [2-( 1 ,l-dioxidothietan-3-yl)ethyl]-lH-py rrolo [2,3-c] pyridin-2- ylJmethy^spiroIcyclopropane-ljS'-pyrrolo^^- JpyridinJ^ HJ-one
Step 1: Preparation of ethyl 5-chloro-l-[2-(l,l-dioxidothietan-3-yl)ethyl]-lH- pyrrolo [2,3-c] pyridine-2-carboxylate
Figure imgf000123_0002
To a cooled solution of ethyl 5-chloro-l-[2-(thietan-3-yl)ethyl]-lH-pyrrolo[2,3-c]pyridine- 2-carboxylate (163 mg, 0.50 mmol) in dichloromethane (10 mL) was added 3-chloroperbenzoic acid (247 mg, 1.0 mmol, 75% purity) slowly at 0 °C. The reaction mixture was stirred for 1 hour while the temperature was allowed to arise to room temperature naturally. The resulting mixture was washed with a saturated aqueous solution of sodium carbonate (10 mL), and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 182 mg of the crude ethyl 5- chloro-l-[2-(l, l-dioxidothietan-3-yl)ethyl]-lH-pyrrolo[2,3-c]pyridine-2-carboxylate as a light yellow semisolid.
Step 2: Preparation of l'-({5-chloro-l-[2-(l,l-dioxidothietan-3-yl)ethyl]-lH- pyrrolo[2,3-c]pyridin-2-yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2 -c]pyridin]-2'(l,H)- one
The title compound was prepared in analogy to Example 4-10 according to Scheme 2 by using ethyl 5 -chloro- 1 - [2-( 1 , 1 -dioxidothietan-3 -yl)ethyl] - 1 H-pyrrolo [2, 3 -c]pyridine-2- carboxylate instead of ethyl 5-chloro-l-[2-(thietan-3-yl)ethyl]-lH-pyrrolo[2,3-c]pyridine-2- carboxylate.
Example 4-12
l'-({5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-pyrrolo[2,3-6]pyridin-2- yl}methyl)spiro[cyclobutane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 4-9 according to Scheme 2 by using methyl 5-chloro-lH-pyrrolo[2,3-6]pyridine-2-carboxylate, 3-(methylsulfonyl)propyl 4- methylbenzenesulfonate and spiro[cyclobutane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one instead of ethyl 5-chloro- 1 -[3-(cyclopropylsulfonyl)propyl]- lH-indole-2-carboxylate and
spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one.
Example 4-13
l'-({5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-pyrrolo[2,3-c]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 4-9 according to Scheme 2 by using 3-(methylsulfonyl)propyl 4-methylbenzenesulfonate instead of 3- (cyclopropylsulfonyl)propyl 4-methylbenzenesulfonate.
Example 4-14
1 '-({5-Chloro-l- [2-(cyclopropylsulfonyl)ethyl] -lH-pyrrolo [3,2-6] pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 4-9 according to Scheme 2 by using methyl 5-chloro-lH-pyrrolo[3,2-b]pyridine-2-carboxylate and 2-(cyclopropylsulfonyl)ethyl 4-methylbenzenesulfonate instead of ethyl 5-chloro-lH-pyrrolo[2,3-c]pyridine-2-carboxylate and 3-(cyclopropylsulfonyl)propyl 4-methylbenzenesulfonate.
Example 4- 15
l'-({5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-pyrrolo[3,2- >]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of 5-chIoro-2-(chloromethyl)-l-[3-(methylsulfonyl)pr<
py rrolo [3,2-6] pyridine
Figure imgf000125_0001
5-Chloro-2-(chloromethyl)-l -[3-(methylsulfonyl)propyl]-lH-pyrrolo[3,2-^]pyridine was prepared in analogy to 5-chloro-2-(chloromethyl)- l-[4-(methylsulfonyl)butyl]- lH-indole in Example 4- 1 by using methyl 5-chloro-lH-pyrrolo[3,2-&]pyridine-2-carboxylate and 3- (methylsulfonyl)propyl 4-methylbenzenesulfonate instead of ethyl 5-chloro- lH-indole-2- carboxylate and 4-(methylsulfonyl)butyl 4-methylbenzenesulfonate.
Step 2: Preparation of l'-({5-chloro-l-[3-(methylsulfonyl)propyI]-lH-pyrroIo[3,2- b] pyridin-2-yl}methyl)spiro [cyclopropane-1 ,3'-pyrrolo [2,3-c] pyridin] -2'(1 'H)-one
To a cooled solution of 5-chloro-2-(chloromethyl)-l -[3-(methylsulfonyl)propyl]-lH- pyrrolo[3,2-£]pyridine (350 mg, 1 .16 mmol) in N,N-dimethylformamide (2 mL) was added a mixture of spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'(l 'H)-one (195 mg, 1.22 mmol) and sodium tert-buoxide (1 15 mg, 1.19 mmol) in N,N-dimethylformamide (2 mL) dropwise. The resulting mixture was heated with stirring at 60 °C for 2 hours. The resulting mixture was purified by preparative HPLC to afford the title product as a solid.
Example 4-16
l'-({5-Chloro-l-[4-(methylsulfonyI)butyl]-lH-pyrrolo[2,3-6]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 4-15 according to Scheme 2 by using methyl 5-chloro- lH-pyrrolo[2,3-&]pyridine-2-carboxylate and l -bromo-4- (methylsulfonyl)butane instead of methyl 5-chloro-lH-pyrrolo[3,2-&]pyridine-2-carboxylate and 3 -(methylsulfonyl)propyl 4-methylbenzenesulfonate . Example 5-1
l'-({5-Chloro-l-[3-(methylsulfinyl)propyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3 ' -pyrrolo [2,3-c] pyridin] -2 ' (1 'H)-one
Step 1: Preparation of {5-chloro-l-[3-(methylsulfinyl)propyl]-lH-indol-2-yl}methanol
Figure imgf000126_0001
{5-Chloro-l -[3-(methylsulfinyl)propyl]-lH-indol-2-yl}methanol was prepared in analogy to { 5 -chloro-l -[4-(methylsulfonyl)butyl]-lH-indol-2-yl} methanol in Example 4-1 according to Scheme 2 by using 3-(methylsulfinyl)propyl 4-methylbenzenesulfonate instead of 4- (methylsulfonyl)butyl 4-methylbenzenesulfonate.
Step 2: Preparation of {5-chloro-l-[3-(methylsulfinyl)propyl]-lH-indol-2-yl}methyl methanesulfonate
Figure imgf000126_0002
{ 5 -Chloro- 1 - [3 -(methyl sulfinyl)propyl] - 1 H-indol-2-yl } methyl methanesulfonate was prepared in analogy to {5-chloro-l-[2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methyl
methanesulfonate in Example 2-1 according to Scheme 2 by using {5-chloro-l-[3- (methylsulfinyl)propyl]-lH-indol-2-yl}methanol instead of {5 -chloro- 1- [2-(ethylsulfonyl)ethyl]- 1 H-indol-2-yl } methanol.
Step 3: Preparation of l'-({5-chloro-l-[3-(methylsulfinyl)propyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyi"rolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 2-1 according to Scheme 2 by using {5 -chloro- 1 - [3 -(methylsulfinyl)propyl]-lH-indol-2-yl} methyl methanesulfonate instead of { 5-chloro- 1 - [2-(ethylsulfonyl)ethyl] - 1 H-indol-2-yl }methyl methanesulfonate.
Example 5-2 l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3-c]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 5-1 according to Scheme 2 by using ethyl 5-chloro-lH-pyrrolo[2,3-c]pyridine-2-carboxylate and 2-(methylsulfonyl)ethyl 4- methylbenzenesulfonate instead of ethyl 5-chloro-lH-indole-2-carboxylate and 3- (methylsulfinyl)propyl 4-methylbenzenesulfonate.
Example 6
l'-({5-Chloro-l-[2-(ethylsulfonyl)ethyl]-lH-pyrrolo[3,2-Z)]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyri"olo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of methyl 5-chloro-l-(phenylsulfonyl)-lH-pyrrolo[3,2-Z>]pyridine- 2-carboxylate
Figure imgf000127_0001
To a suspension of methyl 5-chloro-lH-pyrrolo[3,2-¾]pyridine-2-carboxylate (7.56 g, 36 mmol) and sodium hydride (1.7 g, 43 mmol, 60% purity in mineral oil) in N,N- dimethylformamide (100 mL) was added benzenesulfonyl chloride (6.1 mL, 47 mmol) dropwise in an ice-water bath. After being stirred at room temperature for 2 hours, the mixture was then poured into ice water (100 mL). The resulting precipitate was collected by filtration, which was washed with petroleum ether (50 mL), and then dried in vacuo to afford 1 1.6 g of 5-chloro-l - (phenylsulfonyl)-lH-pyrrolo[3,2-6]pyridine-2-carboxylate as a pale white solid.
Step 2: Preparation of [5-chloro-l-(phenylsulfonyl)-lH-pyrrolo[3,2-Z>]pyridin-2- yljmethanol
Figure imgf000127_0002
To a suspension of lithium aluminium hydride (1.9 g, 50 mmol) in tetrahydrofuran (150 mL) at 0 °C was added methyl 5-chloro-l-(phenylsulfonyl)-lH-pyrrolo[3,2-0]pyridine-2- carboxylate (1 1.6 g, 33 mmol) in portions. After being stirred at room temperature for 3 hours, the resulting mixture was quenched with methanol, and then filtered through a celite pad. The filtrate was concentrated in vacuo to afford 9.7 g of the product as brown oil. MS obsd. (ESI+) [(M+H)+] 323.
Step 3: Preparation of 5-chloro-2-(chloromethyl)-l-(phenylsulfonyl)-lH-pyrrolo[3,2- b] pyridine
Figure imgf000128_0001
To a solution of [5-chloro-l-(phenylsulfonyl)-lH-pyrrolo[3,2-0]pyridin-2-yl]methanol (1.93 g, 6.0 mmol) in dichloromethane (150 mL) was added a solution of thionyl chloride (2.7 mL, 37 mmol) in dichloromethane (10 mL) in an ice- water bath. After being stirred at room temperature for 4 hours, the mixture was concentrated in vacuo to afford a light brown solid which was used for next step without further purification.
Step 4: Preparation of l'-{[5-chloro-l-(phenylsulfonyl)-lH-pyrrolo[3,2-6]pyridin-2- yl] methyl}spiro [cyclopropane-1 ,3 '- rrolo [2,3-c] pyridin]-2'(l 'H)-one
Figure imgf000128_0002
To a suspension of spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one (960 mg, 6.0 mmol) and sodium hydride (0.72 g, 18 mmol) in N,7V-dimethylformamide (10 mL) was added a solution of 5-chloro-2-(chloromethyl)-l-(phenylsulfonyl)-lH-pyrrolo[3,2-¾]pyridine (2.04 g, 6.0 mmol) in N,N-dimethylformamide (5 mL) dropwise in an ice-water bath. After being stirred at room temperature for 1 hour, the reaction mixture was then poured into ice-water (20 mL) and then extracted with dichloromethane (30 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate, and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with 0 - 5% methanol in dichloromethane) to afford 600 mg of 1 '- { [5-chloro- 1 -(phenylsulfonyl)- 1 H-pyrrolo[3,2-Z>]pyridin-2-yl]mefhyl} spiro[cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l'H)-one as a brown solid. MS obsd. (ESI+) [(M+H)+] 465.
Step 5: Preparation of l'-[(5-chloro-lH-pyrrolo[3,2-A]pyridin-2- yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Figure imgf000129_0001
A mixture of -{[5-chloro-l-(phenylsulfonyl)-lH-pyrrolo[3,2-0]pyridin-2- yl]methyl}spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one (167 mg, 0.36 mmol) and tetrabutylammonium fluoride in tetrahydrofuran (1 mL, 1.0 M) in tetrahydrofuran (2 mL) was stirred at room temperature for 16 hours. The resulting mixture was concentrated in vacuo. The residue was extracted with ethyl acetate (20 mL x 2). The organic layer was washed with a saturated aqueous solution of ammonium chloride (20 mL x 2) and water (20 mL x 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was used for next step without further purification. MS obsd. (ESI+) [(M+H)+] 325.
Step 6: Preparation of l'-({5-chloro-l-[2-(ethylsulfonyl)ethyl]-lH-pyrroIo[3,2- b] pyridin-2-yl}methyI)spiro [cyclopropane-1,3 '-pyrrolo [2,3-c] pyridin] -2 ' (1 'H)-one
A mixture of r-[(5-chloro-lH-pyrrolo[3,2-0]pyridin-2-yl)methyl]spiro[cyclopropane-l ,3'- pyrrolo[2,3-c]pyridin]-2'(rH)-one (84 mg, 0.26 mmol), sodium tert-butoxide (90 mg, 1.0 mmol) and (ethylsulfonyl)ethene (63.5 mg, 0.52 mmol) in acetonitrile (5 mL) was stirred at room temperature for 6 hours. The resulting mixture was quenched with water, then filtered and washed with acetonitrile (10 mL x 3). The filtrate was concentrated in vacuo. The residue was purified by preparative HPLC to afford 8.1 mg of the title product as colorless oil.
Example 7-1
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l,(2'H)- yl)methyl]-lH-indol-l-yl}-N^V-dimethylpropane-l-sulfonamide
Step 1: Preparation of l'-[(5-chloro-lH-indol-2-yl)methyl]spiro[cyclopropane-l,3'- pyrrolo [2,3-c]pyridin] -2 ' (1 'H)-one
Figure imgf000130_0001
Γ- [(5 -Chloro- 1 H-indol-2-yl)methyl] spn^
one was prepared in analogy to l'-[(5-chloro-lH-pyrrolo[3,2- ?]pyridin-2- yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one in Example 6 by using ethyl 5-chloro- lH-indole-2-carboxylate instead of methyl 5-chloro-lH-pyrrolo[3,2-&]pyridine-2- carboxylate.
Step 2: Preparation of 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]-l 2'J^-yl)methyl]-lH-indoN
A mixture of l '-[(5-chloro-lH-indol-2-yl)methyl]spiro[cyclopropane-l ,3'-pyrrolo[2,3- c]pyridin]-2'( H)-one (150 mg, 0.46 mmol), cesium carbonate (200 mg, 0.62 mmol) and 3- chloro-N,N-dimethylpropane-l -sulfonamide (90 mg, 0.49 mmol) in N,N-dimethylformamide (4 mL) was heated with stirring at 80 °C for 1 hour. The resulting mixture was purified by preparative HPLC to afford 6 mg of the title product.
Example 7-2
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyi'iOlo[2,3-c]pyridin]-l'(2,H)- yl)methyl]-lH-pyrrolo[2 -6]pyridin-l-yl}-7V^V-dimethylpropane-l-sulfonamide
The title compound was prepared in analogy to Example 7-1 according to Scheme 3 by using methyl 5-chloro-lH-pyrrolo[2,3-&]pyridine-2-carboxylate instead of ethyl 5-chloro-lH- indole-2-carboxylate.
Example 7-3
2-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyi"i"olo[2,3-c]pyridin]-l'(2'H)- y^methyll-lH-indol-l-ylj-TV^V-dimethylethanesulfonamide
The title compound was prepared in analogy to Example 7-1 according to Scheme 3 by using 2-chloro-N,N-dimethylethanesulfonamide instead of 3-chloro-N,N-dimethylpropane-l- sulfonamide.
Example 7-4 -({5-Chloro-l-[3-(morpholin-4-ylsulfonyl)propyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 7-1 according to Scheme 3 by using 4-[(3-chloropropyl)sulfonyl]morpholine instead of 3-chloro-N,N-dimethylpropane-l - sulfonamide.
Example 7-5
-({5-Chloro-l-[3-(pyrrolidin-l-ylsulfonyl)propyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyriOlo[2,3-c]pyridin]-2'( H)-one
The title compound was prepared in analogy to Example 7-1 according to Scheme 3 by using l-[(3-chloropropyl)sulfonyl]pyrrolidine instead of 3-chloro-N,N-dimethylpropane-l - sulfonamide.
Example 7-6
l'-[(5-Chloro-l-{3-[(3-oxopiperazin-l-yl)sulfonyl]propyl}-lH-indol-2- yl)methyl]spiro[cyclopropane-l,3'-pyriOlo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 7- 1 according to Scheme 3 by using 4-[(3-chloropropyl)sulfonyl]piperazin-2-one instead of 3-chloro-N,N-dimethylpropane- l - sulfonamide.
Example 7-7
l'-({5-Chloro-l-[2-(l,l-dioxido-l,2-thiazolidin-2-yl)ethyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyriOlo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 7-1 according to Scheme 3 by using 2-(2-bromoethyl)-l ,2-thiazolidine 1 ,1 -dioxide instead of 3-chloro-N,N-dimethylpropane- l - sulfonamide.
Example 7-8
l'-({5-Chloro-l-[4-(l,l-dioxido-l,2-thiazolidin-2-yl)butyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyri' lo[2,3-c]pyridin]-2,( H)-one
The title compound was prepared in analogy to Example 7-1 according to Scheme 3 by using 2-(4-bromobutyl)- l ,2-thiazolidine 1 ,1 -dioxide instead of 3-chloro-N,N-dimethylpropane-l- sulfonamide. Example 7-9
l'-({5-Chloro-l-[3-(l,l-dioxidothiomorpholin-4-yl)propyl]-lH-indol-2- lJmeth ^spirotc clopropane-ljS'-p rrolo^jS-clp ridinJ-l l'HJ-one
The title compound was prepared in analogy to Example 7- 1 according to Scheme 3 by using 4-(3-bromopropyl)thiomorpholine 1 , 1 -dioxide instead of 3-chloro-N,N-dimethylpropane-l - sulfonamide.
Example 7-10
l'-({5-Chloro-l-[3-(l,l-dioxido-l,2-thiazolidin-2-yl)propyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 7-1 according to Scheme 3 by using 2-(3-bromopropyl)-l ,2-thiazolidine 1 , 1-dioxide instead of 3-chloro-N,N-dimethylpropane- 1 -sulfonamide.
Example 8
l'-{[5-Chloro-l-(3-hydroxypropyl)-lH-indol-2-yl]methyl}spiro[cyclopropane-l,3'- pyrrolo [2,3-c] py ridin] -2' (1 'H)-one
Step 1: Preparation of l'-[(5-chloro-lH-indol-2-yl)methyl]spiro[cyclopropane-l,3'- pyrrolo [2,3-c] pyridin] -2'(1 'H)-one
Figure imgf000132_0001
1 '- [(5-chloro- 1 H-indol-2-yl)methyl] spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c] pyridin] -2'( 1 H)- one was prepared in analogy to 1 '-[(5-chloro- lH-pyrrolo[3,2-&]pyridin-2- yl)methyl]spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one in Example 6 by using ethyl 5-chloro- lH-indole-2-carboxylate instead of methyl 5-chloro-lH-pyrrolo[3,2- )]pyridine-2- carboxylate.
Step 2: Preparation of -{[5-chloro-l-(3-hydroxypropyl)-lH-indol-2- yi]methyi}spiro[cyciopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one To a solution of l'-[(5-chloro-lH-indol-2-yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]-2'(l'H)-one (163 mg, 0.50 mmol) in acetonitrile (5 mL) was added 3-bromopropan-l- ol (217 mg, 1.5 mmol), cesium carbonate (488 mg, 1.5 mmol) and tetrabutylammonium bromide (156 mg, 0.50 mmol). The resulting mixture was heated under reflux overnight. After being cooled to room temperature, the mixture was concentrated in vacuo. The residue was dissolved in dichloromethane (10 mL). The solution was washed with brine, and then drier over sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford the title product.
Example 9
l'-[{5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2- yl}(2H2)methyl]spiro[cyclopropane-l,3'-pyi"i'olo[2,3-c]pyridin]-2,(l,H)-one
Step 1: Preparation of l'-[(5-chloro-lH-indol-2-yl)(2H2)methyl]spiro[cyclopropane- 1 ,3 '-pyrrolo [2,3-c] pyridin] -2'(1 'H)-one
Figure imgf000133_0001
1 '-[(5 -Chloro- 1 H-indol-2-yl)(2H2)methyl] spiro [cyclopropane- 1 ,3 '-pyrrolo [2 ,3 -c] pyridin] - 2'(l'H)-one was prepared in analogy to l'-[(5-chloro-lH-pyrrolo[3,2-0]pyridin-2- yl)methyl]spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one in Example 6 in Scheme 3 by using ethyl 5 -chloro- lH-indole-2-carboxylate and lithium aluminum deuteride instead of methyl 5-chloro-lH-pyrrolo[3,2-6]pyridine-2-carboxylate and lithium aluminum hydride.
Step 2: Preparation of l'-[{5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2- yl}(2H2)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 6 according to Scheme 3 by using r-[(5-chloro-lH-indol-2-yl)(2H2)meth^
one and (methylsulfonyl)ethane instead of l'-[(5-chloro-lH-pyrrolo[3,2-6]pyridin-2- yl)methyl] spiro [cyclopropane- 1 ,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one and (ethylsulfonyl)ethene.
Example 10
1 '- [ {5-Chloro- 1- [3-(methylsulfonyl)propyl] -lH-indol-2- ylJ^Hi^ethylJspirotcyclopropane-ljS'-pyriOlo^^-cJpyridinJ^ l'HJ-one The title compound was prepared in analogy to Example 7-1 according to Scheme 3 by using 1 '-[(5 -chloro- 1 H-indol-2-yl)(2H2)methyl] spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]- 2'(l 'H)-one and 3-(methylsulfonyl)propyl 4-methylbenzenesulfonate instead of ethyl 5-chloro- l /-indole-2-carboxylate, spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one and 3- chloro-JV, N-dimethylpropane- 1 -sulfonamide.
Example 11
Ethyl S-iS-chloro- -Ii '-o ospiroIcyclopro ane-l^'-pyrroloPjS-^pyridinJ-l^ 'H)- yl)methyl]-lH-indol-l-yl}propanoate
Step 1: Preparation of (5-chloro-lH-indol-2-yl)methanol
Figure imgf000134_0001
(5-Chloro-lH-indol-2-yl)methanol was prepared in analogy to lH-indol-2-ylmethanol in Example 1-1 by using ethyl 5-chloro-lH-indole-2-carboxylate instead of lH-indole-2- carboxylate.
Step 2: Preparation of 2-({[teri-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH-indole
Figure imgf000134_0002
To a cooled solution of (5-chloro-lH-indol-2-yl)methanol (1.82 g, 10.0 mmol) in dichloromethane (20 mL) at 0 °C in an ice bath was added a solution of imidazole (1.0 g, 15.0 mmol) in dichloromethane (20 mL) slowly and then followed by addition of a solution of tert- butyl(chloro)dimethylsilane (2.26 g, 15.0 mol) in dichloromethane (10 mL) dropwise under nitrogen atmosphere. After being stirred for 15 minutes, the mixture was allowed to warm to room temperature and then stirred at room temperature overnight. The reaction mixture was then diluted with dichloromethane (50 mL) and then washed with water (50 mL) and brine (50 mL). The organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by flash chromatography (eluting with 5% ethyl acetate in petroleum ether) to give 2.0 g of 2-({[½ri-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH-indole as a white solid.
Step 3: Preparation of ethyl 3-[2-({[teri-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH- indol-l-yl]propanoate
Figure imgf000135_0001
A mixture of 2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH-indole (1.18 g, 4.0 mmol), cesium carbonate (2.6 g, 8.0 mmol) and ethyl 3-bromopropanoate (1 mL, 8.0 mmol) in N,N-dimethylformamide (10 mL) was heated with stirring at 100 °C for 2 hours. The resulting mixture was filtered. The filtrate was concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient eluting with 0 - 40% ethyl acetate in petroleum ether) to afford 1.38 g of ethyl 3-[2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH-indol-l- yl]propanoate as a white solid. MS obsd. (ESf ) [(M+H)+] 396.
Step 4: Preparation of ethyl 3-[5-chloro-2-(hydroxymethyl)-lH-indol-l-yl]propanoate
Figure imgf000135_0002
A mixture of ethyl 3-[2-({ [tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH-indol-l- yljpropanoate (1.38 g, 3.5 mmol) and 1.0 M solution of tetrabutylammonium fluoride in tetrahydrofuran (5 mL) was stirred at 25°C for 4 hours. The resulting mixture was quenched by adding 10 mL of saturated aqueous solution of ammonium chloride. The mixture was then extracted with ethyl acetate (20 mLx 3), and then washed with a saturated aqueous ammonium chloride solution (50 mL χ 3) and brine. The organic layer was dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel
chromatography to afford 0.7 g of ethyl 3-[5-chloro-2-(hydroxymethyl)-lH-indol-l- yl]propanoate as a brown solid. MS obsd. (ESf ) [(M+H)+] 282.
Step 5: Preparation of ethyl 3-(5-chloro-2-{[(methylsulfonyl)oxy]methyl}-lH-indol-l- yl)propanoate
Figure imgf000136_0001
To a solution of ethyl 3-[5-chloro-2-(hydroxymethyl)-lH-indol-l-yl]propanoate (700 mg, 2.5 mmol) and triethylamine (1 mL, 7.5 mmol) in dichloromethane (20 mL) was added methanesulfonyl chloride (0.4 ml, 5 mmol) dropwise in an ice-water bath. After being stirred at 0°C for 30 minutes, the resulting mixture was neutralized with a saturated aqueous solution of sodium bicarbonate and then extracted with dichloromethane (20 mL x 2). The combined organic layer was washed with a saturated aqueous solution of sodium bicarbonate (20 mL x 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 720 mg of ethyl 3- (5-chloro-2-{ [(methylsulfonyl)oxy]methyl}-lH-indol-l-yl)propanoate as a brown solid which was used for next step without further purification.
Step 6: Preparation of ethyl 3-{5-chIoro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo[2,3-c]pyridin]-l'(2'H)-yI)methyl]-lH-indol-l-yl}propanoate
A mixture of ethyl 3-(5-chloro-2-{[(methylsulfonyl)oxy]methyl}-lH-indol-l-yl)propanoate (720 mg, 2.0 mmol), cesium carbonate (1.3 g, 4.0 mmol) and spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one (320 mg, 2.0 mmol) in acetonitrile (20 mL) was heated with stirring at 85 °C for 30 minutes. The mixture was then filtered and washed with acetonitrile (20 mL x 2). The filtrate was concentrated in vacuo. The residue was purified by preparative HPLC to afford 480 mg of the title product as a white solid.
Example 12
l'-({5-Chloro-l-[2-(l,l-dioxidothietan-3-yl)ethyl]-lH-pyrrolo[2,3-Z»]pyridin-2- yl}methyl)spiro [cyclopropane-1,3 '-pyrrolo [2,3-c] pyridin] -2' (1 'H)-one
Step 1: Preparation of 2-(l,l-dioxidothietan-3-yl)ethanol
Figure imgf000136_0002
To a cooled solution of 2-(thietan-3-yl)ethanol (682 mg, 5.8 mmol) in dichloromethane was added 3-chloroperbenzoic acid (2.86 g, 1 1.6 mmol) in portions in an ice bath. The mixture was stirred for 2.5 hours while the temperature was allowed to arise to room temperature naturally. The resulting mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (50 mL). The organic solution was washed with a saturated aqueous solution of sodium carbonate (50 mL x 3), and then dried over sodium sulfate and then concentrated in vacuo to afford 800 mg of viscous oil.
Step 2: Preparation of 2-(l,l-dioxidothietan-3-yl)ethyl 4-methylbenzenesulfonate
Figure imgf000137_0001
A mixture of 2-(l ,l-dioxidothietan-3-yl)ethanol (150 mg, 1.0 mmol), 4- methylbenzenesulfonyl chloride (190.7 mg, 1.0 mmol) and triethylamine (139 μΐ., 1.0 mmol) was stirred at room temperature for 4 hours. The resulting mixture was concentrated in vacuo. The residue was purified by flash column (gradient eluting with 20 - 40% ethyl acetate in petroleum ether) to afford 190 mg of viscous oil.
Step 3: Preparation of 2-({fier/-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH- pyrrolo [2,3-6] pyridine
Figure imgf000137_0002
2-({ [rerr-Butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH-pyrrolo[2,3-6]pyridine was prepared in analogy to 2-({ [rerr-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH-indole in
Example 1 1 by using methyl 5-chloro-lH-pyrrolo[2,3- ]pyridine-2-carboxylate instead of ethyl 5-chloro-lH-indole-2-carboxylate.
Step 4: Preparation of 2-({[fcri-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-l-[2-(l,l- dioxidothietan-3-yl)ethyl]-lH-pyrrolo [2,3-*] pyridine
Figure imgf000138_0001
A mixture of 2-(l ,l-dioxidothietan-3-yl)ethyl 4-methylbenzenesulfonate (190 mg, 0.625 mg), 2-({[½r/-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH-pyrrolo[2,3-0]pyridine (185 mg, 0.625 mmol) and potassium carbonate (173 mg, 1.25 mmol) in acetonitrile (10 mL) was heated with stirring at 70 °C overnight. The resulting mixture was then concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient eluting with 0 - 5 % methanol in dichloromethane) to afford 250 mg of 2-({[½r/-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-l- [2-(l ,l-dioxidothietan-3-yl)ethyl]-lH-pyrrolo[2,3-0]pyridine as a brown viscous.
Step 5: Preparation of {5-chloro-l-[2-(l,l-dioxidothietan-3-yl)ethyl]-lH-pyrrolo[2,3- 6]pyridin-2-yl}methanol
Figure imgf000138_0002
A mixture of 2-({ [½ -butyl(dimethyl)silyl]oxy}methyl)-5-chloro- l-[2-(l , 1 -dioxidothietan- 3-yl)ethyl]-lH-pyrrolo[2,3-6]pyridine (270 mg, 0.63mmol) and 1% of concentrated hydrochloric acid in ethanol (20 mL) was heated under reflux for 1 hour. After being cooled to room
temperature, the mixture was basified with a saturated solution of sodium bicarbonate (20 mL) and then concentrated in vacuo to remove the organic solvent. The residual aqueous layer was extracted with dichloromethane (20 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient eluting with 0 - 5 % methanol in dichloromethane) to afford 90 mg of {5-chloro-l-[2-(l ,l-dioxidothietan-3-yl)ethyl]-lH-pyrrolo[2,3-0]pyridin-2-yl}methanol.
Step 6: Preparation of l'-({5-chloro-l-[2-(l,l-dioxidothietan-3-yl)ethyl]-lH- pyrrolo[2,3-6]pyridin-2-yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2 l'H)- one The title compound was prepared in analogy to Example 4-15 according to Scheme 4 by using { 5 -chloro- 1 - [2-( 1 , 1 -dioxidothietan-3 -yl)ethy 1] - 1 H-pyrrolo [2,3 - >]pyridin-2-yl } methanol instead of {5-chloro-l-[3-(methylsulfonyl)propyl]-lH-pyrrolo[3,2- )]pyridine-2-yl}methanol.
Example 13
Ethyl 3-{5-chloro-7-fluoro-2-[(2,-oxospiro[cyclopropane-l,3'-pyi"i"olo[2,3-c]pyridin]- l'(2'H)-yl)methyl]-lH-indol-l-yl}propanoate
Step 1: Preparation of 2-({[ieri-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-7-fluoro- lH-indole
2-({ [tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-7-fluoro- lH-indole was prepared in analogy to 2-({ [tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro- lH-indole in Example 1 1 by using methyl 5-chloro-7-fluoro-lH-indole-2-carboxylate instead of ethyl 5 -chloro- lH-indole-2- carboxylate.
Step 2: Preparation of ethyl 3-[2-({[ieri-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-7- fluoro-lH-indol-l-yl]propanoate
Figure imgf000139_0002
To a mixture of 2-({ [tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-7-fluoro-lH-indole (100 mg, 0.40 mmol), cesium carbonate (221.6 mg, 0.68 mmol) and N,N-dimethylformamide (4 mL) was added ethyl prop-2-enoate (68.1 mg, 0.68 mmol) at room temperature. After being stirred overnight, the reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over sodium sulfate, and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient eluting with 0 - 40% ethyl acetate in petroleum ether) to give 80 mg of ethyl 3-[2-({ [tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro- 7-fluoro-lH-indol-l-yl]propanoate as colorless oil.
Step 3: Preparation of ethyl 3-[5-chloro-7-fluoro-2-(hydroxymethyl)-lH-indol-l- yl]propanoate
Figure imgf000140_0001
To a solution of ethyl 3-[2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-7-fluoro-lH- indol-l-yl]propanoate (480 mg, 1.16 mmol) in tetrahydrofuran (10 mL) was added 1.0 M of tetrabutylammonium fluoride (3 mL) in tetrahydrofuran at 0 °C. After being stirred for 1 hour, the mixture was diluted with a saturated aqueous solution of sodium bicarbonate (20 mL) and then extracted with ethyl acetate (20 mL). The organic layer was dried over sodium sulfate, and then concentrated in vacuo. The residue was purified by flash silica gel chromatography
(gradient eluting with 0 - 5% methanol in dichloromethane) to afford 350 mg of ethyl 3-[5- chloro-7-fluoro-2-(hydroxymethyl)-lH-indol-l-yl]propanoate as a white solid.
Step 4: Preparation of ethyl 3-(5-chloro-7-fluoro-2-{[(methylsulfonyl)oxy]methyl}-lH- indol-l-yl)propanoate
Figure imgf000140_0002
To a solution of ethyl 3-[5-chloro-7-fluoro-2-(hydroxymethyl)-lH-indol-l-yl]propanoate (350 mg, 1.17 mmol) and triethylamine (355.2 mg, 3.51 mmol) in dichloromethane (10 mL) was added methanesulfonyl chloride (201.6 mg, 1.76 mmol) dropwise at 0 °C. After being stirred at room temperature for 30 minutes, the reaction was quenched with a saturated aqueous solution of sodium bicarbonate (10 mL). The organic layer was separated, and then dried over sodium sulfate and then concentrated in vacuo to afford the crude ethyl 3-(5-chloro-7-fluoro-2- {[(methylsulfonyl)oxy]methyl}-lH-indol- l-yl)propanoate which was used for next step without further purification.
Step 5: Preparation of ethyl 3-{5-chloro-7-fluoro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo^^-cJpyridinJ-l 'HJ-y^methylJ-lH-indol-l-ylJpropanoate
A mixture of ethyl 3-(5-chloro-7-fluoro-2-{ [(methylsulfonyl)oxy]methyl}-lH-indol-l- yl)propanoate from Step 4, spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one (160.2 mg, 1.0 mmol) and cesium carbonate (652 mg, 2.0 mmol) in acetonitrile (10 mL) was stirred at room temperature overnight, then at 80 °C for 1 hour. The reaction mixture was then diluted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient eluting with 0 - 5% methanol in dichloromethane) to afford 270 mg of the title product as a brown solid.
Example 14-1
l'-({5-Chloro-l-[3-(S-methylsulfonimidoyl)propyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of ethyl -(3-bromopropyl)-5-chloro-lH-indole-2-carboxylate
Figure imgf000141_0001
A suspension of ethyl 5-chloro-lH-indole-2-carboxylate (40 g, 0.18 mol), 1 ,3-dibromo- propane (181 g, 0.90 mol) and potassium carbonate (49.68 g, 0.36 mol) in acetone (500 mL) was heated under reflux for 16 hours. The mixture was concentrated in vacuo to remove the solvent. The residue was diluted with water (1000 mL), and then extracted with ethyl acetate (300 mL x 2). The combined organic layer was dried over sodium sulfated and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with 0 - 10% ethyl acetate in petroleum ether) to afford 38.5 g of ethyl l-(3-bromopropyl)-5-chloro-lH-indole-2- carboxylate.
Step 2: Preparation of ethyl 5-chloro-l-[3-(methylsulfanyl)propyl]-lH-indole-2- carboxylate
Figure imgf000141_0002
A solution of ethyl l -(3-bromopropyl)-5-chloro-lH-indole-2-carboxylate (38.5 g, 0.112 mol) and sodium methanethiolate (9.4 g, 0.135 mol) in ethanol (500 mL) was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo. The residue was diluted with water (200 mL) and then extracted with ethyl acetate (100 mL x 2). The combined organic layer was washed with brine (100 mL) and water (100 mL), and then dried over sodium sulfate and then concentrated in vacuo to afford 34.1 g of the crude ethyl 5-chloro-l-[3- (methylsulfanyl)propyl]-17J-indole-2-carboxylate, which was used without further purification.
Step 3: Preparation of {5-chloro-l-[3-(methylsulfan l)propyl]-lH-indol-2-yl}methanol
Figure imgf000142_0001
To a cooled suspension of lithium aluminum hydride (2.89 g, 0.076 mol) in tetrahydrofuran (250 mL) was added ethyl 5-chloro-l-[3-(methylsulfanyl)propyl]-lH-indole-2-carboxylate (15.9 g, 0.051 mol) in portions at 0 °C. After the addition, the reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was then cooled to 0 °C and the reaction was quenched by addition of methanol slowly. The resulting mixture was then filtered and the filter cake was washed with dichloromethane. The filtrate was concentrated in vacuo. The residue was purified by flash silica gel chromatography to afford 1 1.7 g of {5-chloro-l-[3- (methylsulfanyl)propyl] - 1 H-indol-2-yl } methanol .
Step 4: Preparation of 2-({[ter/-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-l-[3- (methylsulfanyl)propyl]-lH-indole
Figure imgf000142_0002
To a cooled solution of {5-chloro-l-[3-(methylsulfanyl)propyl]-lH-indol-2-yl}methanol (5.38g, 20 mmol), teri-butyl(chloro)dimethylsilane (3.24 g, 22 mmol) and 4- dimethylaminopyridine (0.244 g, 2.0 mmol) in dichloromethane (100 mL) was added
triethylamine (3.03 g, 30 mmol) dropwise at 0 °C. After being stirred for 15 minutes, the resulting mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched with methanol (30 mL) and the resulting mixture was concentrated in vacuo. The residue was purified by flash chromatography (eluting with 0 - 20% ethyl acetate in petroleum ether) to give 5.76 g of 2-({ [tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-l-[3- (methylsulfanyl)propyl]-lH- indole as a white solid.
Step 5: Preparation of 2-({[ieri-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-l-[3- (methylsulfinyl)propyl]-lH-indole
Figure imgf000143_0001
To a cooled solution of 2-({ [iert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-l-[3- (methylsulfanyl)propyl]-lH-indole (5.76 g, 15 mmol) in dichloromethane (150 mL) was added 3- chlorobenzene-l-carboperoxoic acid (3.3 g, 15 mmol, 85%) in portions at 0 °C. The resulting mixture was then warmed naturally to room temperature and then stirred at room temperature for 16 hours. The reaction mixture was quenched by the addition of a saturated aqueous solution of sodium bicarbonate (50 mL) and a saturated aqueous solution of sodium thiosulfate (50 mL). The separated organic layer was washed with brine (50 mL), and then dried over sodium sulfate and then concentrated in vacuo. The residue was purified by flash column to afford 4.14 g of 2- ( { [ieri-butyl(dimethyl)silyl]oxy } methyl)-5-chloro- 1 - [3 -(methylsulfinyl)propyl] - 1 H- indole.
Step 6: Preparation of N-[{3-[2-({[iert-Butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH- ίndol-l-yl]propyl}(methyl)o ido-λ6-sulfanylidene]-2,2,2-trifluoroacetamide
Figure imgf000143_0002
To a suspension of 2-({[iert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-l -[3- (methylsulfinyl)propyl]-lH-indole (800 mg, 2.0 mmol), trifluoroacetamide (452 mg, 4.0 mmol), magnesium oxide (320 mg, 8.0 mmol), and rhodium(II) acetate (22 mg, 2.5 mol%) in
dichloromethane (10 mL) was added bis(acetyloxy)(phenyl)^3-iodane (966 mg, 3.0 mmol) at room temperature. The resulting mixture was stirred overnight and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient eluting with ethyl acetate in petroleum ether) to afford 510 mg of N-[{3-[2-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-5- chloro-lH-indol-l-yl]propyl}(methyl)oxido- 6-sulfanylidene]-2,2,2-trifluoroacetamide. MS obsd. (ESI+) [(M+H)+] 511.
Step 7: Preparation of {5-chloro-l-[3-(S-methylsulfonimidoyl)propyl]-lH-indol-2- yl}methanol
Figure imgf000144_0001
To a mixture of N-[{3-[2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-lH-indol-l- yl]propyl}(methyl)oxido-λ6-sulfanylidene]-2,2,2-trifluoroacetamide (51 1 mg, 1.0 mmol) in tetrahydrofuran (2 mL) was added 1% concentrated hydrochloric acid in ethanol (50 mL) dropwise. The resulting mixture was heated under reflux overnight and then concentrated in vacuo. The residue was dissolved in ethyl acetate (25 mL). The organic phase was washed with a saturated aqueous solution of sodium carbonate (25 mL) and brine (25 mL), and then dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient eluting with ethyl acetate in petroleum ether) to afford 240 mg of { 5 -chloro- 1 - [3 -(S-methylsulfonimidoyl)propyl] - 1 H-indol-2-yl } methanol .
Step 8: Preparation of 5-chloro-2-(chloromethyl)-l-[3-(5- methylsulfonimidoyl)propyl]-lH-indole
Figure imgf000144_0002
To a solution of {5-chloro-l-[3-(5'-methylsulfonimidoyl)propyl]-lH-indol-2-yl}methanol (200 mg, 0.67 mmol) in dichloromethane was added thionyl dichloride (96 mg, 0.80 mmol) slowly. The mixture was stirred at room temperature for 3 hours. The resulting mixture was concentrated in vacuo to afford the crude 5-chloro-2-(chloromethyl)-l-[3-(5'- methylsulfonimidoyl)propyl]-lH-indole as a solid, which was used for next reaction without further purification.
Step 9: Preparation of l'-({5-chloro-l-[3-(S-methylsulfonimidoyl)propyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
To a suspension of spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one (1 15 mg, 0.66 mmol) and sodium hydride (80 mg, 1.98 mmol) in A^N-dimethylformamide (2 mL) was added 5-chloro-2-(chloromethyl)-l -[3-(5'-methylsulfonimidoyl)propyl]-lH-indole (200 mg, 0.66 mmol) in N-dimethylformamide (1 mL) drop wise in an ice- water bath. After being stirred at room temperature for 1 hour, the reaction mixture was poured into ice-water (20 mL) and then extracted with dichloromethane (30 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient eluting with 0 - 5% methanol in dichloromethane) to afford the title product.
Example 14-2
r-({5-Chloro-l-[2-(S-methylsulfonimidoyl)ethyI]-lH-indol-2- yl}methyl)spiro[cydopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 14-1 according to Scheme 5 by using 1 ,2-dibromoethane instead of 1,3-dibromo-propane.
Example 14-3
l*-({5-ChIoro-l-[4-(5-methylsulfonimidoyl)butyl]-lH-pyrrolo[2,3-6]pyridin-2- yl}methyl)spiro[cydopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 14-1 according to Scheme 5 by using methyl 5-chloro-lH-pyrrolo[2,3-6]pyridine-2-carboxylate and 1 ,4-dibromobutane instead of ethyl 5-chloro-lH-indole-2-carboxylate and 1 ,3-dibromo-propane.
Example 14-4
l'-({5-Chloro-l-[2-(5-methylsulfonimidoyl)ethyl]-lH-pyrrolo[2,3-6]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrr lo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 14-1 according to Scheme 5 by using methyl 5-chloro-lH-pyirolo[2,3-0]pyridine-2-carboxylate and 1 ,2-dibromoethane instead of ethyl 5-chloro-lH-indole-2-carboxylate and 1,3-dibromo-propane. Example 15
N-[(2-{5-Chloro-2-[(2'-oxospiro [cycIopropane-l,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)- I)meth l]-lH-indoI-l- I}eth I)(meth I)oxido-λ6-suIfan lidene]acetamide
To a solution of l'-({5-chloro-l-[2-(5'-methylsulfonimidoyl)ethyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one (100 mg, 0.233 mmol) in dichloromethane (2 mL) was added triethylamine (42 μί, 0.303 mmol) at 0 °C and then followed by the addition of the acyl chloride (18.9 mg, 0.233 mmol) dropwise. After being stirred for about 1 hour at 0 °C, the reaction mixture was warmed to room temperature and stirred overnight. The resulting mixture was then diluted with water (20 mL) and then extracted with
dichloromethane (20 mLx 2). The combined organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel chromatography
(gradient eluting with 0 - 5% methanol in dichloromethane) to afford the title product.
Example 16-1
3-{5-ChIoro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2 -c]pyridin]-l'(2'H - yl)methyl]-lH-indol-l-yl}propanoic acid
A mixture of ethyl 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- l '(2'H)-yl)methyl]-lH-indol-l-yl}propanoate (190 mg, 0.45 mmol) in tetrahydrofuran (5 mL) and 2.0 N of aqueous solution of lithium hydroxide (4 mL) was stirred at 25 °C for 3 hours. The resulting mixture was neutralized with a 3 N aqueous hydrochloric acid solution and then extracted with dichloromethane (20 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by
preparative HPLC to afford 38 mg of the title product as a light yellow solid.
Example 16-2
3-{5-ChIoro-7-fluoro-2-[(2'-oxospiro[cycIopropane-l,3'-pyrrolo[2,3-c]pyridin]- l'(2'H)-yl)methyl]-lH-indol-l-yI}propanoic acid
To a solution of ethyl 3-{5-chloro-7-fluoro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3- c]pyridin]-l'(2'H)-yl)methyl]-lH-indol-l-yl}propanoate (270 mg, 0.61 mmol) in tetrahydrofuran (10 mL) was added an aqueous solution of lithium hydroxide monohydrate (102.7 mg, 2.44 mmol, in 1 mL of water) at room temperature. After being stirred for 4 hours, the reaction was diluted with dichloromethane (10 mL) and then extracted with water (10 mL x 2). The combined aqueous layer was acidified with 1 N hydrochloric acid to pH 3 and then extracted with dichloromethane (20 mL x 2). The combined organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was stirred with methanol. The solid was collected by filtration and washed with methanol, and then dried in vacuo to afford 100 mg of the title product as a light yellow solid.
Example 17
Methyl 4-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l'(2,H)- yl)methyl]-li/-indol-l-yl}butanoate
Step 1: Preparation of ethyl 4-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo[2,3-c]pyridin]-l'(2'H)-yl)methyl]-lH-indol-l-yl}butanoate
Figure imgf000147_0001
Ethyl 4-{5-chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- (2'H)- yl)methyl]-lH-indol-l-yl}butanoate was prepared in analogy to Example 7-1 according to Scheme 3 by using ethyl 4-bromobutanoate instead of 3-chloro-N,N-dimethylpropane-l- sulfonamide.
Step 2: Preparation of 4-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c] py ridin] -1 ' (2 'H)-y l)methyl] - lH-indol- 1-yl} butanoic acid
Figure imgf000147_0002
4-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyiTolo[2,3-c]pyridin]-l 2'H)-yl)methyl]- lH-indol- 1-yl} butanoic acid was prepared in analogy to Example 16-1 according to Scheme 6 by using ethyl 4- { 5 -chloro-2- [(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin] - 1 '(2'H)- yl)methyl]-lH-indol-l-yl}butanoate instead of ethyl 3-{5-chloro-2-[(2'-oxospiro[cyclopropane- l,3'-pyrrolo[2,3-c]pyridin]-r(2'H)-yl)methyl]-lH-indol-l-yl}propanoate.
Step 3: Preparation of methyl 4-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo^jS-cJpyridinJ-l 'HJ-y^methylJ-lH-indol-l-ylJbutanoate
To a solution of 4-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- r(2'H)-yl)methyl]-lH-indol-l-yl}butanoic acid (41.0 mg, 0.10 mmol) in methanol (20 mL) was added thionyl chloride (0.3 mL) in an ice-water bath. The mixture was stirred at 50 °C for 2 hours and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 5 mg of the title product as a white solid.
Example 18-1
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyi"i"olo[2,3-c]pyridin]-l'(2'H)- yl)methyl]-lH-indol-l-yl}propanamide
A mixture of ethyl 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- l'(2'H)-yl)methyl]-lH-indol-l-yl}propanoate (190 mg, 0.45 mmol) in methanol (10 mL) and 7 N solution of ammonia in methanol (5 mL) was heated with stirring at 80 °C for 16 hours. The mixture was concentrated in vacuo. The residue was purified by preparative HPLC to afford 16 mg of the title product as a white solid.
Example 18-2
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-6]pyridin]- (2,H)- yl)methyl]-lH-indol-l-yl}propanamide
Step 1: Preparation of methyl 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo[2,3-6]pyridin]-l'(2,H)-yl)methyl]-li -indol-l-yl}propanoate
Figure imgf000148_0001
Methyl 3 - { 5 -chloro-2- [(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -£]pyridin]- 1 '(2'H)- yl)methyl]-lH-indol-l-yl}propanoate was prepared in analogy to Example 6 by using ethyl 5- chloro- 1 H-indole-2-carboxylate, spiro [cyclopropane- 1 ,3 '-pyrrolo[2,3 -b]pyridin] -2'( 1 'H)-one and methyl prop-2-enoate instead of methyl 5-chloro-lH-pyrrolo[3,2- >]pyridine-2-carboxylate, spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one and (ethylsulfonyl)ethene.
Step 2: Preparation of 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- b] pyridin] -1 ' (2 'H)-yl)methyl] -lH-indol-l-yl} propanamide
The title compound was prepared in analogy to Example 18-1 according to Scheme 6 by using methyl 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-0]pyridin]- (2'H)- yl)methyl]-lH-indol-l-yl}propanoate instead of ethyl 3-{5-chloro-2-[(2'-oxospiro[cyclopropane- 1 , 3 '-pyrrolo [2,3 -c]pyridin] - 1 '(2'H)-yl)methyl] - 1 H-indol- 1 -yl } propanoate.
Example 18-3
4-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l,(2'//)- yl)methyl]-lH-indol-l-yl}butanamide
The title compound was prepared in analogy to Example 18-1 according to Scheme 6 by using methyl 4- { 5-chloro-2- [(2'-oxospiro[cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin]- 1 2'H)- yl)methyl]-lH-indol-l-yl}butanoate instead of ethyl 3-{5-chloro-2-[(2'-oxospiro[cyclopropane- 1 , 3 '-pyrro lo [2, 3 -cjpyridin] - l'(2'H)-y l)methy 1] - 1 H-indol- 1 -yl }propanoate.
Example 19-1
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)- yl)methyl]-lH-indol-l-yl}-N-(cyclopropylsulfonyl)propanamide
A mixture of 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- (2'H)- yl)methyl]-lH-indol-l-yl}propanoic acid (200 mg, 0.5 mmol), cyclopropanesulfonamide (121 mg, 1.0 mmol), N-[3-(dimethylamino)propyl]-N1-ethylcarbodiimide hydrochloride (192 mg, 1.0 mmol), and 4-dimethylamiopryidine (13 mg, 0.1 mmol) in dichloromethane (6 mL) was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo. The residue was purified by preparative HPLC to afford 12 mg of the product as a light yellow solid.
Example 19-2
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo [2,3-c]pyridin]-l'(2'H)- yl)methyl]-lH-indol-l-yl}-N-(cyclopropylsulfonyl)-N-methylpropanamide
The title compound was prepared in analogy to Example 19-1 according to Scheme 6 by using N-methyl(cyclopropane)methanesulfonamide instead of cyclopropanesulfonamide. Example 19-3
S-iS-Chloro-l-til'-o ospirotcyclopropane-l^'-pyrrolo^jS-clpyridinJ-l l'H)- yl)methyl]-lH-indol-l-yl}-N-methyl-N-(methylsulfonyl)propanamide
The title compound was prepared in analogy to Example 19-1 according to Scheme 6 by using N-methylmethanesulfonamide instead of cyclopropanesulfonamide.
Example 20
3-(2-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)- yl)methyl]-lH-indol-l-yl}ethyl)imidazolidine-2,4-dione
Step 1 : Preparation of l'-[(5-chloro-lH-indol-2-yl)methyl]spiro[cyclopropane-l,3'- pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Figure imgf000150_0001
r-[(5-Chloro-lH-indol-2-yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2 rH)- one was prepared in analogy to l'-[(5-chloro-lH-pyrrolo[3,2- j]pyridin-2- yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one in Example 6 according to Scheme 3 by using ethyl 5-chloro-lH-indole-2-carboxylate instead of methyl 5-chloro-lH- pyrrolo[3,2-6]pyridine-2-carboxylate.
Step 2: Preparation of l'-{[l-(2-bromoethyl)-5-chloro-lH-indol-2- yl]methyl}spiro[cyclopropane-l,3'-pyri"olo[2,3-c]pyridin]-2'(l'H)-one
Figure imgf000150_0002
A mixture of l'-[(5-chloro- lH-indol-2-yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]-2'(rH)-one (550 mg, 1.7 mmol), 1 ,2-dibromoethane (1.6 g, 8.5 mmol) and potassium carbonate (1.2 g, 8.5 mmol) in acetone (100 mL) was stirred at 70 °C for 96 hours. The suspension was filtered and the filtrate was concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with 33% ethyl acetate in petroleum ether) to afford 0.2 g of 1 '- { [ 1 -(2-bromoethyl)-5-chloro-lH-indol-2-yl]methyl} spiro [cyclopropane- 1 ,3'-pyrrolo[2,3- cjpyridin] -2'( 1 'H)-one.
Step 3: Preparation of 3-(2-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]-1^2'H -yl)methyl]-lH-indol-l-yl}ethyl)imidazolidine-2,4-dione
A mixture of l'-{[l-(2-bromoethyl)-5-chloro-lH-indol-2-yl]methyl}spiro[cyclopropane- l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one (50 mg, 0.12 mmol), imidazolidine-2,4-dione (58 mg, 0.58 mmol), tetrabutylazanium fluoride (3.2 mg) and potassium carbonate (80 mg, 0.58 mmol) in tetrahydrofuran (8 mL) was stirred at room temperature for 72 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by preparative HPLC to afford 2.0 mg of the title product.
Example 21
l'-[(5-Chloro-l-{3-[(3R)-3-hydroxypyrrolidin-l-yl]propyl}-lH-indol-2- yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2,( H)-one
Step 1: Preparation of -{[l-(3-bromopropyl)-5-chloro-lH-indol-2- yl]methyl}spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Figure imgf000151_0001
A mixture of l'-[(5-chloro-lH-indol-2-yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]-2'(rH)-one (50 mg, 0.15 mmol), cesium carbonate (250 mg, 0.77 mmol) and 1,3- dibromo -propane (1.0 g, 5.0 mmol) in acetonitrile (4 mL) was heated with stirring at 80 °C for 1 hour, and then the reaction mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with 33% ethyl acetate in petroleum ether) to afford 70 mg of Γ- { [ 1 -(3 -bromopropyl)-5 -chloro- 1 H-indol-2-yl]methyl } spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3- cjpyridin] -2'( 1 'H)-one.
Step 2: Preparation of -[(5-chloro-l-{3-[(3i?)-3-hydroxypyrrolidin-l-yl]propyl}-lH- indol-2-yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one
A mixture of l '-{[l-(3-bromopropyl)-5-chloro-lH-indol-2-yl]methyl}spiro[cyclopropane- l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one (70 mg, 016 mmol), cesium carbonate (250 mg) and (3R)- pyrrolidin-3-ol (150 mg, 1.7 mmol) in N.N-dimethylformamide (4 mL) was heated with stirring at 80 °C for 1 hour, and then the reaction mixture was concentrated in vacuo. The residue was purified by preparative HPLC to afford 2.0 mg of the title product.
Example 22- 1
l'-({5-Chloro-l-[3-(ethylsulfonyl)propyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of ethyl 5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-indole-2- carbox late
Figure imgf000152_0001
A mixture of ethyl l-(3-bromopropyl)-5-chloro- lH-indole-2-carboxylate (1.0 g, 2.9 mmol) and sodium ethanesulfmate (1.0 g, 8.7 mmol) in NN-dimethylformamide (10 mL) was heated with stirring at 80 °C overnight. The reaction mixture was cooled and then diluted with ethyl acetate (40 mL), and then washed with brine. The organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with 33% ethyl acetate in petroleum ether) to afford 680 mg of ethyl 5-chloro-l-[3- (ethylsulfonyl)propyl]-lH-indole-2-carboxylate.
Step 2: Preparation of {5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-indol-2-yl}methanol
Figure imgf000152_0002
To a slurry of lithium aluminium hydride (96 mg, 2.5 mmol) in anhydrous tetrahydrofuran (5 mL), which was cooled to 0 °C, was added a solution of ethyl 5-chloro-l-[3- (ethylsulfonyl)propyl]-lH-indole-2-carboxylate (600 mg, 1.68 mmol) in anhydrous
tetrahydrofuran (10 mL) dropwise. After being stirred at 0 °C for 1 hour, the reaction was quenched by addition of IN hydrochloric acid (10 mL) slowly. After being stirred for 10 minutes, the mixture was basified by the addition of a saturated aqueous solution of sodium bicarbonate (10 mL) and then filtered through a celite pad. The filter cake was washed with dichloromethane (50 mL). The organic layer was separated and the aqueous layer was extracted with dichloromethane (20 mL x 3). The combined organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with 0 - 50% ethyl acetate in petroleum ether) to afford 420 mg of {5-chloro-l-[3- (ethylsulfonyl)propyl]-lH-indol-2-yl}methanol.
Step 3: Preparation of {5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-indol-2-yl}methyl methanesulfonate
Figure imgf000153_0001
To a solution of {5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-indol-2-yl}methanol (400 mg, 1.27 mmol) in dichloromethane (10 mL) was added methanesulfonyl chloride (219 mg, 1.9 mmol) and triethylamine (0.353 ml, 2.54 mmol) slowly at 0 °C. The mixture was stirred at 0 °C for 2 hours and then diluted with dichloromethane (10 mL). The organic layer was washed with water, and then dried over sodium sulfate and then concentrated in vacuo to afford 415 mg of the crude {5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-indol-2-yl}methyl methanesulfonate which was used for the next step without any purification.
Step 4: Preparation of l'-({5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyi"i" lo[2,3-c]pyridin]-2'(l'H)-one
A mixture of {5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-indol-2-yl}methyl
methanesulfonate (415 mg, the crude product from the Step 3), spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one (203 mg, 1.27 mmol) and 2-(tert-butylimino)-N,N-diethyl-l,3- dimethyl-l ,3,2 5-diazaphosphinan-2-amine (522 mg, 1.91 mmol) in acetonitrile (10 mL) was heated with stirring at 80 °C for 30 minutes. The resulting mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (30 mL). The organic layer was washed with water, and then dried over sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 80 mg of the title product.
Example 22-2
l'-({5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3 ' -pyrrolo [2,3-6] pyridin] -2 ' (1 'H)-one
The title compound was prepared in analogy to Example 22-1 according to Scheme 8 by using spiro[cyclopropane-l,3'-pyrrolo[2,3-¾]pyridin]-2'( H)-one instead of spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one.
Example 22-3
l'-({5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-indol-2-yl}methyI)spiro[cyclopropane- l,3'-pyrrolo[2,3-c]pyridin]-2"(l'H)-one
The title compound was prepared in analogy to Example 22-1 according to Scheme 8 by using spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one instead of spiro [cyclopropane- l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one.
Example 23
l'-({5-Chloro-l-[3-(ethylsulfonyl)propyl]-lH-pyrrolo[2,3-6]pyridin-2- yl} methyl)spiro [cyclopropane- 1 ,3 ' -pyrrolo [2,3-c] pyridin] -2' (1 'H)-one
Step 1: Preparation of {5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-pyrrolo[2,3- 6]pyridin-2-yl}methanol
Figure imgf000154_0001
{5-Chloro-l -[3-(ethylsulfonyl)propyl]-lH-pyrrolo[2,3-¾]pyridin-2-yl}methanol was prepare in analogy to {5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-indol-2-yl}methanol in Example 22-1 by using methyl 5-chloro-lH-pyrrolo[2,3-&]pyridine-2-carboxylate instead of ethyl 5- chloro- 1 H-indole-2-carboxylate.
Step 2: Preparation of 5-chloro-2-(chloromethyl)-l-[3-(ethylsuIfonyI)propyl]-lH- pyrrolo [2,3-6] pyridine
Figure imgf000154_0002
A solution of {5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-pyrrolo[2,3-6]pyridin-2- yl}methanol (474 mg, 1.5 mmol) in anhydrous dichloromethane was added thionyl dichloride (155 μί, 3.0, mmol). The reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (20 mL). The solution was washed with a saturated aqueous solution of sodium bicarbonate (20 mL). The organic layer was dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 427 mg of 5-chloro-2-(chloromethyl)-l-[3-(ethylsulfonyl)propyl]-lH-pyrrolo[2,3-0]pyridine as a yellow solid which was used for the next step without any purification.
Step 3: Preparation of l'-({5-chloro-l-[3-(ethylsulfonyl)propyl]-lH-pyrrolo[2,3- 0]pyridin-2-yl}methyl)spiro[cyclopropane-1 '-pyi"rolo[2,3-c]pyridin]-2'(l'H)-one
To a cooled solution of 5-chloro-2-(chloromethyl)-l-[3-(ethylsulfonyl)propyl]-lH- pyrrolo[2,3- >]pyridine and spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one (240 mg 1.5 mmol) in anhydrous N,N-dimethylformamide (10 mL) at 0 °C was added sodium hydride (90 mg, 2.25 mmol) in portions. The reaction mixture was stirred for 3 hours while the temperature was raised to room temperature naturally. The resulting mixture was diluted with brine (30 mL) and then extracted with ethyl acetate (30 mL x 3). The combined organic layer was washed with brine (40 mL x 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 318.6 mg of the title product as a white solid.
Example 24- 1
l'-({5-Chloro-l-[2-(piperazin-l-yl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 '-pyrrolo[2 -c]pyridin]-2 l H)-one
Step 1: Preparation of tert-buty\ 4-(2-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo[2 -c]pyridin]-l 2'H)-yl)methyl]-lH-indol-l- l}ethyl)piperazine-l-carboxylate
Figure imgf000155_0001
To a solution of tert-butyl 4-(2-bromoethyl)piperazine-l-carboxylate (130 mg, 0.44 mmol) in acetone (20 mL) was added l'-[(5-chloro-lH-indol-2-yl)methyl]spiro[cyclopropane-l,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one (142 mg, 0.44 mmol) and potassium carbonate (182 mg, 1.32 mmol). The reaction was heated under reflux for 48 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by preparative TLC (10% methanol in dichloromethane) to afford 130 mg of fert-butyl 4-(2-{5-chloro-2-[(2'- oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2, 3 -c]pyridin] - 1 '(2'H)-yl)methyl] - 1 H-indol- 1 - yl} ethyl )piperazine-l -carboxylate.
Step 2: Preparation of l'-({5-chloro-l-[2-(piperazin-l-yl)ethyl]-lHr-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
To a cooled solution of tert-butyl 4-(2-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo [2,3 -cjpyridin] - 1 '(2'H)-yl)methyl] - 1 H-indol- 1 -yl } ethyl)piperazine- 1 -carboxylate (130 mg, 0.24 mmol) in ethyl acetate (10 mL) was added hydrochloride solution in ethyl acetate (100 mL) at 0 °C. After being stirred at room temperature overnight, the reaction mixture was concentrated in vacuo. The residue was purified by preparative HPLC. The combined eluent from preparative HPLC was concentrated in vacuo and then basified with sodium bicarbonate to pH >7. The residue was extracted by dichloromethane (20 mL χ 3). The combined organic layer was dried over sodium sulfate, and then filtered and then concentrated in vacuo. The residue was added a few drops of methanol and 1 mL of water, and then was dried by lyophilization to afford 19.1 mg of the title product.
Example 24-2
l'-ilS-Chloro-l-^-Cpiperazin-l-ylsulfony^propyll-l T-indol^- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of tert-butyl 4-[(3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo[2 -c]pyridin]-l'(2' )-yl)methyl]-lJyr-indol-l-yl}propyl)sulfonyl]piperazine-l- carboxylate
Figure imgf000156_0001
ter t-Butyl 4- [(3 - { 5-chloro-2-[(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3-c]pyridin] - (2'H)-yl)methyl]-lH-indol-l-yl}propyl)sulfonyl]piperazine-l -carboxylate was prepared in analogy to Example 7-1 according to Scheme 3 by using tert-butyl 4-[(3- chloropropyl)sulfonyl]piperazine-l -carboxylate instead of 3-chloro-N,N-dimethylpropane-l- sulfonamide.
Step 2: Preparation of l'-({5-chloro-l-[3-(piperazin-l-ylsulfonyl)propyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
A solution of tert-butyl 4-[(3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]-l 2'H)-yl)methyl]-lH-indol-l -yl}propyl)sulfonyl]piperazine-l -carboxylate (31.2 mg, 0.05 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.5 mL). The reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated in vacuo. The residue was purified by preparative HPLC to afford 10 mg of l'-({5-chloro-l-[3- (piperazin-l-ylsulfonyl)propyl]-lH-indol-2-yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3- c]pyridin]-2'(l 'H)-one.
Example 24-3
1 '- [(5-Chloro- 1 - {3-[(lR,4R)-2,5-diazabicyclo [2.2.1] hept-2-ylsulfonyl] propyl}-lH-indol- 2-yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one
Step 1: Preparation of tert-butyl (lR,4R)-5-[(3-{5-chloro-2-[(2'- oxospiro[cyclopropane-1 '-pyrrolo[2 -c]pyridin]-l'(2'H)-yl)methyl]-lH-indol-l- yl}propyl)sulfonyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
Figure imgf000157_0001
tert-Buty\ (17?,4i?)-5-[(3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3- c]pyridin]-l 2'/^-yl)methyl]-lH-indol-l -yl}propyl)sulfonyl]-2,5-diazabicyclo[2.2.1]heptane-2 carboxylate was prepared in analogy to Example 7-1 according to Scheme 3 by using tert-butyl (li?,47?)-5-[(3-chloropropyl)sulfonyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate instead of 3- chloro-N,N-dimethylpropane- 1 -sulfonamide. Step 2: Preparation of l'-[(5-chloro-l-{3-[(lR,4R)-2,5-diazabicyclo[2.2.1]hept-2- ylsulf onyl] propyl}-lH-indol-2-yl)methyl] spiro [cyclopropane-1,3 '-pyrrolo [2,3-c] pyridin] - 2'(l'H)-one
The title compound was prepared in analogy to Example 24-2 according to Scheme 9 by using tert-butyl (li?,4i?)-5-[(3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin] - 1 '(2 'H)-yl)methyl] - 1 H-indol- 1 -yl } propyl) sulfonyl] -2 ,5 -diazabicyclo [2.2.1]heptane-2- carboxylate instead of tert-butyl 4-[(3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]- 1 '(2'H)-yl)methyl]- 1 H-indol- 1 -yl }propyl)sulfonyl]piperazine- 1 -carboxylate.
Example 24-4
l'-({5-Chloro-l-[3-(2-oxopiperazin-l-yl)propyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of tert-butyl 4-(3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo[2 -c]pyridin]-l'(2'H)-yl)methyl]-lH-indol-l-yl}propyl)-3-oxopiperazine-l- carboxylate
Figure imgf000158_0001
A mixture of tert-butyl 3 -oxopiperazine-1 -carboxylate (240 mg, 1.2 mmol), 1 ,3- dibromopropane (264 mg, 1.2 mmol) and potassium /e -butoxide (172 mg, 1.8 mmol) in N,N- dimethylformamide (2 mL) was stirred at room temperature for 1 hour. Then l'-[(5-chloro-lH- indol-2-yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one (96.9 mg, 0.3 mmol) and another batch of potassium tert-butoxide(l 15 mg, 1.2 mmol) were added to the reaction mixture. The resulting mixture was stirred at room temperature for another one hour. The reaction mixture was diluted with water (10 mL) and then extracted with ethyl acetate (20 mL). The organic layer was dried over sodium sulfate and then concentrated in vacuo to afford the crude tert-butyl 4-(3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- (2'H)-yl)methyl]-lH-indol-l-yl}propyl)-3-oxopiperazine-l-carboxylate which was used for the next step without any purification.
Step 2: Preparation of l'-({5-chloro-l-[3-(2-oxopiperazin-l-yl)propyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyi"rolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 24-2 according to Scheme 9 by using tert-butyl 4-(3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3,-pyrrolo[2,3-c]pyridin]- (2'H)- yl)methyl]-lH-indol-l-yl}propyl)-3-oxopiperazine-l-carboxylate instead of tert-butyl 4-[(3-{5- chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l 2'H)-yl)methyl]-lH-indol-l- yl}propyl)sulfonyl]piperazine-l-carboxylate.
Example 24-5
-{[l-(2-Aminoethyl)-5-chloro-lH-indol-2-yl]methyl}spiro[cyclopropane-l,3'- pyrrolo [2,3-c] pyridin] -2'(1 'H)-one
Step 1: Preparation of tert-butyl (2-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo[2,3-c]pyridin]-l'(2'H)-yl)methyl]-lH-indol-l-yl}ethyl)carbamate
Figure imgf000159_0001
tert-Butyl (2- { 5 -chloro-2-[(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin]- 1 '(2'H)- yl)methyl]-lH-indol-l-yl}ethyl)carbamate was prepared in analogy to Example 7-1 in Scheme 3 by using tert-butyl (2-bromoethyl)carbamate instead of 3-chloro-N,N-dimethylpropane-l- sulfonamide.
Step 2: Preparation of l'-{[l-(2-aminoethyl)-5-chloro-lH-indol-2- yl]methyl}spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 24-2 according to Scheme 9 by using /er/-butyl (2- { 5 -chloro-2- [(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] - 1 '(2'H)- yl)methyl]-lH-indol-l-yl}ethyl)carbamate instead of tert-butyl 4-[(3-{5-chloro-2-[(2'- oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-r(2'H)-yl)methyl]-lH-indol-l- yl}propyl)sulfonyl]piperazine-l-carboxylate.
Example 25-1 3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)- yl)methyl]-lH-pyrrolo[2,3-6]pyridin-l-yl}-N-methylpropane-l-sulfonamide
To a flask containing cooled concentrated sulfuric acid (2 mL) was added N-benzyl-3-{5- chloro-2- [(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo[2,3-c]pyridin]- 1 '(2'H)-yl)methyl]- 1 H- pyrrolo[2,3-0]pyridin-l -yl}-N-methylpropane-l -sulfonamide (60 mg, 0.1 1 mol) at 0 °C. The resulting mixture was stirred at 0 °C for 15 minutes, then basified with 4 N aqueous solution of sodium hydroxide to pH>7 at 0 °C. The mixture was extracted with ethyl acetate (20 mL). The organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford the title product.
Example 25-2
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyi"i"olo[2,3-c]pyridin]-l'(2'H)- yl)methyl]-lH-indol-l-yl}-N-methylpropane-l-sulfonamide
Step 1: Preparation of N-benzyl-3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'- pyrrolo[2 -c]pyridin]-l 2'H)- l)methyl]-lH-indol-l-yl}-N-methylpropane-l-sulfonamide
Figure imgf000160_0001
N-Benzyl-3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)- yl)methyl]-lH-indol-l-yl} -N-methylpropane-l -sulfonamide was prepared in analogy to Example 4-8 according to Scheme 2 by using ethyl 5-chloro-lH-indole-2-carboxylate instead of methyl 5- chloro-lH-pyrrolo[2,3-6]pyridine-2-carboxylate.
Step 2: Preparation of 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]-l'(2'H)-yl)methyl]-lH-indol-l-yl}-N-methylpropane-l-sulfonamide
The title compound was prepared in analogy to Example 25-1 according to Scheme 10 by using N-benzyl-3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-l 2'H)- yl)methyl]-lH-indol-l -yl}-N-methylpropane-l -sulfonamide instead of N-benzyl-3-{5-chloro-2- [(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-l 2'H)-yl)methyl]-lH-pyrrolo[2,3- 6]pyridin- 1 -yl } -N-methylpropane- 1 -sulfonamide.
Example 25-3
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3,-pyi'i'olo[2,3-c]pyridin]-l'(2,H)- yl)methyl]-lH-pyrrolo[2,3-Z>]pyridin-l-yl}propane-l-sulfonamide
Step 1: Preparation of 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]-l 2*ii)-yl)methyl]-lH-pyrrolo[2,3-Z)]pyridin-l-yl}-N^V-bis(4- methoxybenzyl)propane-l-sulfonamide
Figure imgf000161_0001
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- (2'H)-yl)methyl]- lH-pyrrolo[2,3-6]pyridin-l -yl} -iV,iV-bis(4-methoxybenzyl)propane-l -sulfonamide was prepared in analogy to Example 4-8 according to Scheme 2 by using N,N-bis(4-methoxybenzyl)propane-l - sulfonamide instead of N-benzyl-3-chloro-N-methylpropane-l -sulfonamide.
Step 2: Preparation of 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]-l 2'H^-yl)methyl]-lH-pyrrolo[2,3-Z>]pyridin-l-yl}propane-l-sulfonamide
A mixture of 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- (2'H)- yl)methyl] - 1 H-pyrrolo[2,3 -6]pyridin- 1 -yl} -N, N-bis(4-methoxybenzyl)propane- 1 -sulfonamide (300 mg, 0.43 mmol) and trifluoroacetic acid (3 mL) was stirred at room temperature for 3 hours. The resulting mixture was basified with 4 N aqueous solution of sodium hydroxide to pH>7 at 0 °C and then extracted with ethyl acetate (20 mL). The organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford the title product.
Example 26-1 r-({l-[2-(4-Acetylpiperazin-l-yl)ethyl]-5-chloro-lH-indol-2- yl} methyl)spiro [cy clopropane-1 ,3' -py rrolo [2,3-c] pyridin] -2' ( 1 'H)-one
To a cooled solution of l '-({5-chloro-l-[2-(piperazin-l-yl)ethyl]-lH-indol-2- yl}methyl)spiro [cyclopropane- 1 , 3 '-pyrrolo [2, 3 -c]pyridin]-2'(l'H)-one (100 mg, 0.23 mmol) in dichloromethane (20 mL) was added triethylamine (70 mg, 0.69 mmol) and acetic anhydride (70 mg, 0.69 mmol) at 0 °C. After being stirred at room temperature overnight, the reaction mixture was washed with water (20 mL). The organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 16.1 mg of the title product.
Example 26-2
N-[(3- {5-Chloro-2-[(2'-oxospiro [cy clopropane-1 ,3'-pyirolo [2,3-c] pyridin] -1 ' (2'H)- yl)methyl]-lH-pyrrolo[2,3-Z>]pyridin-l-yl}propyl)sulfonyl]acetamide
A mixture of 3 - { 5-chloro-2-[(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin]- 1 '(2'H)- yl)methyl]-lH-pyrrolo[2,3-0]pyridin-l-yl}propane-l-sulfonamide (50 mg, 0.1 1 mmol), acetic anhydride (45 mg, 0.44 mmol) and ethyldiisopropylamine (57 mg, 0.44 mmol) N,N- dimethylformamide (4 mL) was heated with stirring at 80 °C for 4 hours. The resulting mixture was purified by preparative HPLC to afford 16.1 mg of the title product.
Example 26-3
N-(2- {5-Chloro-2- [(2'-oxospiro [cyclopropane-1 ,3'-pyrrolo [2,3-c] pyridin] -1 '(2'H)- yl)methyl]-lH-indol-l-yl}ethyl)acetamide
To a cooled solution of l '-{[l-(2-aminoethyl)-5-chloro-lH-indol-2- yl]methyl}spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one (100 mg, 0.27 mmol) and triethylamine (50 mg, 0.50 mmol) in N,N-dimethylformamide (5 mL) was added acetyl chloride (23.4mg, 0.30 mmol) at 0 °C . After being stirred at room temperature for 2 hours, the mixture was concentrated in vacuo. The residue was purified by preparative HPLC to afford 10 mg of the title product.
Example 27-1
l'-[(5-Chloro-l-{2-[4-(methylsulfonyl)piperazin-l-yl]ethyl}-lH-indol-2- y^methylJspirotcyclopropane-ljS'-pyrroloPjS-clpyridinJ^ l'HJ-one To a cooled solution of l '-({5-chloro-l-[2-(piperazin-l-yl)ethyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one (100 mg, 0.23 mmol) in dichloromethane (20 mL) was added triethylamine (70 mg, 0.69 mmol) and methanesulfonyl chloride (0.510 g, 4.4 mmol) at 0 °C. After being stirred at room temperature overnight, the reaction mixture was washed with water (20 mL). The organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 8.6 mg of the title product.
Example 27-2
N-(2-{5-Chloro-2-[(2'-oxospiro[cyclopropane-1 '-pyrrolo[2 -c]pyridin]-l,(2'H)- yl)methyI]-lH-indoI-l-yI}ethyI)methanesulfonamide
The title compound was prepared in analogy to Example 27-1 according to Scheme 1 1 by using 1 '- { [ 1 -(2-aminoethyl)-5 -chloro- 1 H-indol-2-y 1] methyl } spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 - c]pyridin]-2'(l 'H)-one instead of l'-({5-chloro-l-[2-(piperazin-l -yl)ethyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one.
Example 27-3
N-(3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-1 ,-pyrrolo[2 -c]pyridin]-l'(2'H)- yl)methyl]-lH-indol-l-yl}propyl)methanesulfonamide
Step 1: Preparation of l'-{[l-(3-aminopropyl)-5-chloro-lH-indol-2- yl] methyl}spiro [cyclopropane-1 ,3'-pyrrolo [2,3-c] pyridin] -2' (l'H)-one
Figure imgf000163_0001
1 '- { [ 1 -(3 - Aminopropyl)-5 -chloro- 1 H-indol-2-yl] methyl } spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one was prepared in analogy to Example 24-5 by using tert-butyl (3-bromopropyl)carbamate instead of tert-butyl (2-bromoethyl)carbamate.
Step 2: Preparation of N-(3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]-l'(2'H)-yl)methyl]-lH-indol-l-yl}propyI)methanesuIfonamide
The title compound was prepared in analogy to Example 27-1 according to Scheme 11 by using !'-{[! -(3 -aminopropyl)-5 -chloro- 1 H-indol-2-yl] methyl} spiro [cyclopropane- 1 ,3 '- pyrrolo [2,3-c]pyridin]-2'( 1 'H)-one instead of 1 '-( { 5-chloro- 1 -[2-(piperazin- 1 -yl)ethyl] - 1 H-indol- 2-yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3-c]pyridin]-2'( 1 'H)-one.
Example 28
l-(2-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3,-pyrrolo[2,3-c]pyridin]-l'(2'H)- yl)methyl]-lH-indol-l-yl}ethyl)urea
A solution of -{[l-(2-aminoethyl)-5-chloro-lH-indol-2-yl]methyl}spiro[cyclopropane- l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one (100 mg, 0.27 mmol), methyl carbamimidothioate and sulfuric acid ( 94 mg,0.50 mmol) in a mixture of ethanol (5 raL) and water (5 mL) was heated under reflux overnight. The resulting mixture was concentrated in vacuo. The residue was purified by preparative HPLC to afford 15 mg of the title product.
Example 29
l'-[(5-Chloro-l-{3-[(2-hydroxyethyl)amino]propyl}-lH-indol-2- y^methylJspiroIcyclopropane-ljS'-pyrrolo^jS-clpyridinJ^ l'HJ-one
A mixture of l'-{[l -(3-aminopropyl)-5-chloro-lH-indol-2-yl]methyl}spiro[cyclopropane- l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one (70 mg, 0.18 mmol), 2-bromoethanol ( 22.5 mg, 0.18 mmol) and cesium carbonate (97.5 mg, 0.30 mmol) in dry acetonitrile (10 mL) was stirred at room temperature overnight. The resulting mixture was filtered. The filtrate was concentrated in vacuo. The residue was purified by preparative HPLC to afford 7 mg of the title product.
Example 30
Methyl (3- {5-chloro-2- [(2'-oxospiro [cyclopropane-l,3'-pyrrolo [2,3-c] pyridin] -1 '(2'H)- yl)methyl]-lH-indol-l-yl}propyl)carbamate
To a solution of l '-{[l-(3-aminopropyl)-5-chloro-lH-indol-2- yl]methyl}spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one (70 mg, 0.18 mmol) and triethylamine (40 mg, 0.40 mmol) in N.N-dimethylformamide (5 mL) was added methyl carbonochloridate (18.8 mg, 0.20 mmol) at 0 °C. The mixture was stirred at room temperature for 2 hours and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 22 mg of the title product.
Example 31 3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyi"rolo[2,3-c]pyridin]- (2'H)- yl)methyl]-lH-indol-l-yl}propyl(2,2,2-trifluoroethyl)carbamate
Step 1: Preparation of -{[5-chloro-l-(3-hydroxypropyl)-lH-indol-2- yl]methyl}spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one
Figure imgf000165_0001
A mixture of l '-[(5-chloro-lH-indol-2-yl)methyl]spiro[cyclopropane-l ,3'-pyrrolo[2,3- c]pyridin]-2,(7 'H)-one (50 mg, 0.15 mmol), cesium carbonate (250 mg, 0.76 mmol) and 3- bromopropan-l -ol (150 mg, 1.09 mmol) in acetonitrile (4 mL) was heated with stirring at 80 °C for 1 hour. The reaction mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluting with 20 - 40% ethyl acetate in petroleum ether) to afford 50 mg of l '-{[5-chloro-l -(3-hydroxypropyl)-lH-indol-2-yl]methyl}spiro[cyclopropane-l,3'- pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one.
Step 2: Preparation of 3-{5-chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3- c]pyridin]- (2'H)-yl)methyl]-lH-indol-l-yl}propyl(2,2,2-trifluoroethyl)carbamate
A mixture of l '-{[5-chloro-l-(3-hydroxypropyl)-lH-indol-2- yl]methyl}spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one (50 mg, 0.13 mmol), cesium carbonate (250 mg, 0.77 mmol) and di-lH-imidazol-l-ylmethanone (87 mg, 0.43 mmol) in tetrahydrofuran (4 mL) was stirred at room temperature overnight. Then 2,2,2- trifluorethanamine (200 mg, 2.0 mmol) was added to the reaction mixture. The mixture was stirred at room temperature overnight. The resulting mixture was purified by preparative HPLC to afford 10 mg of the title product.
Example 32-1
-({6-Chloro-3-[2-(ethylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- l,3'-pyrrolo[2,3-Z>]pyridin]-2'(l'H)-one
Step 1: Preparation of [6-chloro-l-(phenylsulfonyl)-l/7-indol-2-yl]methanol
Figure imgf000166_0001
[6-Chloro-l-(phenylsulfonyl)-lH-indol-2-yl]methanol was prepared in analogy to [5- chloro-l-(phenylsulfonyl)-lH-pyrrolo[3,2-0]pyridin-2-yl]methanol in Example 6 by using ethyl 5-chloro-lH-indole-2-carboxylate instead of methyl 5-chloro-l-(phenylsulfonyl)-lH-pyrrolo[3,2- 6]pyridine-2-carboxylate.
Step 2: Preparation of {6-chloro-3-[(E)-2-(ethylsulfonyl)ethenyl]-l-(phenylsulfonyl)- lH-indol-2-yl}methanol
Figure imgf000166_0002
A mixture of [6-chloro-l-(phenylsulfonyl)-lH-indol-2-yl]methanol (2.68 g, 6.0 mmol), ethanesulfonyl-ethene (1.56 mL, 15 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxy-l,l'- biphenyl (252 mg, 0.60 mmol), allylpalladium chloride dimmer (222 mg, 0.60 mmol) and sodium acetate (984 mg, 12 mmol) in N.N-dimethylacetamide (15 mL) was heated to microwave irradiation for 25 minutes at 130 °C. The mixture was diluted with ethyl acetate (100 mL), and then washed with water (50 mL x 2). The organic layer was dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 2.4 g of {6-chloro-3-[(E)-2-(ethylsulfonyl)ethenyl]-l- (phenylsulfonyl)-lH-indol-2-yl}methanol as a yellow solid.
Step 3: Preparation of {6-chloro-3-[2-(ethylsulfonyl)ethyl]-l-(phenylsulfonyl)-lH- indol-2-yl}methanol
Figure imgf000167_0001
To a suspension of nickel(II) chloride (680 mg, 5.24 mmol) in methanol (150 mL) was added sodium borohydride (198 mg, 5.24 mmol) in an ice bath. After the mixture was stirred at 0 °C for 15 minutes, a solution of {6-chloro-3-[(E)-2-(ethylsulfonyl)ethenyl]-l-(phenylsulfonyl)- lH-indol-2-yl} methanol (2.3 g, 5.24 mmol) in methanol (50 mL) was added slowly to the mixture. After the resulting mixture was stirred at 0 °C for another 15 minutes, sodium borohydride (396 mg, 10.48 mmol) was added in one portion. The reaction mixture was then stirred at 0 °C for 7 hours. The reaction was quenched with water (50 mL). The mixture was filtered. The filtrate was concentrated in vacuo to remove the organic solvent. The residual aqueous phase was extracted with dichloromethane. The organic layer was washed with brine, and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 1.68 g of {6-chloro-3-[2-(ethylsulfonyl)ethyl]-l-(phenylsulfonyl)-lH-indol-2-yl}methanol as a yellow solid, which was used for next step without further purification. MS obsd. (ESI+) [(M+H)+] 424.
Step 4: Preparation of {6-chloro-3-[2-(ethylsulfonyl)ethyl]-l-(phenylsulfonyl)-lH- indol-2-yl} methyl methanesulfonate
Figure imgf000167_0002
To a cooled solution of {6-chloro-3-[2-(ethylsulfonyl)ethyl]-l-(phenylsulfonyl)-lH-indol- 2-yl}methanol (441 mg, 1.0 mmol) and triethylamine (0.42 mL, 3.0 mmol) in dichloromethane (50 mL) was added methanesulfonyl chloride (0.3 mL, 3.9 mmol) dropwise in an ice bath. After being stirred at 0 °C for 3 hours, the mixture was neutralized with a saturated aqueous solution of sodium bicarbonate and then extracted with dichloromethane (30 mL x 2). The combined organic layer was washed with a saturated aqueous sodium bicarbonate solution (30 mL x 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 0.5 g of {6-chloro- 3-[2-(ethylsulfonyl)ethyl]- l-(phenylsulfonyl)-lH-indol-2-yl}methyl methanesulfonate as a light yellow solid, which was used for next step without further purification.
Step 5: Preparation of l'-({6-chloro-3-[2-(ethylsulfonyl)ethyl]-l-(phenylsulfonyl)-lH- indol-2-yl}methyl) spiro [cyclopro ane-l,3'-pyrrolo [2,3-6] pyridin]-2 ' (1 'H)-one
Figure imgf000168_0001
A mixture of {6-chloro-3-[2-(ethylsulfonyl)ethyl]-l-(phenylsulfonyl)-lH-indol-2- yl}methyl methanesulfonate (415 mg, 0.8 mmol), cesium carbonate (521 mg, 1.6 mmol) and spiro[cyclopropane-l ,3'-pyrrolo[2,3-&]pyridin]-2'(rH)-one (128 mg, 0.8 mmol) in acetonitrile (8 mL) was heated at 85 °C for 16 hours. The mixture was filtered. The filtrate was concentrated in vacuo to afford 362 mg of l'-({6-chloro-3-[2-(ethylsulfonyl)ethyl]-l-(phenylsulfonyl)-lH-indol- 2-yl}methyl) spiro[cyclopropane-l ,3'-pyrrolo[2,3- ?]pyridin]-2'(rH)-one as a brown solid, which was used for next step without further purification. MS obsd. (ESI+) [(M+H)+] 584.
Step 6: Preparation of l'-({6-chloro-3-[2-(ethylsulfonyl)ethyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-6]pyridin]-2'(l'H)-one
A mixture of l'-({6-chloro-3-[2-(ethylsulfonyl)ethyl]-l-(phenylsulfonyl)-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-¾]pyridin]-2'( H)-one (360 mg, 0.61 mmol) and a solution of tetrabutyl ammonium fluoride in tetrahydrofuran (1.0 M, 4 mL) in tetrahydrofuran (2 mL) was stirred at room temperature for 16 hours. Then the mixture was concentrated in vacuo. The residue was extracted with ethyl acetate (30 mL x 2). The combined organic layer was washed with a saturated aqueous solution of ammonium chloride (30 mL x 3) and water (30 mL x 3), and then dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 60 mg of the title product as a white solid.
Example 32-2
r-({6-Chloro-3-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3 ' -py rrolo [2 ,3-c] pyridin] -2 ' (1 'H)-one The title compound was prepared in analogy to Example 32-1 according to Scheme 13 by using (methylsulfonyl)ethene and spiro[cyclopropane-l,3,-pyrrolo[2,3-c]pyridin]-2'( H)-one instead of (ethylsulfonyl)ethane and spiro[cyclopropane-l,3'-pyrrolo[2,3-0]pyridin]-2'( H)-one.
Example 33
l'-({6-Chloro-3-[3-(methylsulfonyl)propyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- 1 ,3'-pyrrolo [2,3-c] pyridin] -2' (1 'H)-one
Step 1: Preparation of ethyl 6-chloro-3-[3-(methylsulfanyl)propanoyl]-lH-indole-2- carboxylate
Figure imgf000169_0001
To a suspension of ferric trichloride (3.9 g, 24 mmol) in 1 ,2-dichloroethane (50 mL) was added 3-(methylsulfanyl)propanoyl chloride (2.77 mL, 24 mmol) in an ice-water bath. After the mixture was stirred at 0 °C for 10 minutes under an argon atmosphere, a solution of ethyl 6- chloro-lH-indole-2-carboxylate (4.5 g, 20 mmol) in 1 ,2-dichloro-ethane (50 mL) was added dropwise to the mixture in an ice-water bath. The mixture was stirred at 0 °C for 1 hour, then poured into ice-water (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layer was washed with a saturated aqueous solution of sodium bicarbonate (50 mL x 3), and then dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with 0 - 30% ethyl acetate in petroleum ether) to afford 2.9 g of ethyl 6-chloro-3-[3-(methylsulfanyl)propanoyl]-lH-indole-2-carboxylate as a light yellow solid. MS obsd. (ESI+) [(M+H)+] 326.
Step 2: Preparation of ethyl 6-chloro-3-[l-hydroxy-3-(methylsulfanyl)propyl]-lH- indole-2-carboxylate
Figure imgf000169_0002
To a solution of ethyl 6-chloro-3-[3-(methylsulfanyl)propanoyl]-lH-indole-2-carboxylate (2.5 g, 7.7 mmol) in methanol (100 mL) was added sodium borohydride (440 mg, 1 1.5 mmol) in portions. After the reaction mixture was stirred at room temperature for 1 hour, the reaction was quenched by water (20 mL). The organic solvent was removed by concentration in vacuo. The residue was extracted with ethyl acetate (50 mL χ 3). The combined organic layer was washed with brine (30 mL x 3), and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 2.5 g of the crude ethyl 6-chloro-3-[l-hydroxy-3-(methylsulfanyl)propyl]-lH- indole-2-carboxylate as a white solid. MS obsd. (ESI+) [(M+H)+] 310.
Step 3: Preparation of ethyl 6-chloro-3-[3-(methylsulfanyl)propyl]-lH-indole-2- carboxylate
Figure imgf000170_0001
To a mixture of ethyl 6-chloro-3-[l-hydroxy-3-(methylsulfanyl)propyl]-lH-indole-2- carboxylate (2.0 g, 6.0 mmol) and triethylsilane (30 mL) was added trifluoroacetic acid (10 mL) dropwise in an ice- water bath. After being stirred at 0 °C for 2 hours, the mixture was neutralized with a saturated aqueous solution of sodium bicarbonate and then extracted with ethyl acetate (100 mL x 2). The combined organic layer was washed with a saturated aqueous solution of sodium bicarbonate (50 mL x 3), and then dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with 0 - 30% ethyl acetate in petroleum ether) to afford 1.5 g of ethyl 6-chloro-3-[3- (methylsulfanyl)propyl]-lH-indole-2-carboxylate as a white solid. MS obsd. (ESI ) [(M+H)+] 312.
Step 4: Preparation of ethyl 6-chloro-3-[3-(methylsulfanyl)propyl]-l-(phenylsulfonyl)- lH-indole-2-carboxylate
Figure imgf000170_0002
To a suspension of ethyl 6-chloro-3-[3-(methylsulfanyl)propyl]-lH-indole-2-carboxylate (1.26 g, 4 mmol) and sodium hydride (0.24 g, 6.0 mmol, 60% in mineral oil) in N,N- dimethylformamide (30 mL) was added benzenesulfonyl chloride (0.62 mL, 4.8 mmol) dropwise in an ice-water bath. The mixture was stirred at room temperature for 4 hours, and then poured into ice- water (100 mL). The resulting precipitate was collected by filtration, which was washed with petroleum ether (50 mL), and then dried in vacuo to afford 1.5 g of ethyl 6-chloro-3-[3- (methylsulfanyl)propyl]-l-(phenylsulfonyl)-lH-indole-2-carboxylate as a pale white solid. MS obsd. (ESI+) [(M+H)+] 452.
Step 5: Preparation of {6-chloro-3-[3-(methylsulfanyl)propyl]-l-(phenylsulfonyl)-lH- indol-2-yl} methanol
Figure imgf000171_0001
To a cooled suspension of lithium aluminium hydride (0.18 g, 4 mmol) in tetrahydrofuran (100 mL) was added ethyl 6-chloro-3-[3-(methylsulfanyl)propyl]-l-(phenylsulfonyl)-lH-indole- 2-carboxylate (0.902 g, 2 mmol) at 0 °C. The mixture was stirred at room temperature for 16 hours. The reaction was quenched with methanol. The resulting mixture was then filtered through a celite pad. The filtrate was concentrated in vacuo to afford 0.5 g of {6-chloro-3-[3- (methylsulfanyl)propyl]-l-(phenylsulfonyl)-lH-indol-2-yl}methanol as brown oil. MS obsd. (ESI+) [(M+H)+] 392.
Step 6: Preparation of {6-chloro-3-[3-(methylsulfonyl)propyl]-l-(phenylsulfonyl)-lH- indol-2-yl} methanol
Figure imgf000171_0002
To a solution of {6-chloro-3-[3-(methylsulfanyl)propyl]-l -(phenylsulfonyl)-lH-indol-2- yl}methanol (0.5 g, 1.28 mmol) in dichloromethane (20 mL) was added 3-chloro-peroxybenzoic acid (0.55 g, 3.2 mmol) at 0 °C. The mixture was then stirred at room temperature for 4 hours. The resulting mixture was neutralized with a saturated aqueous solution of sodium sulfite and then extracted with dichloromethane (30 mL x 2). The combined organic layer was washed successively with a saturated aqueous solution of sodium sulfite (30 mL x 2), a saturated aqueous solution of sodium bicarbonate (30 mL x 2), and water (30 mL x 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with 0 - 10% methanol in dichloromethane) to afford 0.32 g of { 6-chloro-3 -[3 -(methylsulfonyl)propyl]- 1 -(phenylsulfonyl)- 1 H-indol-2-yl } methanol as colorless oil. MS obsd. (ESI+) [(M+H)+] 424.
Step 7: Preparation of {6-chloro-3-[3-(methylsulfonyl)propyl]-l-(phenylsulfonyl)-lH- indol-2-yl}methyl methanesulfonate
Figure imgf000172_0001
To a solution of {6-chloro-3-[3-(methylsulfonyl)propyl]-l-(phenylsulfonyl)-lH-indol-2- yljmethanol (320 mg, 0.7 mmol) and triethylamine (0.59 ml, 4.2 mmol) in dichloromethane (20 mL) was added methanesulfonyl chloride (0.17 ml, 2.1 mmol) dropwise in an ice-water bath. After being stirred at 0 °C for 1 hour, the resulting mixture was neutralized with a saturated aqueous solution of sodium bicarbonate and then extracted with dichloromethane (30 mL x 2). The combined organic layer was washed with a saturated aqueous solution of sodium bicarbonate (30 mL x 2), and then dried over anhydrous sodium sulfate and then concentrated in vacuo to afford 363 mg of {6-chloro-3-[3-(methylsulfonyl)propyl]-l-(phenylsulfonyl)-lH-indol-2- yl} methyl methanesulfonate as a light yellow solid which was used for next step without further purification.
Step 8: Preparation of l'-({6-chloro-3-[3-(methylsulfonyl)propyl]-l-(phenylsulfonyl)- lH-indol-2-yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-£,]pyridin]-2'(l'i )-one
Figure imgf000173_0001
A suspension of {6-chloro-3-[3-(methylsulfonyl)propyl]-l -(phenylsulfonyl)-lH-indol-2- yl}methyl methanesulfonate (364 mg, 0.7 mmol), cesium carbonate (684 mg, 2.1 mmol) and spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one (90 mg, 0.56 mmol) in acetonitrile (10 mL) was heated with stirring at 85 °C for 20 minutes. The mixture was filtered. The filtrate was concentrated in vacuo to afford 300 mg of l'-({6-chloro-3-[3-(methylsulfonyl)propyl]-l- (phenylsulfonyl)-lH-indol-2-yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2 H)- one as a brown solid which was used for next step without further purification. MS obsd. (ESI+) [(M+H)+] 584.
Step 9: Preparation of l'-({6-chloro-3-[3-(methylsulfonyl)propyl]-lH-indol-2- yl}methyl)spirofcyclopropane-l,3'-pyrrolof2,3-c]pyridin]-2'(l'H)-one
A mixture of l '-({6-chloro-3-[3-(methylsulfonyl)propyl]-l-(phenylsulfonyl)-lH-indol-2- yl} methyl), spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one (300 mg, 0.51 mmol), 1.0 M tetrabutylammonium fluoride in tetrahydrofuran (2 mL) and tetrahydrofuran (2 mL) was stirred at room temperature for 24 hours. The resulting mixture was concentrated in vacuo. The residue was dissolved with ethyl acetate (60 mL). The solution was washed with a saturated aqueous solution of ammonium chloride (30 mL x 3) and water (30 mL x 3), and then dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 125 mg of the title product as a light yellow solid.
Example 34-1
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of 4-chloro-N-[2-(methylsulfonyl)ethyl]-2-nitroaniline
Figure imgf000174_0001
A mixture of 4-chloro-2-nitroaniline (3.44 g, 20.0 mmol), (methylsulfonyl)ethene (2.0 mL, 22.8 mmol) and cesium carbonate (9.78 g, 30.0 mmol) in acetonitrile (40 mL) was heated with stirring at 80 °C for 1.5 hours. The resulting mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluting with 0 - 8% methanol in dichloromethane) to afford 4.70 g of 4-chloro-N-[2-(methylsulfonyl)ethyl]-2-nitroaniline as an orange solid.
Step 2: Preparation of 4-chloro-N1- 2-(methylsulfonyl)ethyl]benzene-l,2-diamne
Figure imgf000174_0002
A mixture of 4-chloro-N-[2-(methylsulfonyl)ethyl]-2-nitroaniline (3.0 g, 10.8 mmol), Raney nickel (1.0 g of suspension in water) and hydrazine hydrate (2 mL, 85% aqueous solution) in methanol (25 mL) was heated with stirring under reflux for 1.5 hours. The resulting mixture was filtered and the filtrate was concentrated in vacuo. The residue was stirred with
dichloromethane (20 mL) and then filtered to afford 1.8 g of 4-chloro-N1-[2- (methylsulfonyl)ethyl]benzene-l,2-diamne as a pale solid.
Step 3: Preparation of 5-chloro-2-(chloromethyl)-l-[2-(methylsulfonyl)ethyl]-lH- benzimidazole
Figure imgf000174_0003
A mixture of 4-chloro-N1-[2-(methylsulfonyl)ethyl] benzene- 1,2-diamine (1.25 g, 5.0 mmol), bromoacetic acid (700 mg, 5.0 mmol) and 6 N hydrochloric acid (10 mL) was heated under reflux for 5 hours. The mixture was then cooled to room temperature, and then basified with sodium bicarbonate. The mixture was extracted with ethyl acetate (20 mL x 3). The combined organic layer was dried over sodium sulfate and then concentrated in vacuo to afford 1.24 g of the crude 5-chloro-2-(chloromethyl)-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazole as a yellow semi-solid.
Step 4: Preparation of l'-({5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one
To a cooled solution of spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one (360 mg,
2.25 mmol) in NN-dimethylformamide (3 mL) was added sodium tert-butoxide (240 mg, 2.5 mmol) at 0 °C. After being stirred at 0 °C for 10 minutes, a solution of 5-chloro-2- (chloromethyl)-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazole (620 mg, 2.01 mmol) in N,N- dimethylformamide (2 mL) was added to the reaction mixture at 0 °C. The resulting mixture was stirred at room temperature for 10 minutes, and then diluted with ethyl acetate (20 mL). The organic layer was washed with brine (15 mL), and then dried over sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 80 mg of the title product as a light brown solid.
Example 34-2
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2-yl}methyl)-4'- fluorospiro[cyclopropane-l,3'-indol]-2'( H)-one
The title compound was prepared in analogy to Example 34-1 according to Scheme 16 by using 5-chloro-2-(chloromethyl)-l -[2-(methylsulfonyl)ethyl]-lH-benzimidazole and 4'- fluorospiro[cyclopropane-l,3'-indol]-2'(rH)-one instead of 5-chloro-2-(chloromethyl)-l-[2- (methylsulfonyl)ethyl]-lH-benzimidazole and spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- 2'(l 'H)-one.
Example 34-3
4'-Chloro- -({5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-indol]-2'( H)-one
The title compound was prepared in analogy to Example 34-1 according to Scheme 16 by using 4'-chlorospiro[cyclopropane-l,3'-indol]-2'(rH)-one instead of spiro [cyclopropane- 1 ,3 '- pyrrolo[2,3-c]pyridin]-2'(rH)-one.
Example 34-4
4'-Bromo- -({5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-indol]-2'( H)-one The title compound was prepared in analogy to Example 34-1 according to Scheme 16 by using 4'-bromospiro[cyclopropane-l,3'-indol]-2'(rH)-one instead of spiro [cyclopropane- 1, 3'- pyrrolo[2,3-c]pyridin]-2'(l'H)-one.
Example 34-5
1 '-( {5-Chloro- 1 - [2-(ethy lsulf onyl)ethyl] -lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3,-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 34-1 according to Scheme 16 by using 5-chloro-2-(chloromethyl)-l-[2-(ethylsulfonyl)ethyl]-lH-benzimidazole instead of5- chloro-2-(chloromethyl)- l-[2-(methylsulfonyl)ethyl]-lH-benzimidazole.
Example 35
r-({5-ChIoro-l-[2-(l,l-dioxidothietan-3-yl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cycIopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1 : Preparation of tert-butyl (4-chloro-2-nitrophenyl)carbamate
Figure imgf000176_0001
A mixture of 4-chloroaniline (5.0 g, 28.97 mmol), di-teri-butyldicarbonate (12.65 mmol, 57.94 mmol) and 4-dimehylaminopyridine (35 mg, 0.29 mmol) in tetrahydrofuran (150 mL) was heated under reflux for 1 hour. After being cooled to room temperature, the mixture was concentrated in vacuo. The residue was stirred with potassium carbonate (12.0 g, 87.0 mmol) in methanol (150 mL) at room temperature for 2 hours. The resulting mixture was diluted with water (120 mL) and then extracted with ethyl acetate (150 mL x 2). The combined organic layer was washed with brine, and then dried over sodium sulfate and then concentrated in vacuo. The residue was purified by flash column to afford 6.3 g of tert-butyl (4-chloro-2- nitropheny 1) carbamate .
Step 2: Preparation of tert-butyl (4-chloro-2-nitrophenyl)[2-(l,l-dioxidothietan-3- yl)ethyl] carbamate
Figure imgf000177_0001
A mixture of tert-butyl (4-chloro-2-nitrophenyl)carbamate (176 mg, 0.67 mmol), 2-(l,l- dioxidothietan-3-yl)ethyl 4-methylbenzenesulfonate (204 mg, 0.67 mmol), potassium carbonate (138 mg, 1.0 mmol), tetrabutylamine iodide ( 40 mg) and acetonitrile (20 mL) was stirred under reflux overnight. The resulting mixture was concentrated in vacuo. The residue was purified by flash column to afford 213 mg of tert-butyl (4-chloro-2-nitrophenyl)[2-(l,l-dioxidothietan-3- yl)ethyl] carbamate.
Step 3: Preparation of tert-butyl (2-amino-4-chlorophenyl)[2-(l,l-dioxidothietan-3- yl)ethyl] carbamate
Figure imgf000177_0002
tert-Butyl (2-amino-4-chlorophenyl)[2-(l , 1 -dioxidothietan-3-yl)ethyl] carbamate was prepared in analogy to 4-chloro-N1-[2-(methylsulfonyl)ethyl]benzene-l,2-diamine in Example 34-1 by using tert-butyl (4-chloro-2-nitrophenyl)[2-(l, l-dioxidothietan-3-yl)ethyl]carbamate instead of 4-chloro-N-[2-(methylsulfonyl)ethyl]-2-nitroaniline.
Step 4: Preparation of l'-({5-chloro-l-[2-(l,l-dioxidothietan-3-yl)ethyl]-lH- benzimidazol-2-yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one
The title compound was prepared in analogy to Example 34-1 according to Scheme 15 by using tert-butyl (2-amino-4-chlorophenyl)[2-(l ,l-dioxidothietan-3-yl)ethyl]carbamate instead of 4-chloro-N'-[2-(methylsulfonyl)ethyl]benzene- 1 ,2-diamine.
Example 36-1 l'-({5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of 4-chloro-N-[2-(methylsulfonyl)propyl]-2-nitroaniline
Figure imgf000178_0001
A mixture of 4-chloro-2-nitroaniline (3.44 g, 20.0 mmol), 3-(methylsulfonyl)propyl 4- methylbenzenesulfonate (5.53 g, 20.0 mmol) and cesium carbonate (9.78 g, 30.0 mmol) in acetonitrile (40 mL) was heated with stirring under reflux overnight. The resulting mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluting with 0 - 8% methanol in dichloromethane) to afford 4.60 g of 4-chloro-N-[2- (methylsulfonyl)propyl]-2-nitroaniline as an orange solid.
Step 2: Preparation of l'-({5-chloro-l-[3-(methylsulfonyl)propyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 34-1 according to Scheme 15 by using 4-chloro-JV-[2-(methylsulfonyl)propyl]-2-nitroaniline instead of 4-chloro-N-[2- (methylsulfonyl)ethyl]-2-nitroaniline.
Example 36-2
l'-({5-Chloro-l-[2-(cyclopropylsulfonyl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 36-1 according to Scheme 15 by using 3-(cyclopropylsulfonyl)ethyl 4-methylbenzenesulfonate instead of 3- (methylsulfonyl)propyl 4-methylbenzenesulfonate .
Example 37-1
l'-({5-Chloro-7-fluoro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of 4-chloro-2-fluoro-N-[2-(methylsulfonyl)ethyl]aniline
Figure imgf000179_0001
To a solution of 4-chloro-2-fluoroaniline (55 g, 375 mmol) in acetonitrile (60 mL) was added (methylsulfonyl)ethene (36 mL, 412 mmol) and cesium carbonate (243 g, 750 mmol). The reaction mixture was refluxed overnight, and then filtered. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography (eluting with 33% ethyl acetate in petroleum ether) to afford 66 g of 4-chloro-2-fluoro-iV-[2-(methylsulfonyl)ethyl]aniline.
Step 2: Preparation of 4-chloro-2-fluoro-N-[2-(methylsulfonyl)ethyl]-6-nitroaniline
Figure imgf000179_0002
To a three-necked bottle containing sulfuric acid (400 mL) was added 4-chloro-2-fluoro-N- [2-(methylsulfonyl)ethyl]aniline (50 g, 200 mmol) in portions. After the mixture was cooled to 0 °C, nitric acid (21.6 g, 240 mmol, 70% w/w) was added dropwise. After being stirred at 0 °C for 1 hour, the mixture was poured into ice- water (1000 mL), and then extracted with ethyl acetate (500 mL x 3). The combined organic layer was washed with water (1000 mL) and brine (1000 mL), and then dried over sodium sulfate and filtered. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography (eluting with 20 - 33% ethyl acetate in petroleum ether) to afford 23.7mg of 4-chloro-2-fluoro-N-[2-(methylsulfonyl)ethyl]-6-nitroaniline.
Step 3: Preparation of 5-chloro-3-fluoro-N2-[2-(methylsulfonyl)ethyl]benzene-l,2- diamine
Figure imgf000179_0003
A solution of 4-chloro-2-fluoro-N-[2-(methylsulfonyl)ethyl]-6-nitroaniline (23 g, 78 mmol) in methanol (500 mL) was hydrogenated with Raney nickel (5 g) under hydrogen atmosphere at room temperature for 30 minutes. The resulting mixture was filtered through silica gel to afford 14 g of 5-chloro-3-fluoro-N2-[2-(methylsulfonyl)ethyl]benzene-l,2-diamine. Step 4: Preparation of 5-chloro-2-(chloromethyl)-7-fluoro-l-[2-(methylsulfonyl)ethyl]- lH-benzimidazole
Figure imgf000180_0001
A mixture of 5-chloro-3-fluoro-N2-[2-(methylsulfonyl)ethyl]benzene-l,2-diamine (14 g, 52.4 mmol), bromoacetic acid (36.5 g, 262 mmol) and concentrated hydrochloric acid (100 mL) was heated at 1 10 °C for 2 hours. The reaction mixture was poured into ice-water (80 g) and then neutralized with sodium bicarbonate. The precipitate was collected by filtration and then dried in vacuo to afford 14.5 g of 5-chloro-2-(chloromethyl)-7-fluoro-l-[2-(methylsulfonyl)ethyl]-lH- benzimidazole.
Step 5: Preparation of l'-({5-chloro-7-fluoro-l-[2-(methylsulfonyl)ethyl]-lH- benzimidazol-2-yl} methyl)spiro [cyclopropane-1 ,3'-pyrrolo [2,3-c] pyridin] -2'(1 'H)-one
To a solution of spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one (7.16 g, 44.7 mmol) in N,N-dimethylformamide (80 mL) was added sodium tert-butoxide (4.5 g, 47 mmol) and the resulting mixture was stirred for 30 minutes to obtain a clear solution. Then this clear solution was added dropwise into a cooled solution of 5-chloro-2-(chloromethyl)-7-fiuoro-l-[2- (methylsulfonyl)ethyl]-lH-benzimidazole (14.5 g, 44.7 mmol) in N,N-dimethylformamide (60 mL) at 0 °C. After the addition, the resulting solution was stirred at 0 °C for 30 minutes. The reaction mixture was diluted with ice water (1500 mL) and then stirred for 15 minutes. The precipitate was collected by filtration, and then washed with water (20 mL x 3) and methanol (10 mL x 2). The collected solid was dissolved in a mixture of ethyl acetate (50 mL) and methanol (5 mL). The mixture was refluxed for 10 minutes and filtered to afford 1 1.5 g of the title product.
Example 37-2
l'-({5,7-Dichloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrr lo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 37-1 according to Scheme 16 by using 2,4-dichloroaniline instead of 4-chloro-2-fluoroaniline.
Example 38-1
l'-{[5-Chloro-l-(oxetan-3-ylmethyl)-lH-benzimidazol-2- yl]methyl}spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of 4-chloro-2-nitro-N- oxetan-3-ylmethyl)aniline
Figure imgf000181_0001
A mixture of oxetan-3-ylmethanamine (250 mg, 2.87 mmol), 4-chloro-l-fluoro-2- nitrobenzene (503 mg, 2.87 mmol) and V-ethyl-N- isopropylpropan-2-amine (1.10 g, 8.52 mmol) in tetrahydrofuran (10 mL) was stirred at room temperature for 3 days. The reaction mixture was concentrated in vacuo. The residue was purified by flash column (eluting with 0 - 50% ethyl acetate in petroleum ether) to afford 300 mg of 4-chloro-2-nitro-N-(oxetan-3-ylmethyl)aniline.
Step 2: Preparation of 4-chloro-N1- oxetan-3-ylmethyl)benzene-l,2-diamine
Figure imgf000181_0002
A mixture of 4-chloro-2-nitro-N-(oxetan-3-ylmethyl)aniline (300 mg, 1.24 mmol) and Raney Nickel (100 mg) in methanol (10 mL) was stirred under hydrogen atmosphere at room temperature for 2 hours. The reaction mixture was filtered through silica pad and the filtrate was concentrated in vacuo. The residue was purified by preparative TLC (ethyl acetate: petroleum ether =1 : 1) to afford 200 mg of 4-chloro- VI-(oxetan-3-ylmethyl)benzene-l ,2-diamine.
Step 3: Preparation of 5-chloro-2-(chloromethyl)-l-(oxetan-3-ylmethyl)-lH- benzimidazole
Figure imgf000181_0003
A mixture of 4-chloro- VI-(oxetan-3-ylmethyl)benzene-l ,2-diamine (200 mg, 0.94 mmol) and 2-chloro-l , l,l-trimethoxyethane (800 mg, 5.17 mmol) in ethanol (10 mL) was heated under reflux for 2 hours. The resulting mixture was concentrated in vacuo. The residue was purified by preparative TLC (ethyl acetate: petroleum ether =1 :1) to afford 200 mg of 5-chloro-2- (chloromethyl)-l-(oxetan-3-ylmethyl)-lH-benzimidazole.
Step 4: Preparation of -{[5-chloro-l-(oxetan-3-ylmethyl)-lH-benzimidazol-2- yl]methyl}spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
A mixture of 5-chloro-2-(chloromethyl)-l-(oxetan-3-ylmethyl)-lH-benzimidazole (200 mg, 0.74 mmol), spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one (1 18 mg, 0.74 mmol) and cesium carbonate (287 mg, 0.81 mmol) in acetonitrile (5 mL) was stirred at room
temperature overnight. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by preparative HPLC to afford 165 mg of the title product.
Example 38-2
l'-({5-Chloro-l-[2-(oxetan-3-yl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of oxetan-3-yli nitrile
Figure imgf000182_0001
To a cooled slurry of sodium hydride (5.56 g, 139 mmol) in tetrahydrofuran (150 mL) was added a solution of diethyl (cyanomethyl)phosphonate (24.6 g, 139 mmol) in tetrahydrofuran (20 mL) drop wise in an ice- water bath. The mixture was stirred at 0 °C for 30 minutes. To the resulting mixture was added a solution of oxetan-3-one (10.0 g, 139 mmol) in tetrahydrofuran (30 mL) drop wise in an ice-water bath. The mixture was warmed naturally to room temperature and then stirred overnight. The resulting reaction mixture was poured into water (200 mL) and then extracted with ethyl acetate (200 mL x 2). The combined organic layer was washed with brine, and then dried over sodium sulfate and then concentrated in vacuo. The residue was purified by flash column (eluting with 0 - 50% ethyl acetate in petroleum ether) to afford 7.0 g of oxetan-3 -ylideneacetonitrile.
Step 2: Preparation of 2-(oxetan-3-yl)-ethylamine
Figure imgf000182_0002
A mixture of oxetan-3 -ylideneacetonitrile (3.0 g, 31.5 mmol) and 7 N ammonia in methanol (200 mL) was stirred with 10% palladium on carbon (600 mg) and platinum(IV) oxide (600 mg) under 50 psi of hydrogen overnight. The reaction mixture was filtered through silica pad and the filtrate was concentrated in vacuo to afford the crude 2-(oxetan-3-yl)-ethylamine which was used directly into next step without any further purification.
Step 3: Preparation of l'-({5-chloro-l-[2-(oxetan-3-yl)ethyl]-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogy to Example 38-1 according to Scheme 15 by using 2-(oxetan-3-yl)-ethylamine instead of oxetan-3-ylmethanamine.
Example 38-3
1 '- { [5-Chloro-7-fluoro-l -(oxetan-3-ylmethyl)-lH-benzimidazol-2- yl]methyl}spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of 4-chloro-2-fluoro-6-nitro-N- oxetan-3-ylmethyl)aniline
Figure imgf000183_0001
A mixture of oxetan-3-ylmethanamine (179 mg, 2.00 mmol, 97% purity), 4-chloro-2- fluoro-6-nitrophenyl trifluoromethanesulfonate (650 mg, 2.00 mmol) and potassium phosphate (424 mg, 2.00 mmol) in acetonitrile (20 mL) was stirred at room temperature overnight under nitrogen atmosphere. The reaction mixture was concentrated in vacuo. The residue was purified by flash column (eluting with 0 - 50% ethyl acetate in petroleum ether) to afford 165 mg of 4- chloro-2-fluoro-6-nitro-N-(oxetan-3-ylmethyl)aniline.
Step 2: Preparation of l'-{[5-chloro-7-fluoro-l-(oxetan-3-ylmethyl)-lH-benzimidazol- 2-yl]methyl}spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one
The title compound was prepared in analogy to Example 38-1 according to Scheme 15 by using 4-chloro-2-fluoro-6-nitro-N-(oxetan-3-ylmethyl)aniline instead of 4-chloro-2-nitro-N- (oxetan-3-ylmethyl)aniline.
Example 39-1
-({l-[(3-Aminooxetan-3-yl)methyl]-5-chloro-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one
Step 1: Preparation of 4-methoxybenzyl (3-{[5-chloro-2-{2'-oxospiro[cyclopropane- 1 '-pyrrolo[2 -c]pyridin]-l 2'H)-yl)methyl}-lH-benzo[d]imidazol-l-yl]methyl}oxetan-3- yl)carbamate
Figure imgf000184_0001
4-Methoxybenzyl (3-{ [5-chloro-2-{2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- r(2'H)-yl)methyl}-lH-benzo[d]imidazol-l-yl]methyl}oxetan-3-yl)carbamate was prepared in analogy to Example 38-1 according to Scheme 15 by using 4-methoxybenzyl [3- (aminomethyl)oxetan-3-yl]carbamate instead of oxetan-3-ylmethanamine.
Step 2: Preparation of l'-({l-[(3-aminooxetan-3-yl)methyl]-5-chloro-lH- benzimidazol-2-yl}methyl)spiro[cyclopropane-1 '-pyrrolo[2 -c]pyridin]-2 l'H)-one
A solution of 4-methoxybenzyl (3-{[5-chloro-2-{2'-oxospiro[cyclopropane-l ,3'- pyrrolo[2,3-c]pyridin]-l 2'/J)-yl)methyl}-lH-benzo[d]imidazol-l-yl]methyl}oxetan-3- yl)carbamate (573 mg, 1.0 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (2.5 mL). The reaction mixture was stirred for 2 hours and then diluted with dichloromethane (20 mL) and then washed with saturated aqueous solution of sodium carbonate (20 mL). The separated aqueous layer was extracted with dichloromethane (20 mL). The combined organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by preparative HPLC to afford 230 mg of the title product as a white solid.
Example 39-2
l'-({l-[(3-Aminooxetan-3-yl)methyl]-5-chloro-7-fluoro-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3,-pyi'iOlo[2,3-c]pyridin]-2'(l'H)-one
The title compound was prepared in analogous to Example 39-1 according to Scheme 17 by using 4-chloro-2-fluoro-6-nitrophenyl trifluoromethanesulfonate instead of 4-chloro-l-fluoro- 2-nitrobenzene. BIOLOGICAL EXAMPLES
Example 40 Viral cytopathic effect (CPE) assay:
To measure anti-RSV activity of compounds, 96-well plates are seeded with 6xl03 cells per well in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). Cells are infected the next day with sufficient RSV Long strain (ATCC) to produce an approximately 80-90%) cytopathic effect after 6 days, in the presence of serial half-log diluted compound in a total volume of 200 per well. The viability of cells is assessed after 6 days using Cell Counting kit-8 (Dojindo Molecular Technologies). The absorbance at 450 nm and referenced at 630 nm is measured to determine 50% effective concentration (EC50).
The compounds of the present invention were tested for their anti-RSV activity, and the activation as described herein. The Examples were tested in the above assay and found to have EC50 of about 0.0001 μΜ to about 10 μΜ. Particular compound of formula (I) were found to have EC50 of about 0.0001 μΜ to about 1 μΜ. Further particular compound of formula (I) were found to have EC50 of about 0.0001 μΜ to about 0.1 μΜ.
Results of CPE assays are given in Table 1.
Example A
A compound of formula I can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
Per tablet
Active ingredient 200 mg
Microcrystalline cellulose 155 mg
Corn starch 25 mg
Talc 25 mg
Hydroxypropylmethylcellulose 20 mg
425 mg
Example B
A compound of formula I can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:
Per capsule
Active ingredient 100.0 mg
Corn starch 20.0 mg
Lactose 95.0 mg Talc 4.5 mg
Magnesium stearate 0.5 mg
220.0 mg

Claims

Claims
1. Compounds of formula (I)
Figure imgf000187_0001
wherein
A is phenyl or pyridinyl, which is unsubstituted or substituted by Ci-6alkyl, Ci-6alkoxy, halogen, trifluoromethyl or cyano;
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is Ci-6alkylsulfonyl-CyH2y-;
when X is nitrogen or -CH, R1 is Ci-6alkylsulfonylphenyl-CyH2y-, thietan-3-yl-CyH2y-, dioxothietan-3-yl-CyH2y-, oxetan-3-yl-CyH2y-, aminooxetan-3-yl-CxH2x-, hydroxy-CxH2X-, C\.
Figure imgf000187_0002
6alkylsufinyl-CyH2y-, trifluoromethyl-CyH2y-aminocarbonyl-0-CxH2x- C1-6alkyl or
Figure imgf000187_0003
Ci-6a l ky l ; or -CyH2y-S02R8, wherein R8 is Ci-6alkyl, cycloalkyl, Ci.
6alkylcarbonylamino, Ci-6alkylamino diCi-6alkylamino, amino, morpholinyl, pyrrolidinyl,
piperazinyl,
Figure imgf000187_0004
or ; or -CyH2y-COR9, wherein R is Ci-6alkoxy, amino, hydroxy, cycloalkylsulfonylamino,
cycloalkylsulfonylaminoiCi-ealkyl) or Ci-6alkylsulfonylamino(Ci-6alkyl); or -CXH2X-NR10RH, wherein R10 is hydrogen, R1 1 is hydrogen, Ci^alkoxycarbonyl, Ci-6alkylcarbonyl, C\
Figure imgf000188_0001
6alkylsulfonyl, hydroxy- CxH2x- or or R10 and R , 1u1, together with the nitrogen atom,
to which they are attached, form
Figure imgf000188_0002
Figure imgf000188_0003
, which is unsubstituted or substituted by hydroxy, Ci_
6alkylcarbonyl or C1 -6alkylsulfonyl;
2 3
R" and RJ are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cycloalkyl;
R is hydrogen or halogen;
W1 is nitrogen or -CR12, wherein R12 is hydrogen or halogen;
W is -CH or nitrogen;
WJ is -CH or nitrogen; provided that at most one of W1, W2 and WJ is nitrogen;
x is 2-6;
y is 1 -6;
or pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 , wherein
A is phenyl, which is unsubstituted or once or twice substituted by Ci-6alkyl, Ci-6alkoxy, halogen, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by C\. 6alkyl or halogen;
X is nitrogen, -CH or -CR ; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is
Figure imgf000188_0004
when X is nitrogen or -CH, R1 is Ci-6alkylsulfonylphenyl-CyH2y-, thietan-3-yl-CyH2y-, dioxothietan-3-yl-CyH2y-, oxetan-3-yl-CyH2y-, aminooxetan-3-yl-CxH2x-, hydroxy-CxH2x-, C\.
Figure imgf000189_0001
6alkylsufmyl-CyH2y-, trifluoromethyl-CyH2y-aminocarbonyl-0-CxH2X-, C1-6alkyl or
Figure imgf000189_0002
Ci-6al kyl ; or -CyH2y-S02R8, wherein R8 is Ci-6alkyl, cycloalkyl, Ci.
6alkylcarbonylamino, Ci-6alkylamino, diCi-6alkylamino, amino, moφholinyl, pyrrolidinyl,
Figure imgf000189_0003
piperazinyl, ; or -CyH2y-COR9 wherein R9 is Ci-6alkoxy, amino, hydroxy, cycloalkylsulfonylamino,
cycloalkylsulfonylamino(Ci.6alkyl) or Ci-ealkylsulfonylaminoCCi-ealkyl); or
Figure imgf000189_0004
1, wherein R10 is hydrogen, R1 1 is hydrogen, Ci-6alkoxycarbonyl, Ci-6alkylcarbonyl, Ci_
Figure imgf000189_0005
6alkylsulfonyl, hydroxy-CxH2x- or , or R and R , 1u1, together with the nitrogen atom,
to which they are attached, form
Figure imgf000189_0006
Figure imgf000189_0007
R 2 and R 3J are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cycloalkyl;
R6 is hydrogen or halogen; 1 12 12
W is nitrogen or -CR , wherein R is hydrogen or halogen;
W2 is -CH or nitrogen;
W3 is -CH or nitrogen; provided that at most one of W1, W2 and W3 is nitrogen;
x is 2-6;
y is 1-6;
or pharmaceutically acceptable salt thereof.
3. A compound according to claim 1 or 2, wherein
A is phenyl, which is unsubstituted or once or twice substituted by methyl, ethyl, fluoro, chloro, bromo, methoxy, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by methyl or chloro;
X is nitrogen, -CH or -CR7; provided that
7 1 7
when X is -CR , R is hydrogen, wherein R is ethylsulfonylethyl, methylsulfonylethyl or methylsulfonylpropyl;
when X is nitrogen or -CH, R1 is acetylaminoethyl, acetylaminosulfonylpropyl, 4- acetylpiperazin-l-ylethyl, amino carbonylethyl, aminocarbonylpropyl, aminoethyl, 3- aminooxetan-3-ylmethyl, aminosulfonylpropyl, carboxy ethyl,
cyclopropylsulfonylaminocarbonylethyl, cyclopropylsulfonylamino(methyl)carbonylethyl, cyclopropylsulfonylethyl, cyclopropylsulfonylpropyl, dimethylaminosulfonylethyl,
dimethylaminosulfonylpropyl, ethoxycarbonylethyl, ethylsulfonylethyl, ethylsulfonylpropyl, hydroxyethylaminopropyl, hydroxypropyl, methoxycarbonylaminopropyl,
methoxycarbonylpropyl, methylaminosulfonylpropyl, methylsulfmylpropyl,
methylsulfonylamino(methyl)carbonylethyl, methylsulfonylaminoethyl,
methylsulfonylaminopropyl, methylsulfonylbutyl, methylsulfonylethyl,
methylsulfonylphenylmethyl, 4-(methylsulfonyl)piperazin- 1 -yl ethyl, methylsulfonylpropyl, oxetan-3-ylethyl, oxetan-3-ylmethyl, piperazin-l-ylethyl, piperazin-l-ylsulfonylpropyl, thietan-
3-ylethyl, (2,2,2-trifluoroethyl)carbamoyloxypropyl,
Figure imgf000190_0001
Figure imgf000191_0001
R and R are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl or cyclopentyl;
R6 is hydrogen, fluoro, chloro or bromo;
W1 is nitrogen, -CH or -CF;
W2 is -CH or nitrogen;
W 3 is -CH or nitrogen; provided that at most one of W 1 , W and W 3 is nitrogen;
or pharmaceutically acceptable salt thereof.
4. A compound according to claim 1 or 2, wherein
A is phenyl, which is unsubstituted or once or twice substituted by Ci-6alkyl, Ci-6alkoxy, halogen, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by C\. 6alkyl or halogen;
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is Ci-6alkylsulfonyl-CyH2y-;
when X is nitrogen or -CH, R1 is Ci-6alkylsulfonylphenyl-CyH2y-, thietan-3-yl-CyH2y-, dioxothietan-3-yl-CyH2y-, oxetan-3-yl-CyH2y-, aminooxetan-3-yl-CxH2x-, hydroxy-CxH2x-, C\.
Figure imgf000192_0001
6alkylsufinyl-CyH2y-, trifluoromethyl-CyH2y-aminocarbonyl-0-CxH2x-, C1-6alkyl or
Figure imgf000192_0002
Ci-6alky' ; or -CyH2y-S02R8, wherein R8 is Ci-6alkyl, cycloalkyl, d.
6alkylcarbonylamino, Ci.6alkylamino, diC1-6alkylamino, amino, morpholinyl, pyrrolidinyl,
Figure imgf000192_0003
piperazinyl,
wherein R9 is Ci-6alkoxy, amino, hydroxy, cycloalkylsulfonylamino,
cycloalkylsulfonylamino(Ci.6alkyl) or Ci-6alkylsulfonylamino(Ci-6alkyl); or -CxH2x-NR1 wherein R10 is hydrogen,Rn is hydrogen, C1-6alkoxycarbonyl, C1-6alkylcarbonyl, Ci_
Figure imgf000192_0004
6alkylsulfonyl, hydroxy- CxH2x- or , or R10 and R11, together with the nitrogen atom,
to which they are attached, form
Figure imgf000192_0005
Figure imgf000193_0001
2 3
R and RJ are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cycloalkyl;
R6 is hydrogen;
W1 is -CH;
W is nitrogen;
W3 is -CH;
x is 2-6;
y is 1-6.
5. A compound according to any one of claims 1 to 4, wherein
A is phenyl, which is unsubstituted or once or twice substituted by methyl, ethyl, fluoro, chloro, bromo, methoxy, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by methyl or chloro;
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is methylsulfonylethyl or
methylsulfonylpropyl;
when X is nitrogen or -CH, R1 is acetylaminoethyl, acetylaminosulfonylpropyl, 4- acetylpiperazin-l-ylethyl, aminocarbonylethyl, aminocarbonylpropyl, aminoethyl, 3- aminooxetan-3-ylmethyl, aminosulfonylpropyl, carboxyethyl,
cyclopropylsulfonylaminocarbonylethyl, cyclopropylsulfonylamino(methyl)carbonylethyl, cyclopropylsulfonylethyl, cyclopropylsulfonylpropyl, dimethylaminosulfonylethyl, dimethylaminosulfonylpropyl, ethoxycarbonylethyl, ethylsulfonylethyl, ethylsulfonylpropyl, hydro xyethylaminopropyl, hydroxypropyl, methoxycarbonylaminopropyl,
methoxycarbonylpropyl, methylaminosulfonylpropyl, methylsulfmylpropyl,
methylsulfonylamino(methyl)carbonylethyl, methylsulfonylaminoethyl,
methylsulfonylaminopropyl, methyl sulfonylbutyl, methylsulfonylethyl, methylsulfonylphenylmethyl, 4-(methylsulfonyl)piperazin- 1 -yl ethyl, methylsulfonylpropyl, oxetan-3-ylethyl, oxetan-3-ylmethyl, piperazin-l-ylethyl, piperazin-l-ylsulfonylpropyl, thietan-
O N -ylethyl, (2,2,2-trifluoroethyl)carbamoyloxypropyl,
Figure imgf000194_0001
Figure imgf000194_0002
R2 and R3 are hydrogen or deuterium simultaneously; R4 and R5, with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl or cyclopentyl;
R6 is hydrogen;
W1 is -CH;
W is nitrogen;
W3 is -CH.
6. A compound according to any one of claims 1, 2 or 4, wherein
A is phenyl, which is unsubstituted or once or twice substituted by Ci-6alkyl, Ci-6alkoxy, halogen, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by Ci. 6alkyl or halogen;
X is nitrogen, -CH or -CR7; provided that
7 1 7
when X is -CR , R is hydrogen, wherein R is Ci-6alkylsulfonyl-CyH2y-; when X is nitrogen or -CH, R1 is Ci-6alkylsulfonylphenyl-CyH2y-, thietan-3-yl-CyH2y-, dioxothietan-3-yl-CyH2y-, oxetan-3-yl-CyH2y-, aminooxetan-3-yl-CxH2x-, hydroxy-CxH2x-, Cj.
O
- Ύ H '22vy— S '
I
C al kvl
6alkylsufinyl-CyH2y-, trifluoromethyl-CyH2y-aminocarbonyl-0-CxH2x-, -6 y or
Figure imgf000195_0001
C1 -6al kyl . Qr _CyH2y_So2R8 ; wherein R8 is Ci -6alkyl, cycloalkyl, Ci.
6alkylcarbonylamino, Ci-6alkyl amino diCi-6alkylamino, amino, morpholinyl, pyrrolidinyl,
piperazinyl,
Figure imgf000195_0002
; or -CyH2y-COR9, wherein R9 is C i-6alkoxy, amino, hydroxy, cycloalkylsulfonylamino,
cycloalkylsulfonylamino(Ci-6alkyl) or Ci-6alkylsulfonylamino(Ci-6alkyl); or -CxH2x-NR10Rn, wherein R10 is hydrogen, Ru is hydrogen, Ci-6alkoxycarbonyl, Ci-6alkylcarbonyl, Ci.
Figure imgf000196_0001
6alkylsulfonyl, hydroxy-CxH2x- or , or R10 and R , u1 1, together with the nitrogen atom,
to which they are attached, form
Figure imgf000196_0002
Figure imgf000196_0003
V_/ N o C1-6alkyl C^alkyl
Figure imgf000196_0004
2 3
R and RJ are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cyclopropyl;
R6 is hydrogen;
W1 is -CH;
W2 is nitrogen;
W3 is -CH;
x is 2-6;
y is 1 -6.
7. A compound according to any one of claims 1 to 6, wherein
A is phenyl, which is unsubstituted or once or twice substituted by methyl, ethyl, fluoro, chloro, bromo, methoxy, trifluoromethyl or cyano; or pyridinyl, which is unsubstituted or once substituted by methyl or chloro;
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is methylsulfonylethyl or
methylsulfonylpropyl;
when X is nitrogen or -CH, R1 is acetylaminoethyl, acetylaminosulfonylpropyl, 4- acetylpiperazin-l -ylethyl, aminocarbonylethyl, aminocarbonylpropyl, aminoethyl, 3- aminooxetan-3-ylmethyl, aminosulfonylpropyl, carboxyethyl, cyclopropylsulfonylaminocarbonylethyl, cyclopropylsulfonylamino(methyl)carbonylethyl, cyclopropylsulfonyl ethyl, cyclopropylsulfonylpropyl, dimethylaminosulfonylethyl,
dimethylaminosulfonylpropyl, ethoxycarbonylethyl, ethylsulfonylethyl, ethylsulfonylpropyl, hydroxyethylaminopropyl, hydroxypropyl, methoxycarbonylaminopropyl,
methoxycarbony lpr opy 1 , methylamino sulfony lpropyl , methy lsulfinylpropyl ,
methylsulfonylamino(methyl)carbonylethyl, methylsulfonylaminoethyl,
methylsulfonylaminopropyl, methylsulfonylbutyl, methylsulfonylethyl,
methylsulfonylphenylmethyl, 4-(methylsulfonyl)piperazin- 1 -yl ethyl, methylsulfonylpropyl, oxetan-3-ylethyl, oxetan-3-ylmethyl, piperazin-l-ylethyl, piperazin-l-ylsulfonylpropyl, thietan-
3-ylethyl, (2,2,2-trifluoroethyl)carbamoyloxypropyl,
Figure imgf000197_0001
Figure imgf000197_0002
Figure imgf000198_0001
2 3
and RJ are hydrogen or deuterium simultaneously;
R4 and R5, with the carbon atom to which they are attached, form cyclopropyl;
R is hydrogen;
W1 is -CH;
W2 is nitrogen;
W3 is -CH.
A compound according to claim 1 or 2, wherein
A is phenyl or pyridinyl, which is once substituted by halogen;
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is Ci-6alkylsulfonyl-CyH2y-;
when X is nitrogen or -CH, R1 is Ci-6alkylsulfonyl-CyH2y- or aminocarbonyl-CyH2y-;
R2 is hydrogen;
R is hydrogen;
R4 and R5, with the carbon atom to which they are attached, form cycloalkyl;
R6 is hydrogen or halogen;
W1 is nitrogen or -CR12, wherein R12 is hydrogen or halogen;
W2 is -CH;
W3 is -CH or nitrogen; provided that W1 and W3 are not nitrogen simultaneously; x is 2-6;
y is 1-6.
A compound according to any one of claims 1, 2, 3 or 8, wherein
Figure imgf000199_0001
X is nitrogen, -CH or -CR7; provided that
when X is -CR7, R1 is hydrogen, wherein R7 is ethylsulfonylethyl;
when X is nitrogen or -CH, R1 is ethylsulfonylethyl, methylsulfonylethyl,
methylsulfonylpropyl or aminocarbonylethyl;
R2 is hydrogen;
R is hydrogen;
R4 and R5, with the carbon atom to which they are attached, form cyclopropyl;
R6 is hydrogen, fluoro, chloro or bromo;
W1 is nitrogen, -CH or -CF;
W2 is -CH;
W3 is -CH or nitrogen;
provided that W 1 and W 3 are not nitrogen simultaneously.
10. A compound according to any one of claims 1 to 9, selected from
r-({ l -[2-(Methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane-l ,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5 -Methoxy- 1 - [2-(methylsulfonyl)ethyl] - 1 H-indol-2-yl }methyl)spiro [cyclopropane- 1 ,3'-pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
l -[2-(Methylsulfonyl)ethyl]-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- l '(2'H)-yl)methyl]-l H-indole-5-carbonitrile;
l '-({ 5-Fluoro- l -[2-(methylsulfonyl)ethyl]- lH-indol-2-yl}methyl)spiro[cyclopropane-l ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
l '-( { 5-Bromo- 1 - [2-(methylsulfonyl)ethyl]- 1 H-indol-2-yl} methyl)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(rH)-one;
l '-({4-Chloro- l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- l ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
l '-( { 7-Chloro- 1 -[2-(methylsulfonyl)ethyl] - 1 H-indol-2-yl}methyl)spiro [cyclopropane- 1 ,3 '- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
1 '-( { 5-Ethyl- 1 - [2-(m ethylsulfonylethyl] - 1 H-indol-2-yl}methyl)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one; r-({5,7-Difluoro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane- l ,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one;
l' { l -[2 Me lsulfonyl)ethyl]-5 fluoromethyl)-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one;
1 '-({ 5 ,6-Difluoro- 1 - [2-(methylsulfonyl)ethyl]- 1 H-indol-2-yl} methyl)spiro [cyclopropane- 1 ,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one;
l'-({5-Chloro-7-fluoro-l-[2-(methylsulfonyl)ethyl]-l H-indol-2- yl }methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo[2,3 -c]pyridin]-2'( 1 'H)-one;
1 '-( { 5 -Methyl- 1 - [2-(methylsulfonyl)ethyl] - 1 H-indol-2-yl } methy l)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one;
l'-({ l-[2-(Methylsulfonyl)ethyl]-lH-pyrrolo[3,2-c]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one;
1 '-( { 5 -Chloro- 1 - [2-(ethylsulfonyl)ethyl] - 1 H-indol-2-yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
l'-({5-Chloro-l-[2-(ethylsulfonyl)ethyl]-lH-pyrrolo[2,3-0]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5 -Chloro- 1 - [2-(ethy lsulfonyl)ethyl] - 1 H-indol-2-yl } methy l)spiro [cyclopropane- 1,3'- pyrrolo [2,3 -&]pyridin]-2'( 1 'H)-one;
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3-b]pyridin-2- y 1 } methy l)spiro [cy clobutane- 1 , 3 '-pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one;
1 '-( { 5 -Chloro- 1 - [2-(methylsulfonyl)ethyl] - 1 H-indol-2-y 1 } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-£]pyridin]-2'(rH)-one;
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3-0]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one;
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3-0]pyridin-2-yl}methyl)-5'- fluorospiro[cyclopropane- l,3'-indol]-2'(rH)-one;
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3-0]pyridin-2- yl}methyl)spiro[cyclopentane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[3,2-0]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one;
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane-l,3'- pyrrolo[3 ,2-c]pyridin]-2'( 1 'H)-one; Γ-( { 5 -Chloro- 1 - [2-(methylsulfonyl)ethyl] - 1 H-indol-2-yl } methyl)spiro [cyclopentane-1,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5 -Chloro- 1 - [2-(methylsulfonyl)ethyl] - 1 H-indol-2-yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridm]-2'(rH)-one;
1 '-( { 5-Chloro- 1 -[4-(methylsulfonyl)butyl] - 1 H-indol-2-yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-({ 5-Chloro- 1 -[4-(methylsulfonyl)benzyl] - 1 H-indol-2-yl } methyl)spiro[cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin] -2'( 1 'H)-one;
r-({5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-pyrrolo[2,3-0]pyridin-2- yl } methyl)spiro[cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
l'-({5-Methyl-l-[2-(methylsulfonyl)ethyl]-lH-pyrrolo[2,3-0]pyridin-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5-Chloro- 1 - [4-(methylsulfonyl)butyl] - 1 H-pyrrolo [3 ,2 -£]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5 -Chloro- 1 - [3 -(cyclopropylsulfonyl)propyl] - 1 H-pyrrolo [3 ,2-¾]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
r-({5-Chloro-l-[4-(methylsulfonyl)butyl]-lH-pyrrolo[2,3-c]pyridin-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
N-Benzyl-3 - { 5-chloro-2- [(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo[2,3 -c]pyridin]- 1 '(2'H)- yl)methyl]-lH-pyrrolo[2,3-0]pyridin-l-yl}-N-methylpropane-l-sulfonamide;
l'-({5-Chloro-l-[3-(cyclopropylsulfonyl)propyl]-lH-pyrrolo[2,3-c]pyridin-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
l'-({5-Chloro-l-[2-(thietan-3-yl)ethyl]-lH-pyrrolo[2,3-c]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( {5-Chloro- 1 - [2-( 1 , 1 -dioxidothietan-3 -yl)ethyl]- 1 H-pyrrolo [2,3 -c]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5 -Chloro- 1 - [3 -(methyl sulfonyl)propyl] - 1 H-pyrrolo [2,3 -Z>]pyridin-2- yl } methyl)spiro [cyclobutane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
l'-({5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-pyrrolo[2,3-c]pyridin-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
l'-({5-Chloro-l-[2-(cyclopropylsulfonyl)ethyl]-lH-pyrrolo[3,2-0]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one; Γ-( { 5 -Chloro- 1 - [3 -(methyl sulfonyl)propyl] - 1 H-pyrrolo [3 ,2-Z>]pyridin-2- yl } methy l)spiro [cyclopropane- 1 , 3 '-pyrrolo [2 ,3 -cjpyridin] -2 '( 1 'H)-one;
1 '-( { 5 -Chloro- 1 - [4-(methylsulfonyl)butyl] - 1 H-pyrrolo [2 ,3 -Z>]pyridin-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3-c]pyridin]-2'( 1 'H)-one;
1 '-( { 5 -Chloro- 1 - [3 -(methylsulfinyl)propyl] - 1 H-indol-2-yl } methyl) spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5 -Chloro- 1 -[2-(methylsulfonyl)ethyl] - 1 H-pyrrolo [2,3 -c]pyridin-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
l'-({5-Chloro-l-[2-(ethylsulfonyl)ethyl]-lH-pyrrolo[3,2- )]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)-yl)methyl]- 1 H-indol- 1 -yl } -N,N-dimethylpropane- 1 -sulfonamide;
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- (2'H)-yl)methyl]- 1 H-pyrrolo [2, 3 -Z>]pyridin- 1 -yl } -N,N-dimethy lpropane- 1 -sulfonamide;
2-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)-yl)methyl]- lH-indol- 1 -yl} -N,N-dimethylethanesulfonamide;
1 '-( { 5 -Chloro- 1 - [3 -(morpholin-4-ylsulfonyl)propyl] - 1 H-indol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
1 '-( { 5 -Chloro- 1 - [3 -(pyrrolidin- 1 -ylsulfonyl)propyl] - 1 H-indol-2- yl } methy l)spiro [eye lopropane- 1 , 3 '-pyrro lo [2, 3 -cjpyridin] -2 '( 1 'H)-one;
1 '- [(5 -Chloro- 1 - { 3-[(3 -oxopiperazin- 1 -yl)sulfonyl]propyl } - 1 H-indol-2- yl)methyl]spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
l'-({5-Chloro-l-[2-(l,l-dioxido-l,2-thiazolidin-2-yl)ethyl]-lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one;
1 '-( { 5 -Chloro- 1 - [4-( 1 , 1 -dioxido- 1 ,2-thiazolidin-2-y l)buty 1] - 1 H-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one;
1 '-( { 5-Chloro- 1 - [3 -( 1 , 1 -dioxidothiomorpholin-4-yl)propyI] - lH-indol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin] -2'( 1 'H)-one;
1 '-({ 5-Chloro- 1 - [3-( 1 , 1 -dioxido- 1 ,2-thiazolidin-2-yl)propyl] - 1 H-indol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin] -2'( 1 'H)-one;
l'-{ [5-Chloro- 1 -(3-hydroxypropyl)-lH-indol-2-yl]methyl} spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one; 1 '- [ { 5 -Chloro- 1 - [2-(methylsulfonyl)ethyl] - 1 H-indol-2-yl } (2H2)methyl] spiro[cyclopropane- l ,3'-pyrrolo[2,3-c]pyridin]-2'(l 'H)-one
l'-[{5-Chloro-l-[3-(methylsulfonyl)propyl]-lH-indol-2- yl}(2H2)methyl]spiro[cyclopropane-l ,3'-pyn:olo[2,3-c]pyridin]-2'( H)-one;
Ethyl 3 - { 5-chloro-2- [(2'-oxospiro[cyclopropane- 1 ,3 '-pyrrolo[2, 3 -cjpyridin]- 1 '(2'H)- yl)methyl]- lH-indol-l-yl}propanoate;
1 '-( { 5-Chloro- 1 - [2-( 1 , 1 -dioxidothietan-3 -yl)ethyl] - lH-pyrrolo [2,3 - ?]pyridin-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
Ethyl 3-{ 5-chloro-7-fluoro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- 1 '(2'H)-yl)methyl] - 1 H-indol- 1 -yl } propanoate;
1 '-( { 5 -Chloro- 1 - [3 -(S-methylsulfonimidoyl)propyl] - 1 H-indol-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
r-CiS-Chloro-l-P-^-methylsulfonimidoy^ethy^- lH-indol^- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5 -Chloro- 1 - [4-(5'-methylsulfonimidoyl)butyl] - 1 H-pyrrolo [2,3 -b]pyridin-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one;
1 '-( { 5-Chloro- 1 - [2-(S-methylsulfonimidoyl)ethyl] - 1 H-pyrrolo [2,3 -b]pyridin-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one;
N-[(2-{ 5 -Chloro-2- [(2'-oxospiro [cyclopropane- 1 , 3 '-pyrrolo [2,3 -cjpyridin] - 1 '(2'H)- yl)methyl]- lH-indol-l-yl} ethyl)(methyl)oxido- 6-sulfanylidene]acetamide;
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- (2'H)-yl)methyl]- 1 H-indol- 1-yl} propanoic acid;
3- { 5-Chloro-7-fluoro-2- [(2'-oxospiro[cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] - 1 '(2'H)- yl)methyl] - 1 H-indol- 1 -yl } propanoic acid;
Methyl 4- { 5 -chloro-2-[(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin]- 1 '(2'H)- yl)methyl] - 1 H-indol - 1 -yl }butanoate;
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-r(2,H)-yl)methyl]- 1 H-indol- 1 -yl } propanamide;
3- {5-Chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3- ?]pyridin]-r(2'H)-yl)methyl]- 1 H-indo 1 - 1 -y 1 } propanamide ;
4- {5-Chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- (2'H)-yl)methyl]- lH-indol- 1 -yl } butanamide; 3- { 5 -Chloro-2- [(2'-oxospiro [cyclopropane- 1 ^
lH-indol-l-yl} -N-(cyclopropylsulfonyl)propanamide;
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-l 2'H)-yl)methyl]- lH-indol- 1 -yl} -jV-(cyclopropylsulfonyl)-N-methylpropanamide;
3- { 5-Chloro-2- [(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin]- 1 '(2'H)-yl)methyl]- lH-indol- 1 -yl} -N-methyl-N-(methylsulfonyl)propanamide;
3-(2-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]- (2'H)- yl)methyl]-lH-indol-l-yl} ethyl)imidazolidine-2,4-dione;
l'-[(5-ChloiO-l-{3-[(3i?)-3-hydroxypyrrolidin-l-yl]propyl}-lH-indol-2- yl)methyl]spiro [cyclopropane- 1,3 '-pyrrolo [2,3 -cjpyridin] -2'(l 'H)-one;
1 '-( { 5-Chloro- 1 -[3 -(ethylsulfonyl)propyl] - 1 H-indol-2-yl} methyl)spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
1 '-( { 5-Chloro- 1 - [3 -(methylsulfonyl)propyl] - 1 H-indol-2-yl } methyl)spiro [cyclopropane- 1,3'- pyrrolo [2,3 -b] pyridin] -2'( 1 'H)-one;
1 '-( { 5-Chloro- 1 - [3 -(methylsulfonyl)propyl] - 1 H-indol-2-yl } methyl) spiro [cyclopropane- 1,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one;
l'-({5-Chloro-l-[3-(ethylsulfonyl)propyl]-lH-pyrrolo[2,3-b]pyridin-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'(l'H)-one;
l'-({5-Chloro-l-[2-(piperazin-l-yl)ethyl]-lH-indol-2-yl}methyl)spiro[cyclopropane-l,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5-Chloro- 1 - [3 -(piperazin- 1 -ylsulfonyl)propyl] - lH-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
l'-[(5-Chloro-l-{3-[(li?,4i?)-2,5-diazabicyclo[2.2.1]hept-2-ylsulfonyl]propyl}-lH-indol-2- yl)methyl] spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one;
1 '-({ 5-Chloro- 1 - [3 -(2-oxopiperazin- 1 -yl)propyl] - 1 H-indol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
Γ- { [ 1 -(2- Aminoethyl)-5-chloro- 1 H-indol-2-yl] methyl } spiro [cyclopropane- 1 ,3 '- pyrrolo [2,3 -c]pyridin]-2'(l'H)-one;
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyiTolo[2,3-c]pyridin]-r(2'H)-yl)methyl]- lH-pyrrolo [2,3 -Cjpyridin- 1 -yl} -N-methylpropane- 1 -sulfonamide;
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l,3'-pyirolo[2,3-c]pyridin]-r(2'H)-yl)methyl]- 1 H-indol- 1 -yl } -N-methylpropane- 1 -sulfonamide; 3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrroto^
1 H-pyrrolo [2,3 -Cjpyridin- 1 -yljpropane- 1 -sulfonamide;
l'-({ l-[2-(4-Acetylpiperazin-l -yl)ethyl]-5-chloro-lH-indol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
N-[(3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)- yl)methyl]-lH-pyrrolo[2,3-^]pyridin-l-yl}propyl)sulfonyl]acetamide;
N-(2- { 5-Chloro-2-[(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] - 1 '(2'H)- yl)methyl] - 1 H-indol- 1 -yl } ethyl)acetamide;
l'-[(5-Chloro- l-{2-[4-(methylsulfonyl)piperazin-l-yl]ethyl}-lH-indol-2- yl)methyl] spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
N-(2-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]- (2'H)- yl)methyl] - 1 H-indol- 1 -yl } ethyl)methanesulfonamide;
N-(3 - {5-Chloro-2- [(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] - 1 '(2'H)- yl)methyl]-lH-indol-l-yl}propyl)methanesulfonamide;
1 -(2- { 5-Chloro-2- [(2'-oxospiro[cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] - 1 '(2'H)- yl)methyl] - 1 H-indol- 1 -yl } ethyl)urea;
1 '- [(5 -Chloro- 1 - { 3 - [(2-hydroxyethyl)amino]propyl } - 1 H-indol-2- yl)methyl] spiro [cyclopropane- l,3'-pyrrolo[2,3-c]pyridin]-2'(l 'H)-one;
Methyl (3 - { 5-chloro-2- [(2'-oxospiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] - 1 '(2'H)- yl)methyl] - 1 H-indol- 1 -y 1 } propyl)carbamate;
3-{5-Chloro-2-[(2'-oxospiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-l'(2'H)-yl)methylJ- 1 H-indol- 1 -yl } propyl (2,2,2-trifluoroethyl)carbamate;
1 '-( { 6-Chloro-3 - [2-(ethy lsulfonyl)ethyl] - 1 H-indol-2-yl } methyl)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-^]pyridin]-2'(l'H)-one;
1 '-( { 6-Chloro-3 - [2-(methylsulfonyl)ethyl]- 1 H-indol-2-yl } methyl)spiro [cyclopropane- 1 ,3'- pyrrolo[2,3-c]pyridin]-2'( H)-one;
r-({6-Chloro-3-[3-(methylsulfonyl)propyl]-lH-indol-2-yl}methyl)spiro[cyclopropane-l,3'- pyrrolo[2,3-c]pyridin]-2'(rH)-one;
l'-({5-Chloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
l,-({5-Chloro- l -[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2-yl}methyl)-4'- fluorospiro [cyclopropane- 1 ,3 '-indol]-2'( 1 'H)-one; 4'-Chloro-l '-({5-chloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-indol]-2'( 1 'H)-one;
4'-Bromo- 1 '-( { 5-chloro- 1 -[2-(methylsulfonyl)ethyl] - lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-indol]-2'( H)-one;
1 '-( { 5 -Chloro- 1 - [2-(ethylsulfonyl)ethyl] - 1 H-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5 -Chloro- 1 - [2-( 1 , 1 -dioxidothietan-3 -yl)ethyl] - 1 H-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
1 '-( { 5 -Chloro- 1 - [3 -(methylsulfonyl)propyl] - 1 H-benzimidazol-2- yl}methyl)spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
l'-({5-Chloro-l-[2-(cyclopropylsulfonyl)ethyl]-lH-benzimidazol-2- yljmethy^spirofcyclopropane-l^'-pyrroloP^-cjpyridinJ^ Hj-one;
r-({5-Chloro-7-fluoro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin]-2'( 1 'H)-one;
l'-({5,7-Dichloro-l-[2-(methylsulfonyl)ethyl]-lH-benzimidazol-2- yl} methyl) spiro [cyclopropane- 1,3 '-pyrrolo [2, 3 -c]pyridin]-2'(l 'H)-one;
l'-{[5-Chloro-l-(oxetan-3-ylmethyl)-lH-benzimidazol-2-yl]methyl}spiro[cyclopropane- 1 ,3 '-pyrrolo [2,3 -cjpyridin] -2'( 1 'H)-one;
1 '-( { 5 -Chloro- 1 - [2-(oxetan-3 -yl)ethyl] - 1 H-benzimidazol-2-yl } methyl)spiro [cyclopropane-
I , 3 '-pyrrolo [2, 3 -c]pyridin] -2'( 1 'H)-one;
1 '- { [5-Chloro-7-fluoro- 1 -(oxetan-3 -ylmethyl)- 1 H-benzimidazol-2- yl]methyl}spiro[cyclopropane-l ,3'-pyrrolo[2,3-c]pyridin]-2'( H)-one;
l'-({ l-[(3-Aminooxetan-3-yl)methyl]-5-chloro-lH-benzimidazol-2- yl } methyl)spiro [cyclopropane- 1 ,3 '-pyrrolo [2,3 -c]pyridin] -2'( 1 'H)-one; and
r-({ l-[(3-Aminooxetan-3-yl)methyl]-5-chloro-7-fluoro-lH-benzimidazol-2- yl}methyl)spiro[cyclopropane-l,3'-pyrrolo[2,3-c]pyridin]-2'(rH)-one.
I I . A process for the preparation of a compound according to any one of claims 1 to 10 comprising the reaction of
(a) a compound of formula (A)
Figure imgf000207_0001
presence of a phosphine reagent and an azidocarbonyl reagent;
Figure imgf000207_0002
in the presence of a base;
Figure imgf000207_0003
with X2-R' in the presence of a base;
(d) a compound of formula (D)
Figure imgf000208_0001
with acyl chloride in the presence of a
(e) a compound of formula (E)
Figure imgf000208_0002
the presence of a base;
a compound of formula (F)
Figure imgf000208_0003
with thionyl chloride;
(g) a compound of formula (F)
Figure imgf000208_0004
with sulfonamide in the presence of N-[3-(dimethylamino)propyl]-N,-ethylcarbodiimide hydrochloride and 4-dimethylamiopryidine;
(h) a compound of formula (G)
Figure imgf000209_0001
with imidazolidine-2,4-dione in the presence of a base;
(j) a compound of formula (G)
Figure imgf000209_0002
with (3/?)-pyrrolidin-3-ol in the presence of a base;
k) a compound of formula (J)
Figure imgf000209_0003
with hydrochloride or trifluoroacetic acid;
(1) a compound of formula (K) C1-6alkyl
Figure imgf000210_0001
with concentrated sulfuric acid;
(m) a compound of formula (M)
Figure imgf000210_0002
with trifluoroacetic acid;
(n) a compound of formula (N)
Figure imgf000210_0003
with methanesulfonyl chloride in the presence of a base;
)
Figure imgf000210_0004
with acetic anhydride or acetyl chloride in the presence of a base; (p) a compound of formula (N)
Figure imgf000211_0001
with methyl carbonochloridate in the presence of a base; (q) a compound of formula (N)
Figure imgf000211_0002
with 2-bromoethanol in the presence of a base;
(r) a compound of formula (N)
Figure imgf000211_0003
with methyl carbamimidothioate in the presence of an acid; (s) a compound of formula (P)
Figure imgf000211_0004
H2N
with ^ in the presence of a base;
t) a compound of formula (Q)
Figure imgf000212_0001
with tetrabutylammonium fluoride;
wherein R1 to R6, W1 to W3, X, A, x and y are defined as in any one of claims 1 to 1 1 ; X2 is chloro, bromo, iodo or 4-methylbenzenesulfonate; L1 is Ci-6alkyl; L2 is Ci-6alkyl; L3 is chloro or
7 8 7 8
-OS02CH3; L is -CxH2x; L is hydrogen or Ci-6alkyl; or L and L , together with the nitro en, to
which the are attached, form
Figure imgf000212_0002
or
Figure imgf000212_0003
; L is -CxH2x- or -CxH2x-sulfonyl; L is hydrogen or Ci-6alkyl; or L
Figure imgf000212_0004
and L , to ether with the nitrogen, to which they are attached, form L14 is
Figure imgf000212_0005
or L15 is Ci-6alkoxycarbonyl-
CxH2x- or Ci-6alkylsulfonyl-CxH2x-.
12. A compound according to any one of claims 1 to 10 for use as therapeutically active substance.
13. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 10 and a therapeutically inert carrier.
14. The use of a compound according to any one of claims 1 to 10 for the treatment or
prophylaxis of respiratory syncytial virus infection.
15. The use of a compound according to any one of claims 1 to 10 for the preparation of a medicament for the treatment or prophylaxis of respiratory syncytial virus infection.
16. A compound according to any one of claims 1 to 10 for the treatment or prophylaxis of respiratory syncytial virus infection.
17. A compound according to any one of claims 1 to 10, when manufactured according to a process of claim 1 1.
18. A method for the treatment or prophylaxis of respiratory syncytial virus infection, which method comprises administering an effective amount of a compound as defined in any one of claims 1 to 10.
19. The invention as hereinbefore described.
PCT/EP2014/059699 2013-05-14 2014-05-13 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection WO2014184163A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201480028073.XA CN105392787B (en) 2013-05-14 2014-05-13 For treating and preventing the azepine oxindole of respiratory syncytial virus infection
KR1020157035224A KR20160007629A (en) 2013-05-14 2014-05-13 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
RU2015148926A RU2015148926A (en) 2013-05-14 2014-05-13 AZA-OXO-INDOLES FOR TREATMENT AND PREVENTION OF RESPIRATORY-SYNCITIAL VIRAL INFECTION
JP2016513325A JP2016518421A (en) 2013-05-14 2014-05-13 Aza-oxo-indoles for the treatment and prevention of respiratory syncytial virus infection
CA2910508A CA2910508A1 (en) 2013-05-14 2014-05-13 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
MX2015015691A MX2015015691A (en) 2013-05-14 2014-05-13 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection.
EP14723783.8A EP2997028A1 (en) 2013-05-14 2014-05-13 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
BR112015028475A BR112015028475A2 (en) 2013-05-14 2014-05-13 new aza-oxo-iris for the treatment or prophylaxis of syncytial respiratory viral infection
US14/942,725 US10189838B2 (en) 2013-05-14 2015-11-16 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
HK16110598.7A HK1222395A1 (en) 2013-05-14 2016-09-06 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection --

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/075594 2013-05-14
CN2013075594 2013-05-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/942,725 Continuation US10189838B2 (en) 2013-05-14 2015-11-16 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Publications (1)

Publication Number Publication Date
WO2014184163A1 true WO2014184163A1 (en) 2014-11-20

Family

ID=50721785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/059699 WO2014184163A1 (en) 2013-05-14 2014-05-13 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Country Status (9)

Country Link
US (1) US10189838B2 (en)
EP (1) EP2997028A1 (en)
JP (1) JP2016518421A (en)
BR (1) BR112015028475A2 (en)
CA (1) CA2910508A1 (en)
HK (1) HK1222395A1 (en)
MX (1) MX2015015691A (en)
RU (1) RU2015148926A (en)
WO (1) WO2014184163A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015110446A1 (en) * 2014-01-24 2015-07-30 F. Hoffmann-La Roche Ag Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
WO2016055780A1 (en) * 2014-10-07 2016-04-14 Re:Viral Ltd Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
US20160159794A1 (en) * 2013-08-15 2016-06-09 Hoffmann-La Roche Inc. Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
JP2016530257A (en) * 2013-08-12 2016-09-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel aza-oxo-indoles for the treatment and prevention of respiratory syncytial virus infection
RU2601749C1 (en) * 2015-09-08 2016-11-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный технический университет" (ВолгГТУ) Method of producing 4'-fluorospiro[cyclopropane-1,3'-indol]-2'(1'h)-one
WO2018025043A1 (en) * 2016-08-04 2018-02-08 ReViral Limited Pyrimidine derivatives and their use in treating or preventing a respiratory syncytial virus infection
US10071999B2 (en) 2015-07-16 2018-09-11 Hoffmann-La Roche Inc. Crystalline forms of (3-amino-oxetan-3-ylmethyl)-[2-(5,5-dioxo-5,6,7,9-tetrahydro-5lambda*6*-thia-8-aza-benzocyclohepten-8-yl)-6-methyl-quinazolin-4-yl]-amine
US10208067B2 (en) 2015-05-20 2019-02-19 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
WO2019122928A1 (en) * 2017-12-22 2019-06-27 ReViral Limited Pharmaceutical compounds
US10562903B2 (en) 2015-12-10 2020-02-18 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US10874672B2 (en) 2015-12-10 2020-12-29 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
US11780839B2 (en) 2018-03-27 2023-10-10 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11858941B2 (en) 2018-06-27 2024-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
US11938136B2 (en) 2015-11-12 2024-03-26 Hoffmann-La Roche Inc. Compositions for treating spinal muscular atrophy

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201711704D0 (en) * 2017-07-20 2017-09-06 Reviral Ltd Pharmaceutical compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062290A2 (en) * 2000-12-20 2002-08-15 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
WO2013068769A1 (en) * 2011-11-10 2013-05-16 Re:Viral Ltd Pharmaceutical compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527814B (en) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 Azabenzimidazoles as respiratory syncytial virus antiviral agents
TWI530495B (en) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 Benzimidazole respiratory syncytial virus inhibitors
TWI501967B (en) 2010-12-16 2015-10-01 Janssen R&D Ireland Azaindoles as respiratory syncytial virus antiviral agents
CN104903313B (en) * 2012-10-16 2017-12-29 爱尔兰詹森科学公司 Rsv antiviral compounds
CN104693211A (en) * 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 Imidazole derivative as antiviral agent and pharmaceutical application thereof
US9850251B2 (en) * 2013-12-10 2017-12-26 Shandong Danhong Pharmaceutical Co., Ltd. Imidazole derivative used as antiviral agent and use therof in preparation of medicament

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062290A2 (en) * 2000-12-20 2002-08-15 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
WO2013068769A1 (en) * 2011-11-10 2013-05-16 Re:Viral Ltd Pharmaceutical compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COMBRINK, K. D. ET AL.: "Respiratory syncytial virus fusion inhibitors. Part 6: An examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, no. 17, 4 August 2007 (2007-08-04), PERGAMON, AMSTERDAM NL, pages 4784 - 4790, XP022184908, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.06.065 *
SIN, N. ET AL.: "Respiratory syncytial virus fusion inhibitors. Part 7: Structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 16, 15 August 2009 (2009-08-15), PERGAMON, AMSTERDAM; NL, pages 4857 - 4862, XP026419096, ISSN: 0960-894X, [retrieved on 20090613] *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670211B2 (en) 2013-08-12 2017-06-06 Hoffmann-La Roche Inc. Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
JP2016530257A (en) * 2013-08-12 2016-09-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel aza-oxo-indoles for the treatment and prevention of respiratory syncytial virus infection
US9890155B2 (en) * 2013-08-15 2018-02-13 Hoffmann-La Roche Inc. Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
US20160159794A1 (en) * 2013-08-15 2016-06-09 Hoffmann-La Roche Inc. Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
CN109879837A (en) * 2014-01-24 2019-06-14 豪夫迈·罗氏有限公司 Prepare the method for preventing and treating the compound of RSV
US10005770B2 (en) 2014-01-24 2018-06-26 Hoffmann-La Roche Inc. Process for the preparation of N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
JP2017503843A (en) * 2014-01-24 2017-02-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ N-[(3-aminooxetane-3-yl) methyl] -2- (1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl) -6-methyl-quinazoline- Process for the preparation of 4-amine
CN109879837B (en) * 2014-01-24 2023-06-09 上海爱科百发生物医药技术股份有限公司 Methods of preparing compounds for preventing and treating RSV
AU2015208244B2 (en) * 2014-01-24 2017-11-02 F. Hoffmann-La Roche Ag Process for the preparation of N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
EP3248969A1 (en) * 2014-01-24 2017-11-29 F. Hoffmann-La Roche AG Process for the preparation of n-[3-(aminomethyl)oxetan-3-yl]carbamate intermediates
WO2015110446A1 (en) * 2014-01-24 2015-07-30 F. Hoffmann-La Roche Ag Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
US10253022B2 (en) 2014-01-24 2019-04-09 Hoffmann-La Roche Inc. Process for the preparation of N-[(3-aminooxetan-3-yl) methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
KR101841866B1 (en) 2014-01-24 2018-03-23 에프. 호프만-라 로슈 아게 Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
AU2015329778B2 (en) * 2014-10-07 2020-04-23 Pfizer Inc. Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV)
US10106539B2 (en) 2014-10-07 2018-10-23 ReViral Limited Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV)
WO2016055780A1 (en) * 2014-10-07 2016-04-14 Re:Viral Ltd Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
JP2017530992A (en) * 2014-10-07 2017-10-19 アールイーヴァイラル リミテッド Spiroindoline for the treatment or prevention of respiratory syncytial virus infection (RSV)
US10208067B2 (en) 2015-05-20 2019-02-19 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
US10071999B2 (en) 2015-07-16 2018-09-11 Hoffmann-La Roche Inc. Crystalline forms of (3-amino-oxetan-3-ylmethyl)-[2-(5,5-dioxo-5,6,7,9-tetrahydro-5lambda*6*-thia-8-aza-benzocyclohepten-8-yl)-6-methyl-quinazolin-4-yl]-amine
US10556896B2 (en) 2015-07-16 2020-02-11 Hoffmann-La Roche Inc. Crystalline forms of (3-Amino-oxetan-3-ylmethyl)-[2-(5,5-dioxo-5,6,7,9-tetrahydro-5lambda*6*-thia-8-aza-benzocyclohepten-8-yl)-6-methyl-quinazolin-4-yl]-amine
RU2601749C1 (en) * 2015-09-08 2016-11-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный технический университет" (ВолгГТУ) Method of producing 4'-fluorospiro[cyclopropane-1,3'-indol]-2'(1'h)-one
US11938136B2 (en) 2015-11-12 2024-03-26 Hoffmann-La Roche Inc. Compositions for treating spinal muscular atrophy
US10562903B2 (en) 2015-12-10 2020-02-18 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US10874672B2 (en) 2015-12-10 2020-12-29 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US10881658B2 (en) 2015-12-10 2021-01-05 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US11638706B2 (en) 2015-12-10 2023-05-02 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
WO2018025043A1 (en) * 2016-08-04 2018-02-08 ReViral Limited Pyrimidine derivatives and their use in treating or preventing a respiratory syncytial virus infection
US10603319B2 (en) 2016-08-04 2020-03-31 ReViral Limited Pyrimidine derivatives and their use in treating or preventing a respiratory syncytial virus infection
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US11141406B2 (en) 2017-12-22 2021-10-12 ReViral Limited Pharmaceutical compounds
WO2019122928A1 (en) * 2017-12-22 2019-06-27 ReViral Limited Pharmaceutical compounds
US11780839B2 (en) 2018-03-27 2023-10-10 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
US11858941B2 (en) 2018-06-27 2024-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease

Also Published As

Publication number Publication date
MX2015015691A (en) 2016-03-04
CA2910508A1 (en) 2014-11-20
US20180072726A9 (en) 2018-03-15
JP2016518421A (en) 2016-06-23
RU2015148926A (en) 2017-06-15
US10189838B2 (en) 2019-01-29
US20160068531A1 (en) 2016-03-10
HK1222395A1 (en) 2017-06-30
EP2997028A1 (en) 2016-03-23
BR112015028475A2 (en) 2017-07-25

Similar Documents

Publication Publication Date Title
EP2997028A1 (en) Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
ES2737696T3 (en) Pyrazolopyridines and pyrazolopyrimidines
ES2929528T3 (en) Pyrazolopyrimidine derivatives as BTK inhibitors for cancer treatment
TW202328124A (en) 1,4-oxazepane derivatives and uses thereof
EP3033341B1 (en) Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
EP3401315A1 (en) Fxr receptor modulator, preparation method therefor, and uses thereof
AU2008282885A1 (en) Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
NZ523566A (en) Imidazopyridine and imidazopyrimidine antiviral agents
JP2013545785A (en) Benzimidazole respiratory syncytial virus inhibitor
IL263148A (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
BR112015022092B1 (en) DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVES, THEIR USES AND PREVENTIVE AND/OR THERAPEUTIC AGENT INCLUDING THEM
CN112292374B (en) Novel phosphoinositide 3-kinase inhibitor and preparation method and application thereof
KR20150110569A (en) Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents
CA3061209A1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
ES2600318T3 (en) New indazoles for the treatment and prophylaxis of respiratory syncytial virus infection
WO2023040998A1 (en) A cyclin-dependent kinase inhibitor
CN105392787A (en) Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
WO2022048498A1 (en) Usp7 inhibitor
WO2022007966A1 (en) Pb2 inhibitor, and preparation method therefor and use thereof
ES2715348T3 (en) Compounds containing fused nitrogen rings for use as CRTH2 antagonists
EP3890731A1 (en) Compounds for the treatment of arenavirus infection
KR20160007629A (en) Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
EP3033333A1 (en) Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
CN116437918A (en) Pyrazolopyridine compounds as TAM inhibitors
OA19688A (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480028073.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14723783

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2014723783

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2910508

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/015691

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016513325

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015028475

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20157035224

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015148926

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015028475

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151112